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Abstract 
Drug resistance is a major concern in the treatment of numerous diseases caused by infectious agents. 
The misuse of current therapies has led to the development of almost complete resistance in some 
cases, creating an urgent need for the development of new drugs. In this study, I assessed the 
effectiveness of compounds against two medically important lung pathogens, Mycobacterium 
tuberculosis and Pseudomonas aeruginosa, using complementary methods of drug discovery and 
assessment.   
The first approach assessed whether high-affinity iron chelators of the pyridoxal isonicotinoyl 
hydrazone (PIH) class can restrict the growth of clinically significant mycobacteria. Screening a library 
of PIH derivatives revealed that one compound derived from the condensation of 2-
pyridylcarboxaldehyde with the first-line anti-tuberculosis drug Isoniazid (INH), namely, 2-
pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH), exhibited nanomolar in vitro activity against 
Mycobacterium bovis Bacille Calmette-Guerin and virulent M. tuberculosis. PCIH displayed minimal 
host cell toxicity and was effective at inhibiting growth of M. tuberculosis within cultured macrophages 
and also in vivo in mice. Further, PCIH restricted mycobacterial growth at high bacterial loads in 
culture, a property not shared with INH. When tested against Mycobacterium avium, PCIH was more 
effective than INH at inhibiting bacterial growth in broth culture and in macrophages, and also reduced 
bacterial loads in vivo. Iron complexation studies indicate a possible role for chelation as a mechanism 
of action, however this could not totally account for its potent efficacy, with structure-activity 
relationship studies suggesting that PCIH acts as a lipophilic vehicle for the transport of its intact INH 
moiety into the mammalian cell and the mycobacterium. These results demonstrate that iron-chelating 
agents such as PCIH may be of benefit in the treatment and control of mycobacterial infection. 
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The second study assessed the ability of a novel series of molecules, termed metal-cyclam complexes 
(MCyC), to inhibit the growth of medically relevant bacteria. Screening of MCyC against a panel of 
gram-positive, gram-negative and mycobacterial strains identified that a subset of MCyC specifically 
inhibited the growth of mycobacteria, exhibiting activity in the low micromolar range in vitro. 
However, none the compounds could restrict the viability of mycobacteria in a non-replicating state, 
suggesting the mode of action of these novel molecules was linked to replication of bacteria.  
Encouragingly, the most effective compound identified, a copper(II)-cyclam complex incorporating 
two naphthalimide pendant groups, could markedly restrict intracellular growth of pathogenic 
mycobacteira but displayed no host-cell cytotoxicity. Finally, the three most effective compounds were 
able to work synergistically with current anti-tuberculosis drugs to inhibit bacterial growth in vivo, 
indicating this series of inhibitors are promising leads for further preclinical and clinical development. 
The final study developed high-throughput screening assays to determine if a library of 1920 
compounds, made up of a diverse series of natural and synthetic products, could inhibit the growth of 
Pseudomonas and mycobacterial species. Only a small proportion of compounds were found to inhibit 
growth of the drug resistant clinical isolate P. aeruginosa CJ2009 (0.3%), however two compounds 
were active in the low micromolar range (3.13 to 6.25 µM). A similarly low number of compounds 
were active against M. avium (0.1%) and two compounds inhibited growth in the mid micromolar 
range (12.5 to 25 µM). There was no overlap in activity between the two bacterial species tested, 
suggesting the identified compounds displayed some specificity for the target organism. However, all 
compounds displayed some level of toxicity against mammalian cells, limiting their potential use in 
their current form. Decoding of compounds revealed that toxicity of some of the compounds may be 
related to their proposed function as either nucleotide or steroid analogs, metal binding capacity or 
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inhibitors of mammalian cellular processes. This study highlights the necessity to identify compounds 
with high selectivity for the pathogen of interest for future clinical development and use.  
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Chapter 1: Literature review 
1.1   Mycobacteriology and disease 
Mycobacteria are a group of slow and fast growing, acid-fast bacilli of the order Actinomycetales, 
family Mycobactericeae. They are non-motile, non-spore forming bacteria with a lipid rich cell wall 
(Rogall et al., 1990, Puzo, 1990). The mycobacterial cell wall is very complex, made up of long fatty-
acid chains and mycolic acids covalently bound to an arabinogalactan-peptidoglycan co-polymer (Song 
et al., 2008). It is this characteristic lipid-rich cell wall that renders mycobacteria resistant to many 
disinfectants and antibiotics, as well as contributing to its many attributes including slow growth, 
antigenicity, propensity to clump in liquid media, and acid-fastness (Davies, 1998).  
Mycobacteria are obligate aerobes that are catalase positive and fall into two main categories of 
growth; slow growing and fast growing, depending on the amount of time it takes for visible colonies 
to appear on solid media (Shinnick and Good, 1994). The bacilli can either be straight or slightly 
curved in shape, and occasionally filamentous (Tsukamura, 1981). The filaments formed are different 
from those of other actinomycetes, in that they are readily able to fragment into rods or coccoid bodies 
when disturbed (Tsukamura, 1981). 
These organisms are classified in the genus Mycobacterium depending on their acid-fastness and the 
presence of mycolic acid containing up to 90 carbons that are cleaved by pyrolysis to methyl esters. A 
high guanine/cytosine content in their deoxyribonucleic acid (DNA) is also typical of mycobacteria 
(Shinnick and Good, 1994). To date, more than 150 species of mycobacterium have been identified, 
most of which are saprophytes found ubiquitously in the environment (Behr, 2013). Whilst these 
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bacteria occur in diverse environments, Mycobacteria are more commonly known as animal pathogens, 
and humans are readily infected by mycobacterial species (Bose, 2008). The most pathogenic species 
include Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium leprae, the causative 
agent of leprosy. 
Of the genus Mycobacterium, M. tuberculosis was the first species to be classified. Subsequently in 
1959, Earnest Runyon developed a nomenclature protocol known as the Runyon classification. This 
classification assisted in organising the clinically important mycobacterial species other than M. 
tuberculosis, depending on growth rate and the ability of the bacteria to produce pigment in the 
presence or absence of light (Rogall et al., 1990, Tsukamura, 1981). For example, Mycobacterium 
avium and M. bovis are classified in Runyon group III, which means they are non-pigmented, slow-
growing bacteria (Stahl and Urbance, 1990). 
1.1.1   Mycobacterium tuberculosis  
One of the most pathogenic species of mycobacterium, M. tuberculosis is a slow-growing, acid-fast 
bacillus that primarily infects mononuclear phagocytes (Flynn and Chan, 2001, Wagner et al., 2005). In 
particular, alveolar macrophages are highly permissible to infection with mycobacteria, as the 
organisms reside within cytoplasmic vacuoles and employ mechanisms to resist acidification and 
phagolysosomal fusion, thus enhancing intracellular survival (Bermudez and Sangari, 2001, Wagner et 
al., 2005).  
M. tuberculosis was first isolated in 1882 by Robert Koch as the causative agent of tuberculosis (Koch, 
1882). It was initially christened tuberculosis by Scholein in 1839 and in 1865 Jean-Antoine Villemin 
showed that tuberculosis could be transmitted by culturing bacteria from humans or cows and injecting 
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it into guinea pigs or rabbits to see if they developed tuberculosis-like disease (Sakula, 1983). 
Following this, Koch also discovered that the bacterium infecting bovine and human populations were 
different, thus describing M. bovis (Taylor et al., 2003). Pathogen transmission occurs primarily via 
aerosol route, infecting the lung, but also the mesenteric, lymphatic, circulatory and genitourinary 
systems, as well as the peripheral and central nervous systems (Bonfioli et al., 2005). Infection is 
initiated upon phagocytosis of bacilli by alveolar macrophages (Russell et al., 2009). Patients with 
pulmonary tuberculosis are able to transmit bacilli throughout the population, however patients with 
non-pulmonary tuberculosis are not infectious (Underwood et al., 2003a). 
Symptoms of the disease are non-specific, including fever, night sweats, chills, malaise, weight loss 
and fatigue (Murray et al., 2005). More specific symptoms include bloody and purulent sputum, which 
is associated with necrosis of the lung. Diagnosis of the disease is by the Mantoux or tuberculin test, 
which tests for a cellular immune response to Mycobacterium, however this is not indicative of active 
disease. Other diagnosis tools which test for active infection are culturing sputum samples, but this can 
take up to 3 weeks (Banfi et al., 2003), or performing an acid-fast stain, however bacteria can be 
difficult to identify in light microscopic examination of a stained smear. More recent diagnostic assays 
include the QuantFERON®-TB Gold test, which is an ELISA measuring the release of IFN- by 
antigen-reactive T lymphocytes cultured with antigens specific to M. tuberculosis (Connell et al., 
2006). These antigens include ESAT-6 and CFP-10, which are present in the genome of M. 
tuberculosis but absent in other mycobacterial species such as the M. bovis BCG vaccine (Arlehamn et 
al., 2012).  
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1.1.2 Tuberculosis epidemiology 
Tuberculosis is the leading cause of death from a single bacterial pathogen worldwide (Arlehamn et al., 
2012) and is the second largest cause of mortality by an infectious disease after HIV (W.H.O, 2012). 
Of the estimated 2 billion people infected, 10 % of people will progress to clinical infection. Co-
infection with HIV increases this risk by a further 10 % per year (Bezuidenhout et al., 2009). The 2012 
report released by the World Health Organisation (WHO) stated that there was an estimated 9 million 
new cases of tuberculosis in 2011 and 1.4 million deaths (W.H.O, 2012). Infection with multi-drug 
resistant (MDR) strains account for approximately 3.7 % of new cases each year, with an estimated 
20% of MDR cases in previously treated TB patients (W.H.O, 2012). Of these approximately 3% of 
MDR cases have been classified extensively-drug resistant (XDR) (C.D.C, 2007). Co-infection with 
HIV accounted for an estimated 1.1 million (13%) of new cases in 2011 (W.H.O, 2012). 
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Figure 1.1: Global incidence of susceptible and multiple-drug resistant Tuberculosis. Adapted from 
www.who.int/tb/data. Absolute number of tuberculosis cases (A) and Multi-drug resistant cases (B) reported globally. 
 
Figure 1.2: Incidence of Tuberculosis cases worldwide (W.H.O, 2012) 
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Due to the success of the DOTS campaign which commenced in 1995 (see 1.4.4) the number of new 
cases have started to decline by approximately 2% per year (Figure 1.1a) (W.H.O, 2012). It still 
remains localised in certain areas (Figure 1.2) with the 22 high burden countries accounting for 89% of 
the global burden, with Asia and Africa accounting for 59% and 26% respectively (W.H.O, 2012). The 
number of MDR-TB cases however, has increased annually, as seen in Figure 1.1b, with 4.3% of all 
new cases being diagnosed as MDR-TB in the 27 high MDR high burden countries (W.H.O, 2012). 
Whilst considered a low-income country disease, areas considered to be low risk have also seen a rise 
in MDR-TB incidence such as the United States, (Taylor et al., 1999), the United Kingdom (Abubakar 
et al., 2008, Kumar et al., 1997) and Australia (Lumb et al., 2008). 
1.1.3   Mycobacterium avium 
M. avium is an opportunistic pathogen that mainly affects the immunocompromised (Sangari et al., 
1999). It is a strongly acid-fast, weakly gram-positive aerobic rod that is found ubiquitously in the 
environment (Davies, 1998). M. avium can be transmitted either by aerosols where it can cause 
pulmonary disease (Yamazaki et al., 2006), or ingested causing disease of the gastrointestinal tract 
(Sangari et al., 1999). M. avium is the only species of mycobacterium that can withstand the high acidic 
environment of the gastro-intestinal tract (Bermudez and Sangari, 2001). This bacterium couples with 
Mycobacterium intracellulare to form the M. avium intracellulare complex (MAC), which 
predominates in South-eastern USA, Western Australia and Japan (Davies, 1998). It is the most 
common infection for people co-infected with HIV in the USA (however M. tuberculosis is more 
prominent in African HIV patients). In patients with AIDS, it is commonly a systemic disease, causing 
infection in almost all organs of the body (Yamazaki et al., 2006). 
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1.2  Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a gram-negative bacterium from the family Pseudomonadaceae that is 
found ubiquitously in the environment. It is aerobic, non-fermentative, and can withstand higher 
temperatures than most other Pseudomonas species (Stanier et al., 1966). It can adapt to a diverse range 
of environments, from soil and surface of plants, to hospital equipment and jet fuel (Pitt, 1986). This 
particular species of Pseudomonas has also shown a unique ability to be pathogenic to mammals 
(Stanier et al., 1966).  
P. aeruginosa is an opportunistic pathogen, causing acute infection in burn wounds, the eye through 
contact lenses and the urinary tract, as well as being the most common lung pathogen in cystic fibrosis 
(CF) patients (Bielecki et al., 2008). PAO1, a laboratory strain of P. aeruginosa, was the 25
th
 genome 
to be sequenced (Stover et al., 2000a). The genome encodes a range of proteins including 
approximately 150 outer membrane, 300 cytoplasmic membrane and 521 regulatory proteins (Stover et 
al., 2000a, Silby et al., 2011) which accounts for its ability to adapt to a wide array of environments. It 
has a diverse range of virulence factors, including lipopolysaccharide and biofilm formation, and 
encodes a number of transporters involved in antibiotic resistance that has lead to its ability to cause 
severe and chronic infection, making it an extremely difficult pathogen to treat.  
LPS is a cell wall associated protein that is composed of 3 distinct regions; the O antigen or long-chain 
O-polysaccaride, lipid A, and the core oligosaccharide (Kocincova and Lam, 2011). Linkages and 
sugar constituents that make up the O antigen are used to type different strains of P. aeruginosa 
(Kocincova and Lam, 2011). The inner core of the oligosaccharide is highly conserved and is necessary 
for cell viability where a mutation within this region leads to a lethal phenotype (Lam et al., 2011). The 
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main functions of LPS are to provide a barrier against the host response to try and evade detection, as a 
means of targeting and interacting with host receptors and antibiotics, and as a potent signalling 
molecule assisting in tissue damage (King et al., 2009).  
Biofilm formation is a virulence factor involved in persistence. It allows bacteria to survive on 
generally uninhabitable environments such as taps and pipes (Kerr and Snelling, 2009) which is why it 
is such a successful nosocomial pathogen (Sanchez et al., 2013). Urinary and lung infections are 
facilitated by the ability for Pseudomonas to exist on catheters and intubation tubes. The presence of a 
biofilm also results in a greater resistance to antibiotics compared to bacteria in a planktonic state (Kerr 
and Snelling, 2009), however the mechanism behind this resistance is yet unknown (Sanchez et al., 
2013). Lastly, the biofilm is linked to chronic infection (Kerr and Snelling, 2009). Whilst early 
infection (in CF patients) is able to be readily treated with antibiotics, in late chronic infection P. 
aeruginosa appears to secrete copious amounts of alginate that result in the formation of a matrix 
which embeds into the lung environment (Eberl and Tummler, 2004). This causes antibiotic resistance 
and allows the bacteria to persist in the lung environment.  
 
1.3   Cystic fibrosis disease and treatment 
1.3.1   Disease state and epidemiology 
Cystic fibrosis (CF) is an autosomal recessive genetic disease effecting 1 in 2,500 live births 
(Vankeerberghen et al., 2002). It is caused by a mutation in the cystic fibrosis transmembrane 
conductance regulator (CFTR) protein which acts as a chloride channel in mucosa lined epithelial cells. 
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This results in the influx of thick mucus secretions into the lung which cannot easily be cleared, 
creating a niche for opportunistic pathogens. Over 1,800 mutations in the CFTR gene have been 
discovered, however not all result in CF disease (Foundation, 2012).  
The disease is characterised by an exocrine pancreatic insufficiency leading to an inability to absorb 
fats and proteins, chronic bacterial lung infection and a reduction in weight despite a voracious appetite 
(Asay, 1965). In both adults and children, signs of liver cirrhosis and diabetes can be present however 
they are rare (Brusilow, 1970). Sterility is experienced in 98% of males, and puberty can be delayed in 
some patients due to nutritional deficiencies (Orenstein et al., 2002). Andersen was the first person to 
categorise CF as an independent disease to celiac, which had a similar symptom profile (Andersen, 
1949). She was also the first to suggest that it was a hereditary disease (Andersen Dh, 1946) however it 
took another 40 years before the gene responsible was discovered (Kerem et al., 1989, Riordan et al., 
1989). 
The major cause of morbidity and mortality in CF patients is a chronic obstructive lung disease and a 
largely neutrophil-dominated inflammatory response (Saiman, 2004). The progression of disease is 
determined by the colonising bacteria within the lung environment, and this in turn determines the 
morbidity and prognosis of the disease state (Eberl and Tummler, 2004). Diagnosis of the disease is 
through a sweat test with confirmation by DNA analysis in which a homozygous genetic profile for the 
mutated CFTR can be found (Orenstein et al., 2002). In 1987-91, the average life expectancy was 
approximately 28 years of age. Today, if managed appropriately, the median age of survival is 36.8 
(Foundation, 2012). 
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1.3.2   Microbial infection 
Due to the mucus-rich environment, the CF lung makes for an adaptable habitat for many bacterial 
species. In early infection, CF lung pathogens are quite varied, however later infection appears to be 
more defined. In the majority of cases, by adulthood the lung will be dominated by P. aeruginosa (as 
shown in Figure 1.3). P. aeruginosa is one of the best studied pathogens infecting the lung. It has a 
variety of virulence factors that allow it to reside in the lung without much challenge both from the host 
immune system and antibiotics (see section 1.2). Studies have shown that P. aeruginosa infection 
causes pronounced obstruction of airways and chronic infection can lead to severe negative clinical 
effects (Lopes et al., 2012, Goss and Ratjen, 2013). In Australia, approximately 59 per cent of patients 
were infected with a clonal strain of P. aeruginosa (O'Carroll et al., 2004) with more than 30 per cent 
of CF patients infected with the Australian Epidemic strain 1 (AES-1) (Tingpej et al., 2010). The AES 
clones have been linked with increased virulence, more hospitalisations and poorer patient outcomes 
compared to infection with non-epidemic strains. Epidemic clonal P. aeruginosa also demonstrate 
extensive antibiotic resistance, with the AES-1 clone exhibiting 97 per cent resistance to both 
Amikacin and Gentamicin and more than 40 per cent resistance to most other commonly used 
antibiotics making this strain incredibly difficult to treat (Tingpej et al., 2010).   
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Figure 1.3: The colonisation profiles of the most common pathogens in CF patients. (Foundation, 2012) 
Other clinically important bacterial species include Haemophilus influenzae, Staphylococcis aureus, 
and Burkholdaria cepacia. Viral and fungal infections can be present in the lung, and other bacterial 
species including Klebsiella and Stenotrophomonas can contribute to morbidity (Harrison, 2007). S. 
aureus and H. influenzae are both common nasal flora of a healthy individual, however they have been 
found in throat swabs of CF patients. S. aureus has been also been found, similarly to P. aeruginosa, in 
the mucus of obstructed airways (Ulrich et al., 1998). Whilst its individual pathogenicity is unknown, it 
has been suggested that S. aureas infection can prime the lung for subsequent chronic P. aeruginosa 
infection by destroying epithelial cells and providing an area for Pseudomonas attachment (Lyczak et 
al., 2002). B. cepacia is an emerging CF pathogen that is believed to be spread via patient-to-patient 
contact or through the environment. It has been associated with severe infection and mortality due to 
respiratory failure (Whiteford et al., 1995). B. cepacia is able to infect epithelial cells of the respiratory 
tract (Burns et al., 1996), possibly accounting for its ability to cause disseminated disease and be highly 
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resistant to antibiotics (Lyczak et al., 2002). Co-infection of B. cepacia with P. aeruginosa has also 
shown to cause a significant reduction in lung function compared to P. aeruginosa infection alone 
(Whiteford et al., 1995).  
Another emerging infection is that of non-tuberculosis mycobacteria (NTM) (Kilby et al., 1992, 
Torrens et al., 1998, Hjelte et al., 1990) with 4% to 20% of CF patients being infected with NTM 
(Lyczak et al., 2002). It has been suggested that whilst the clinical importance of such an infection is 
not well established, it could account for those patients who deteriorate without an obvious cause 
(Hjelte et al., 1990). As mycobacteria are slow-growing they can be outgrown by other bacterial 
species within the test culture making it difficult to detect (Kilby et al., 1992). This co-infection with 
NTM could be more prevalent than currently known. 
1.3.3   Current drugs in use 
Historically, patients with CF rarely lived to their teenage years due to lack of a proper diagnosis and 
poorly controlled lung infections. In 1964 a therapeutic regimen was suggested for children suffering 
from CF which was directed at three factors of disease; the obstructive lung lesion, secondary 
pulmonary infection and nutritional and pancreatic defects (Matthews et al., 1964). Drugs were given 
in combination targeting all three factors rather than controlling individual characteristics of the 
disease. The introduction of this regimen appeared successful and saw a gradual increase in average 
life-expectancy (Orenstein et al., 2002). As CF is classified by a pancreatic deficiency and weight loss, 
adequate nutrition is essential for treatment. Improving the nutrition of patients has led to increased 
weight, healthier BMI levels, and improved lung function (Shoff et al., 2013, White et al., 2013, Beker 
et al., 2001). This can be achieved in patients through enzyme replacement therapy to assist in the 
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breakdown of fats (Orenstein et al., 2002) or nocturnal tube feeding for direct nutrient supply 
(Steinkamp and von der Hardt, 1994, White et al., 2013).  
As chronic infection is currently the major dictator of morbidity and mortality, the predominant aim is 
to treat the infection in the lung. A variety of treatments are available to assist in bacterial removal or 
the improvement of the lung environment to a more normal state. They include mucus thinners (Reeves 
et al., 2012, Frederiksen et al., 2006), CFTR modulators (Jih and Hwang, 2013, Wilschanski et al., 
2011), anti-inflammatory medication  (Lands and Stanojevic, 2013, Noel et al., 2012), and antibiotics 
(Assael et al., 2012, Fernandez-Olmos et al., 2012). Prophylactic or aggressive antibiotic treatment can 
lead to a delay or prevention of chronic infection, although not in all cases (Harrison, 2007). 
Treatments for CF are increasing the life expectancy for patients, however antibiotics to eradicate the 
chronic lung infection are still needed due to antibiotic failure. 
The biggest issue with treatment is the increasing drug resistance of P. aeruginosa strains. In hospital 
settings resistance to commonly used medications such as Piperacillin, Ciprofloxacin, and Imipenem 
have been increasing from 2 to 4.6 per cent per year (Xu et al., 2013). In 2011, one study showed 
Gentamicin and Ticarcillin resistance in hospitals was greater than 70 per cent, and resistance to the 
last line carbapenems were greater than 40 per cent (Xu et al., 2013). Within individual patients, 
resistance can occur over the lifetime of the infection, making treatment of chronic infection extremely 
difficult (Mouton et al., 1993). Pseudomonas resistance is highly prevalent due to multiple resistance 
mechanisms intrinsically built into the bacterium and this has resulted in some clinical isolates being 
resistant to all FDA-approved treatments (Talbot et al., 2006). 
Chapter 1: Literature Review 
14 | P a g e  
 
There are new drugs coming through the drug ‘pipeline’, however none have been approved for human 
use and no new antibiotics possess a novel mode of action (Hurley et al., 2012). Intravenous 
carbapenems are in clinical trials and have been shown to be effective at restricting the growth of P. 
aeruginosa. One such compound in phase 3 trials, Doripenem, has an MIC90 of 4 µg/mL against 
imipenem-resistant strains and appears to have similar activity to meropenem which is already used in 
Pseudomonas treatment (Alvarez-Lerma et al., 2009).  
Other trials have explored the inhalation of already established antibiotics, such as collistin, 
tobramycin, and gentamicin (Ryan et al., 2011). Tobramycin, collistin and aztreonam are currently used 
as an aerosolised treatment to manage chronic Pseudomonas infection (Lam et al., 2013). Collistin 
inhalation therapy was the first to be used in chronic infection. It has high levels of activity against P. 
aeruginosa and low levels of resistance, and in one study it appeared to improve patient well-being and 
prevent lung function deterioration as well as reduce the inflammatory response commonly witnessed 
upon completion of intravenous therapies (Jensen et al., 1987). Tobramycin is the most widely used 
inhaled antibiotic being stable under a multitude of conditions, possessing low levels of resistance, 
having a prolonged post-antibiotic effect and having a high activity level relative to gentamicin (Smith, 
2002). The success of these inhaled compounds has meant that more than 60 per cent of chronically 
infected CF patients are receiving at least one inhaled antibiotic as part of their treatment regimen 
(Moskowitz et al., 2008).  
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1.4   Tuberculosis treatment and prevention 
1.4.1   BCG and vaccination 
Currently, the only available vaccine for tuberculosis is the BCG vaccine (Liu et al., 2009) which is a 
highly attenuated strain of M. bovis, known as Mycobacterium bovis Bacille Calmette-Guerin (BCG). It 
is one of the most widely used vaccines in human history, being both relatively safe and inexpensive 
(Gerberry, 2009). Historically, after the success of the smallpox vaccine, the initial vaccine trial was to 
inoculate patients with M. bovis directly (Davies, 1998). This proved unsuccessful due to the 
unforeseen virulence of that particular strain, however the work of two French bacteriologists, Albert 
Calmette and Camille Guerin, whose work included culturing mycobacterium in various media, 
showed that by culturing M. bovis in a glycerin-bile-potato medium, a less virulent form of M. bovis 
could be created (Davies, 1998, Ritz et al., 2008). In 1924, after 230 passages over a 13 year period, a 
strain was developed that could be used as an attenuated vaccine (Ritz et al., 2008). 
Initially the vaccine was given orally. France was the only European nation that initially took on the 
BCG vaccine, administering it to infants across the country (Hawgood, 2007). Following this 
Scandinavian countries developed the vaccine to be administered intradermally, and this was offered in 
a mass vaccination campaign throughout Europe in the 1950’s (Davies, 1998).   
The BCG vaccine, despite its wide usage, displays a varying efficacy from 0-80% (Liu et al., 2009). It 
does prove to be useful in preventing meningitis in children, as well as protecting those infected from 
severe infection (Ritz et al., 2008). Vaccination with BCG results in varying levels of protection against 
pulmonary tuberculosis (Brewer, 2000, Honaker et al., 2008) and transmission is not reduced by the 
vaccine (Maartens and Wilkinson, 2007). It has been suggested that the variation is due to genetic 
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differences between BCG and M. tuberculosis, such as the absence of genes in BCG such as ESAT-6 
and CFP10, which are expressed by M. tuberculosis (Hoft, 2008, Behr et al., 1999) resulting in 
differences in antigenicity and protective efficacy. Genetic difference amongst the BCG strains has 
resulted in further phenotypic differences that affect antigenicity (Honaker et al., 2008).  
Currently, research is focussed on the development of new vaccines, however this will not be discussed 
further in this thesis as it is not a topic of the research described here. It is acknowledged that the most 
effective way to control tuberculosis is the combination of highly protective vaccines to prevent 
infection/disease, together with efficacious drugs to treat those already infected. However, there are 
several factors which necessitate the development of novel, more effective drugs for the control of 
tuberculosis. These include the emergence of multi-drug resistant strains of M. tuberculosis, the 
dangerous interplay between HIV and tuberculosis co-infection and the shortcomings of current 
mainstay anti-mycobacterial drugs. 
1.4.2   Multi-drug resistance 
Three types of drug resistance are defined by the WHO: primary, secondary and initial. Primary 
resistance is defined as the presence of a resistant strain of M. tuberculosis in a patient who denies 
having had any previous treatment (I.U.T.L.D, 1998). ‘Secondary’ or ‘acquired resistance’ is defined as 
the presence of resistant strains of M. tuberculosis in patients who have undergone treatment for 4 
weeks or longer (I.U.T.L.D, 1998). Isolation of resistant strains from patients where previous treatment 
history cannot be obtained are defined as having initial resistance (I.U.T.L.D, 1998). 
Drug resistance, as a subgroup from the above categories, is divided into monoresistance and 
polyresistance. They are defined as resistance to one of the first-line drugs of tuberculosis 
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chemotherapy, INH, Rifampicin, Ethambutol and Para-aminosalicylic acid, for monoresistance, or 
resistance to two or more first line drugs for polyresistance (Loddenkemper et al., 2002). Multi-drug 
resistance (MDR) is defined as a resistance to at least rifampicin and Isoniazid (W.H.O, 2012), the two 
most potent anti-tuberculosis drugs, and is classified as polyresistance. 
The global spread of MDR tuberculosis is such that it has been declared a pandemic (Farmer and Kim, 
1998, Zager and McNerney, 2008). MDR has established due to a combination of factors, including 
inadequate chemotherapy and treatment regimens, confinement and therefore lack of quarantine 
measures, population growth and the increased incidence of HIV (Johnson et al., 2006, W.H.O, 2012, 
I.U.T.L.D, 1998). During the initial stages of drug therapy, when streptomycin was the main-line drug, 
resistance developed due to the implementation of this mono-therapy (Loddenkemper et al., 2002). 
Because of this, treatment thereafter was multi-faceted. 
Initially treatment was an 18-24 month course, however with the introduction of rifampicin in the 
1960’s, chemotherapy reduced to a 6-8 month course and there was an overall decline in M. 
tuberculosis. The decline in incidence led to complacency, decreased funding and monitoring of 
tuberculosis disease for 20 years (Espinal, 2003). Surveillance did not resume until after an increase in 
HIV/AIDS incidence in the 1980’s led to outbreaks of both susceptible and resistant strains of M. 
tuberculosis (Johnson et al., 2006).  
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Figure 1.4: Percentage of  MDR-TB cases in newly diagnosed patients (W.H.O, 2012)  
In 2000, it was estimated that 3.2% of the 8.7 million new tuberculosis cases were MDR (Dye et al., 
2002b). That has since increased to 3.1% of 9.27 million new cases of tuberculosis in 2007 (W.H.O, 
2009), and currently it is estimated that 3.7% of new cases are MDR (W.H.O, 2012). These ‘new’ cases 
were determined as patients who had not received any prior anti-tuberculosis treatment or who had 
only been on a course of drugs for up to one month (Dye et al., 2002a). The most affected countries 
with the highest incidence of MDR tuberculosis include India, China, Russian Federation and South 
Africa, however the highest proportion relative to population is Belarus, Estonia and Kazakhstan 
(Figure 1.4) (W.H.O, 2012). 
These new cases of MDR tuberculosis not only mean that resistance is arising from poor treatment 
practices or treatment failure but also that the resistant strains have been able to be transmitted within 
Chapter 1: Literature Review 
19 | P a g e  
 
the population (Dye et al., 2002a). Treatment of MDR tuberculosis requires a prolonged 
chemotherapeutic course, and the use of second-line drugs which are highly toxic and very expensive 
(Zager and McNerney, 2008). Standard short course therapy can effectively treat 30-50% of MDR 
cases if correctly monitored (Bottger and Springer, 2008), however for those patients to whom short 
course therapy is ineffective, the cost of the drug regime to control MDR tuberculosis is typically 
hundreds of times greater (Dye et al., 2002b).  
1.4.3   DOTS regime 
A new treatment regime implemented by the W.H.O was directly-observed treatment and short-course 
chemotherapy (DOTS). Patients would receive a cocktail of first-line drugs and a medical professional 
or similar would monitor and record the treatment being taken (Cox et al., 2008). Sputum samples are 
taken monthly, and patients remained on the DOTS program until they produce two consecutive 
negative samples (Johnson et al., 2006). This was to prevent patients from prematurely stopping 
treatment, therefore reducing the risk of acquired resistance.  
There are five key elements that form the basis of the DOTS strategy. These elements are commitment 
by the government, detection of each case by sputum smear microscopy, a standard 6-8 month 
treatment regime, a constant and regular supply of all necessary tuberculosis drugs and a standard 
recording and reporting system (DeRiemer et al., 2005). From this framework, four drug regimes were 
developed. Within these regimes, there is an intensive phase of treatment, where a patient will receive 
up to four first line drugs, and then a continuation phase using only rifampicin and isoniazid, which are 
the two most potent anti-tuberculosis drugs (Johnson et al., 2006). 
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There is evidence that the DOTS regime has a success rate of 90% in countries or areas where correct 
procedures had been in place prior to the DOTS implementation (Espinal and Dye, 2005). However, in 
countries where resistance was already prevalent, there was a high level of treatment failure and death 
(Espinal and Dye, 2005). Overall, DOTS has increased treatment success since its implementation both 
globally and in high burdened countries such as Africa and Asia (Figure 1.5). 
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Figure 1.5: Treatment success for new cases of tuberculosis treated under DOTS between 1994 and 2006. Adapted 
from W.H.O (2009). 
DOTS therapy, whilst being effective in controlling cases of susceptible tuberculosis and preventing 
the increase in MDR incidence, is still not enough to control MDR tuberculosis itself. This is due to the 
fact that MDR tuberculosis is already resistant to rifampicin and isoniazid, which are the two most 
effective components of the DOTS regime. This has two implications; firstly, that the treatment will be 
ineffective and secondly, that this treatment practise could encourage resistance to pyrazinamide and 
ethambutol in patients with otherwise susceptible strains (Farmer and Kim, 1998). 
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Whilst the practise of DOTS can be used in MDR cases, it is harder to develop a standardised regimen 
due to the variation in resistance. This means that patients can be monitored when taking their 
medication, however success rates are more difficult to judge due to differences in treatment length and 
efficacy of drug combinations used during treatment. 
1.4.4   Extensive-drug resistance 
Extensive drug resistance (XDR) is defined as MDR that includes resistance to any fluoroquinolone 
and one of the second-line injectable drugs; kanamycin, amikacin and capreomycin (Madariaga et al., 
2008). It was first described in March, 2005, by the US Centre for Disease Control and Prevention 
(C.D.C, 2007), and was brought to the public’s attention in October of that same year (Jassal and 
Bishai, 2009).  
The first cases of XDR tuberculosis were seen in the KwaZulu-Natal Province of South Africa, in 
patients suffering from Acquired Immune Deficiency Syndrome (AIDS) (Chan et al., 2009). Of those 
infected with XDR, 98% of cases resulted in death (Gandhi et al., 2006). A study conducted with the 
assistance and management of the Stop TB Partnership Green Light Committee (GLC), created in 
2000, showed that in a population based assessment, 19% of XDR cases were found in Latvia, which 
has one of the highest MDR case rates (Jassal and Bishai, 2009). Currently, XDR tuberculosis has been 
identified in 49 countries worldwide (Sotgiu et al., 2009) and with a high fatality rate and a median 
survival of 16 days it remains virtually untreatable (Hwang et al., 2009). Thus, there is an urgent need 
for the development of new treatment for XDR cases. 
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1.4.5   Current drugs in use 
Streptomycin was the first antibiotic used in anti-tuberculosis treatment (Proust et al., 1982). It was 
discovered in 1943 (Loddenkemper et al., 2002) and first marketed in 1947 (Conti et al., 2004). The 
drug  was initially effective, with bactericidal efficacy against M. tuberculosis (Proust et al., 1982) that 
translated to a marked improvement in prognosis for 51% of patients studied (Davies, 1998). However, 
the implementation of antibiotic monotherapy resulted in resistance within 2-3 months of its initial use 
(Jassal and Bishai, 2009, Davies, 1998).  
Subsequently, agents such as p-amino salicylic acid (PAS), discovered by Lutz Eric Lehmann in 
Sweden in 1946, and Isoniazid (INH), which was discovered in 1952, were used in combination 
therapies against tuberculosis (Ross and Horne, 1976). The British Medical Research Council (MRC) 
trialled both PAS and isoniazid in mono-therapeutic regimes and also in combination therapy trials 
using both PAS and isoniazid or with the inclusion of streptomycin (Iseman, 2002). Isoniazid proved to 
be bactericidal after the first 24 hours, similarly to streptomycin, however PAS was strictly 
bacteriostatic (Ross and Horne, 1976). Streptomycin, whilst being highly effective was also quite toxic 
to patients, conversely PAS was relatively non-toxic, however was not as efficacious (Vilcheze and 
Jacobs, 2007). INH proved to be the most effective, although appeared to be selective for slow-growing 
strains of mycobacteria. It selectively killed actively replicating bacteria, showing no effect on those in 
a latent state (Vilcheze and Jacobs, 2007). 
Despite the success of these drugs, further research was conducted to discover new anti-microbials, as a 
precaution to avoid the problems associated with the development of streptomycin resistance. This led 
to the discovery of pyrazinamide in 1952, cycloserine in 1955, ethambutol and capreomycin in 1961, 
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and rifampicin in 1966 (Loddenkemper et al., 2002). The introduction of pyrazinamide and rifampicin 
in particular, resulted in the treatment course being reduced 3-fold, with relapse rates of less than 2% 
(Iseman, 2002).  
In the 1970s, the British MRC implemented a short-course chemotherapy regime, which since has 
become the recommended protocol for treatment of tuberculosis (Balganesh et al., 2008). It is typically 
a 6 month treatment program. In the first two months, patients are given a combination of four first-line 
drugs, including rifampicin, isoniazid, pyrazinamide, and ethambutol or streptomycin. Subsequently, a 
four month course of rifampicin and isoniazid is implemented and cure rates can be as successful as 
90% (Espinal and Dye, 2005). 
An increase in drug resistance has led to an urgent need for the discovery of new drugs. Despite this, no 
new compound has been introduced into the standard treatment program since the 1960s (de Souza, 
2006). Current treatment for resistant mycobacteria can last on average 24 months, and rely on second-
line drugs that are toxic and costly (Espinal and Farmer, 2009). New compounds need to be 
bactericidal, have an extended safety profile to accommodate for prolonged treatment duration 
(Balganesh et al., 2008) and ultimately have a shorter treatment duration to encourage patient 
adherence (Chan and Iseman, 2002).  
1.4.6 New chemotherapies  
In December 29
th
 2012, the FDA approved the first tuberculosis drug in over 40 years. Bedaquiline, an 
enzyme inhibitor preventing bacterial replication and transport, has been approved for the use in MDR 
cases along with a standard combination therapy (Goldenberg, 2013). Whilst this was a milestone for 
TB treatment, the drug has serious safety concerns and the possibility of resistance developing is likely 
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if not regulated appropriately. It is therefore important that the research and development of new 
chemotherapies be made a priority. 
As shown in Figure 1.6, there are a number of drugs in development, both at the discovery stage and in 
clinical trials. Delamanid is currently in phase III trials. It was discovered by conducting a screen 
using nitro-dihydro-imidazooxazole derivatives and targets mycolic acid biosynthesis (Matsumoto et 
al., 2006). An early bactericidal study concluded that Delamanid showed promising anti-bacterial 
activity after 14 days, however was not as effective as the current treatment regime (Diacon et al., 
2011). Later clinical studies appeared more successful with a 100% increase in sputum culture 
conversion in Delamanid treated patients compared to placebo treated (~48% and 24% respectively), 
with 80% of patients classified as having MDR-TB (Gler et al., 2012). Another study showed 
favourable outcomes and a reduced level of mortality in MDR and XDR patients when treated with 
Delamanid (Skripconoka et al., 2013). There were numerous side effects experienced, most of which 
were gastrointestinal issues (vomiting etc), however they were only marginally more prevalent than the 
placebo treated group (Gler et al., 2012). 
Novel regimens are also in phase II trials. In a randomised study conducted in 2012, the combination of 
PA-824, pyrazinamide and moxifloxacin appeared to be the most effective of those assessed and was 
just as effective as the current regimen. This is particularly promising as this combination is an INH- 
and RIF-independent regimen, useful for treatment and prevention of MDR-TB. One negative result 
from this combination however, was that there were side effects leading to three withdrawals (out of 
85) from this trial (Diacon et al., 2012). Other regimes combining bedaquiline (TMC-207), sutezolid 
(PNU-100480) and PA-824 showed a significant bacterial load reduction in murine models compared 
to RIF/INH/PZA control, with a lower number of relapses (Williams et al., 2012). Whilst these 
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combinations are efficacious there are some safety concerns and therefore new compounds that are 
both safe and effective need to be developed. 
 
Figure 1.6: New drug pipeline for tuberculosis treatment (www.newtbdrugs.org, 2012) 
There are also numerous compounds that are in the developmental phase. Studies into nutritional 
supplementation have been conducted, looking at whether fat-soluble vitamins are able to restrict 
mycobacterial growth (Sinclair et al., 2011, Greenstein et al., 2012). This works on the premise that 
vitamins are involved in immune function, particularly pertaining to macrophages and lymphocytes 
(Sinclair et al., 2011). Currently, no clinically relevant benefit has been established. 
Benzothiazinones are a class of compound that inhibits the enzyme involved in arabinan biosynthesis. 
Ortho nitro-dialkyldithiocarbamate derivatives were chemically modified to create a variety of 
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compounds to be tested against mycobacteria (Makarov et al., 2006). These modifications led to a 
series of compounds, nitrobenzothiazones, which showed promising results with regards to specificity 
and potency against mycobacteria (Makarov et al., 2009). BTZ043 is in preclinical development 
(Figure 1.6), having been the most successful. Murine studies have shown that this compound is highly 
efficacious, being significantly more potent than INH and rifampicin (Makarov et al., 2009). It has also 
been shown to have a synergistic effect with the current therapies rifampicin, INH and moxifloxacin, as 
well as with the novel compounds bedaquiline and PA-824 (Lechartier et al., 2012).  
 
1.5. Iron and mycobacterium 
1.5.1 Iron and the host 
Iron is important for many biological processes including DNA synthesis, erythropoiesis, and electron 
transport (Richardson et al., 2008). In the host immune system, iron is required for the essential 
functions of macrophages by promoting the production of nitric oxides and the NADPH oxidative 
burst. It is also required in the production of certain cytokines (Cronje et al., 2005). Iron in excess 
however, is toxic, requiring the need for iron regulation within the body (Crichton et al., 2002). Iron 
chelation therapy is currently indicated in thalassemia, myelodysplasia, and other haematological 
conditions and is being investigated for the treatment of certain cancers. 
Iron is transported into a mammalian cell by receptor mediated endocytosis. Typically, iron serum 
levels are between 3-5 µg/mL which it is predominantly bound to transferrin (Crichton et al., 2002). 
Iron-bound transferrin binds to the transferrin receptor 1 (TfR1), which is upregulated when 
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intracellular iron levels are low (Yu et al., 2006). Within the intracellular space, a change in pH from 
neutral to acidic results in the iron being released from transferrin, and it can then be used by the cell 
for various functions (Richardson et al., 2008). 
When a macrophage is stimulated by interferon-γ (IFN-γ), this induces the downregulation of the 
transferrin receptor, which is required to move intracellular iron out of the cell (Collins, 2003, Sow et 
al., 2007). This results in iron being kept intracellularly, thus allowing the macrophage to function 
appropriately. Paradoxically, the accumulation of iron interferes with macrophage function, particularly 
with respect to NFκB activation and nitric oxide production required for phagocytosis (Crichton et al., 
2002). Iron is also used by M. tuberculosis as a co-factor for a number of enzymatic processes, a fact 
that has facilitated the exploration of iron chelation therapy as a method of treatment against 
tuberculosis. 
1.5.2 The use of iron in Mycobacterium tuberculosis infection 
Mycobacteria use iron as a cofactor for over 40 different enzymes encoded within the genome (Cronje 
and Bornman, 2005, Yellaboina et al., 2006). There are many iron-regulated genes that are conserved 
within the mycobacterial species, including fatty acid biosynthesis, iron storage, and amino acid 
biosynthesis (Yellaboina et al., 2006). One of the virulence factors possessed by mycobacteria are 
siderophores, which are low-molecular weight compounds with a high affinity for iron (Winkelmann, 
2002). The siderophore acts by being released into the extrabacillary space within the macrophage. 
They then bind to the iron molecules available and are reinternalised by the bacteria (De Voss et al., 
2000). There are two types of siderophore in Mycobacteria; exochelins and mycobactins (Winkelmann, 
2002). Pathogenic mycobacteria, particularly M. tuberculosis, only produce mycobactins containing a 
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salicylic acid derived moity (Byers and Arceneaux, 1998). When M. tuberculosis H37Rv was mutated 
causing a deletion of the mbtB gene encoding a siderophore, there was a reduction in the growth of M. 
tuberculosis compared to wild-type mycobacteria under iron limitation, but this effect could be 
reversed when cultured in a high iron medium (De Voss et al., 2000). This study highlighted the 
importance of siderophore production under conditions of iron limitation.  
To further demonstrate the importance of iron on mycobacterial growth, one study found that the 
number of M. tuberculosis in mice supplemented with iron were higher in both the spleen and lung 
compared to the control mice (Lounis et al., 2001). In HIV positive patients, M. tuberculosis infection 
(as well as M. avium infection) was more prominent in patients with high iron grades (de Monye et al., 
1999). Together, these studies suggest that limiting iron availability may be an effective strategy to 
treat mycobacteria.  
The effect of iron on mycobacterial growth has led to the study of iron chelation therapy as a treatment 
for mycobacterial infection. Chelation therapy inhibited the growth of extracellular M. tuberculosis 
bacteria, but displayed limited efficacy against internalised bacteria (Cronje et al., 2005). In vitro 
studies showed iron chelators were able to inhibit growth of M. avium in macrophages to a moderate 
extent. However, effects were limited in mice (Gomes et al., 2001). Although the studies were 
independent, both acknowledged that whilst iron limitation could reduce mycobacterial numbers, more 
effective iron chelators are required. 
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1.6   The current study 
Drug resistance is an increasing problem throughout the world. Numerous bacterial strains, particularly 
those that are hospital borne, are developing almost complete resistance and the development of new 
compounds is not meeting the need of the patients. In the case of Pseudomonas infection in CF 
patients, some strains exhibit complete resistance to the main chemotherapies, causing a resurgence in 
use of potentially toxic compounds such as Polymyxin B, or lung transplants being the only viable 
therapy. In comparison, for drug susceptible strains of M. tuberculosis, the current therapies are very 
effective, cheap and relatively non-toxic. However, there is a 6-8 month treatment program and the 
incidence of drug resistant strains is on the increase. This has led to a need not only for new drugs to 
combat drug resistance but also a requirement to identify compounds that can reduce the treatment time 
whilst still being as affordable, effective and non-toxic. 
The central aim of this project was to discover new compounds that could potentially be used in the 
treatment of chronic lung diseases, particularly those due to P. aeruginosa and M. tuberculosis. This 
was approached through the use of complimentary methods for drug discovery, including targeted 
discovery using the knowledge of bacterial growth requirements or whole cell screening with libraries 
comprised of  novel natural and synthetic compounds. 
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Hypothesis: That novel chemical classes can be identified that effectively restrict the growth of 
bacterial lung pathogens. 
Specific Aims:   
1. To determine if highly effective iron chelators can inhibit mycobacterial growth both in vitro 
and in vivo.    
2. To determine if a defined set of novel cyclam-containing compounds display anti-bacterial 
properties  
3. To screen a diverse library of natural and synthetic compounds to identify new structures 
against Pseudomonas and Mycobacterial pathogens. 
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Chapter 2: Material and Methods 
Materials 
2.1 Media and supplements 
2.1.1 Bacterial culture media 
From Sigma Aldrich Australia, unless otherwise stated. 
Albumin-Dextrose-Catalase (ADC) - 5 % w/v BSA + 2 % w/v dextrose + 0.003 % w/v 
catalase in triple distilled water (TDW). Store at 4 
o
C. 
Filter sterilised at room temperature. 
Luria agar - 30.5 g Luria agar powder (Bacto laboratories Pty Ltd, Pritchard, Australia) in 1 L 
reverse osmosis (RO) water, final concentrations 1 % w/v Bacot-tryptone + 0.05 % w/v Bacto-
yeast extract + 1 % w/v NaCl + 1.5 % w/v agar. 
Autoclaved at 121 
o
C for 20 minutes. 
Luria broth (LB) - 15.5 g Luria broth powder (Bacto laboratories Pty Ltd) in 1 L RO water, 
final concentrations 1 % w/v Bacto-tryptone + 0.05 % w/v Bacto-yeast extract + 1 % w/v NaCl.  
Autoclaved at 121 
o
C for 20 minutes.  
Difco Middlebrook 7H9 medium - 4.7 g Middlebrook 7H9 powder (Bacto laboratories Pty 
Ltd) in 900 mL dH2O + 100 mL ADC + 5 mL 50 % v/v glycerol + 4 mL 10 % v/v tween 80.  
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Autoclave at 121 
o
C for 15 minutes. Store in dark conditions at room temperature. 
Difco Middlebrook 7H10 agar - 19 g Middlebrook 7H9 powder (Bacto laboratories Pty Ltd) 
in 900 mL dH2O + 100 mL Oleic ADC + 5 mL 50 % v/v glycerol + 4 mL 10 % v/v tween  
Autoclave at 121 
o
C for 15 minutes. 
Oleic ADC (OADC) - 5 % w/v BSA + 2 % w/v dextrose + 0.004 % w/v catalase + 0.85 % w/v 
NaCl + 0.05 % w/v Oleic acid in TDW. Store at 4 
o
C. 
10 % Tween 80 - 10% v/v Tween in distilled water (dH2O), heated then filter sterilised. 
50 % Glycerol - 50 % v/v glycerol (Fluka, BioChemika) in dH2O, heated then filter sterilised. 
2.1.2 Cell culture 
From Sigma Aldrich Australia, unless otherwise stated. 
Complete DMEM - DMEM (GIBCO) + 10 % foetal bovine serum (FBS) + 200 µM L-
glutamine + 1 mM HEPES buffer solution. Store at 4 
o
C. 
Complete RPMI - RPMI (GIBCO) + 10 % FBS + 200 µM L-glutamine + 1 mM HEPES buffer 
solution + 1 % v/v β-mercaptoethanol. 
Foetal bovine serum (FBS) - Heat inactivated at 65 
o
C. Store at -20 
o
C in 25 mL aliquots. 
HEPES buffer solution - 1 M stock solution (GIBCO). Store at 4 
o
C.  
L- Glutamine - 200 mM stock solution (GIBCO). Store at 4 
o
C. 
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β-mercaptoethanol - 14.3 M stock solution, >99% (SIGMA). Store at 4 oC.  
2 % FBS in Phosphate buffered saline (PBS) - 2 mL heat inactivated foetal bovine serum in 
98 mL 1x PBS.  
Phorbol-Myristate-Acetate (PMA) - 2 mg/mL in dH2O. 
 
2.2 Reagents 
2.2.1 Restriction digestion and electrophoresis 
All enzymes and buffers from New England Biolabs Inc. 
NEBuffer 3 - 100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM Dithiothreitol, pH 
7.9 at 25 °C.  
NEBuffer 4 - 50 mM potassium acetate, 20 mM Tris-acetate, 10 mM Magnesium Acetate, 
1 mM Dithiothreitol, pH 7.9 at 25 °C. 
TAE buffer - 40 mM Tris-acetate, 1 mM EDTA, pH 8.3 (Sigma Aldrich, Australia). 
TSS buffer - 10% w/v PEG 8000, 5% v/v DMSO, 30 mM MgCl2, Luria broth (Bacto 
laboratories Pty Ltd). 
2.2.2 Miscellaneous 
From Sigma Aldrich Australia. 
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Decanal (n-decyl aldehyde) - diluted 1 in 100 in 100 % ethanol. Use immediately. 
Diethylenetriamine nitric oxide (DETANO) – 100 mM stock concentration. 
Dimethyl Sulphoxide (DMSO) - 100%. 
Resazurin - 0.05 % w/v Resazurin in dH2O. Store at 4 
o
C.  
 
2.3 Compounds 
From Sigma Aldrich, unless otherwise stated. 
Isoniazid (INH) – Stored at room temperature in powder form. 
Rifampicin - Stored at room temperature in powder form. 
Pyridoxal Isonicotinic Hydrazone (PIH) derivatives - Provided by Prof. Des Richardson, School of 
Pathology, University of Sydney. Stored at room temperature in powder form. Compound structures 
are shown in chapter 3. PIH and its analogues were synthesized by established procedures by a simple 
1-step synthesis between commercially available aromatic aldehydes and hydrazides (Sigma-Aldrich) 
(Kalinowski et al., 2008). The following PIH analogues were examined in the current study: 2-
pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH); 2-pyridylcarboxaldehyde benzoyl hydrazone 
(PCBH); 2-pyridylcarboxaldehyde 3-bromobenzoyl hydrazone (PC3BBH); 2-pyridylcarboxaldehyde 4-
bromobenzoyl hydrazone (PC4BBH); 2-pyridylcarboxaldehyde p-hydroxybenzoyl hydrazone (PCHH); 
2-pyridylcarboxaldehyde p-aminobenzoyl hydrazone (PCAH); 2-pyridylcarboxaldehyde 2-
thiophenecarboxyl hydrazine (PCTH); 2-pyridylcarboxaldehyde p-nitrobenzoyl hydrazone (PCNH); 
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and 2-pyridylcarboxaldehyde p-trifluoromethylbenzoyl hydrazone (PCTFH). Log Pcalc values of the 
ligands were the average log P values calculated in ChemDraw v4.5 using Crippen’s fragmentation 
(Ghose and Crippen, 1987), Viswanadhan’s fragmentation (Viswanadhan et al., 1989), and Broto’s 
methods (Broto, 1984).  
Methyl Pyridoxal Isonicotinic Hydrazone (MPIH) derivatives - Provided by Prof. Des Richardson, 
School of Pathology, University of Sydney. Stored at room temperature in powder form. The following 
MPIH analogues were examined in the current study: HMPAH, methyl pyrazinylketone p-
aminobenzoyl hydrazone; HMPBH, methyl pyrazinylketone benzoyl hydrazone; HMP3BBH, methyl 
pyrazinylketone m-bromobenzoyl hydrazone; HMP4BBH, methyl pyrazinylketone p-bromobenzoyl 
hydrazone; HMPHH, methyl pyrazinylketonep-hydroxybenzoyl hydrazone; HMPIH, methyl 
pyrazinylketone Isonicotinoyl hydrazone; HMPNH, methyl pyrazinylketone p-nitrobenzoyl hydrazone; 
HMPTH, methyl pyrazinylketone thiophenecarboxyl hydrazone; HMPTFH, methyl pyrazinylketone p-
trifluoromethylbenzoyl hydrazone (Kalinowski et al., 2008). 
Metal-cyclam complex compounds - Provided by Associate Professor Peter Rutledge and Associate 
Professor Matthew Todd from the School of Chemistry, University of Sydney. Some compounds 
previously described in Yu et al (2011), Yu et al (2013a) and Yu et al (2013b). Compound structures 
shown in Appendix 1. 
All above drugs were supplied in powder form. Primary stock solutions were made at the concentration 
of 50 mM or 10 mM in 100% DMSO, depending on the experiment. Typically, secondary stock 
solutions were prepared from the primary stock by diluting the solution 1 in 100 in a separate 1.5 mL 
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eppendorf tube, and 10 L of this solution used for inhibition assays (1 in 1000 of primary stock, 0.1 % 
DMSO). 
Compound Library - 1920 compounds obtained from the Queensland Compound Library. Details of 
the compounds described in Chapter 5 (section 5.2.3). Compounds supplied in 5 µL liquid droplets in 
100% DMSO in 96 well plates. 
 
Methods 
2.4 Mycobacterial culture 
All bacterial experiments were conducted in a PC2 or PC3 laboratory, using Class II cabinets. OGTR 
approval was sought and held for any bacterial strain used in experiments. 
 
2.4.1 Mycobacterium bovis BCG Pasteur and Mycobacterium avium 104 
Stocks of each bacterium stored at -80 
o
C were grown in 25 mL falcon tubes in complete Middlebrook 
7H9 medium. Cultures were incubated rolling at 37 
o
C within a dry incubator, maintaining growth 
through passaging at log phase (OD600 of 0.5-1.0). Cultures in log phase were either used for 
experiments or to make stocks (in 25% glycerol) in 1.5 mL eppendorf tubes and were stored at -80 
o
C 
until needed. Plasmid transformed BCG and M. avium were cultured using the same methodology as 
above, but Middlebrook 7H9 medium or 7H10 solid medium were supplemented with 25 µg/mL 
hygromycin. 
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To enumerate the number of bacteria within the stock solutions or for experimental samples, 1 in 10 
serial dilutions were made and selected dilutions were plated onto 3 replicate Middlebrook 7H10 
quadrant plates. Plates were incubated at 37 
o
C in a CO2 incubator for 3 weeks, and bacterial counts 
determined and expressed as colony forming units per mL of culture (CFU/mL).  
2.4.2 Mycobacterium tuberculosis MT103 
Stocks of M. tuberculosis MT103 (Pérez et al., 2001) stored at -80 
o
C were grown in cell culture flasks 
in complete Middlebrook 7H9 medium. Cultures were incubated at 37 
o
C without agitation in a 5 % 
CO2 incubator, maintaining growth at log phase (OD600 of 0.5-1.0). Cultures in log phase were either 
used for experiments or to make stocks (in 25% glycerol) in 1.5 mL eppendorf tubes and were stored at 
-80 
o
C until needed.  
2.4.3 Pseudomonas aeruginosa  
Stocks stored at -80 
o
C were grown in 15 mL falcon tubes in LB medium. Cultures were incubated at 
37 
o
C in a shaker, until log phase (OD600 of 0.6-1.2) was reached (16-24 hours).  
 
2.5 Construction of M. avium luciferase strain 
2.5.1 Plasmid extraction from mycobacteria 
BCG transformed with plasmid pSMT1 (Figure 2.1- (Snewin et al., 1999)) was grown to log phase 
(OD600 of 0.45-1.0) and the culture pelleted by centrifugation at 6000 g for 3 minutes. The supernatant 
was discarded and the pellet resuspended in 125 µL of solution 1 (Qiagen Plasmid Mini kit, Qiagen 
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Australia) + lysozyme (500 µg/mL), followed by an overnight incubation at 37 
o
C. A further 60 minute 
incubation was conducted at 55 
o
C followed by addition of 125 µL of solution 2. BL buffer was then 
added, mixed by inverting, and allowed to incubate for 1-5 minutes until it became clear. Immediately 
afterwards, NE buffer was added and mixed by inverting 3 times, and the entire suspension was micro-
centrifuged for 10 minutes at 10,000 g. The clear lysate was transferred to a DNA binding column, 
spun at 13,000 rpm for 1 minute and the flow-through discarded. WP buffer was added to the DNA 
binding column and centrifuged again at 10,000 g for 1 minute, and flow-through discarded. An 
additional centrifugation was completed to dry the plasmid, and this was then eluted into an 1.5 mL 
eppendorf tube using 50 µL of triple distilled water by centrifuging for 2 minutes at 10,000 g.  
 
Figure 2.1. Map of the pSMT1 plasmid. The luxAB site encodes the luciferase gene, which is 
controlled by the Hsp60 promoter. BamHI and XbaI restriction sites surrounding the luciferase gene 
can be utilized to verify plasmid integrity. Contains hygromycin resistance gene for selection 
(reproduced from Snewin et al., 1999) 
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2.5.2 Transformation of plasmid into E. coli via heat-shock 
2.5.2.1 Preparation of competent E. coli cells 
Stocks of E. coli DH5 were grown to log phase (OD600 of 0.5-1.0) in LB broth. The cells were 
centrifuged at 6000 g for 10 minutes at 4 
o
C. The supernatant was decanted, and the pellet resuspended 
gently in 5 mL TSS buffer. Ten percent v/v glycerol was added to the suspension, and cells were frozen 
in 100 µL aliquots at -80 
o
C. 
2.5.2.2 Heat-shock 
E. coli competent cells were removed from -80 
o
C storage and thawed slowly on ice. Two µL of the 
extracted pSMTI plasmid and 100 µL of the cell stock were added to a cold eppendorf tube and 
incubated on ice for 30 minutes. The eppendorf tube was then incubated at 42 
o
C for 45 seconds and 
immediately returned to ice with the addition of 400 µL sterile LB broth supplemented with 0.04 % 
glucose. The mixture was shaken for 4 hours at 37 
o
C to facilitate expression of the hygromycin 
resistance gene. Finally, the mixture was plated out onto LB plates supplemented with 50 µg/mL 
hygromycin and incubated overnight at 37 
o
C. 
2.5.2.3 Plasmid extraction from E. coli 
To determine whether the colonies that grew on the LB plates were true transformants, 6 colonies were 
selected from the plate and each single colony was cultured in 10 mL LB medium supplemented with 
hygromycin (100 µg/mL) and incubated overnight at 37 
o
C. The E. coli cells were pelleted for 10 
minutes at 6000 g, the supernatant discarded and the pellet resuspended in 250 µL of RS buffer. 
Plasmid was extracted using a Plasmid Mini kit (Qiagen) according to manufacturer’s instructions and 
Chapter 2: Materials and Methods 
40 | P a g e  
 
DNA was eluted in 50 µL dH2O. Two µL of plasmid was digested with restriction enzymes BamHI and 
XbaI (Figure 2.1) and appropriate buffer (NEBuffer3 and NEBuffer4) for 1 hour at 37
o
C. For 
electrophoresis, a 50 mL 1 % agarose gel in TAE buffer was prepared and 1 mg/L Ethidium bromide 
added. Loading dye was added to the restriction digestion mix, in a 1 in 6 dilution, and loaded into the 
wells of the gel. The gel was run for 1 hour at 100 V, and visualised using a UV transilluminator 
(Novex Australia Pty Ltd).  
2.5.3 Electroporation of plasmid pSMT1 into M. avium competent cells 
2.5.3.1 Preparation of electrocompetant M. avium cells 
Stocks of M. avium 104 strain were grown to log phase (OD600 of 0.5-1.0) in complete Middlebrook 
7H9 broth. The culture was then centrifuged for 5 minutes at 1465 g and the supernatant removed. The 
pellet was resuspended in 30 mL of 10 % (v/v) glycerol and this process was repeated for a total of 
three times. After the final spin, the pellet was resuspended in 1.5 mL of 10 % (v/v) glycerol. One 
hundred and fifty µL volumes of the suspension was aliquoted into eppendorf tubes and stored at -80 
o
C until needed. 
2.5.3.2 Electrotransformation  
Electrocompetent cells of M. avium, taken from -80 
o
C, were thawed slowly on ice. In a cold 1.5 mL 
eppendorf tube, 150 µL of the cell suspension was mixed with 5 µL of plasmid DNA (pSMT1) and this 
mixture was allowed to sit on ice for 1 minute. Concurrently, the Gene pulser apparatus (BioRad) was 
set at 25 µF and 2.5 kV, and the pulse controller was set to 200 Ω. The mixture of cells and DNA was 
transferred to a cold electroporation cuvette and pulsed twice (producing a time constant of 4-5 
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milliseconds each pulse). Immediately after pulsing, 400 µL of Middlebrook 7H9 medium was added 
to the electroporation cuvette, and the total volume was then transferred to a M
c
Cartney bottle 
containing 2 mL 7H9 medium. The culture was then allowed to incubate rolling overnight at 37 
o
C.  
2.5.3.3 Verifying plasmid transformation 
The overnight transformation culture was centrifuged for 5 minutes at 2000 rpm. The pellet was 
resuspended in 500 µL of 7H9 medium and plated onto three 7H10 agar plates supplemented with 25 
µg/mL hygromycin, and incubated for 10 days at 37 
o
C in 5 % CO2. Colonies were then picked and 
cultured in Middlebrook 7H9 complete medium supplemented with 25 µg/mL hygromycin, and 
luminescence was measured after 3 seconds shaking using 1 % Decanal (Sigma Australia) substrate 
and the FLUOstar Omega microplate reader (BMG LABTECH Australia). Cultures showing highest 
luminescent readings were used for subsequent experiments. 
2.6 Resazurin Reduction Assay 
The Alamar blue assay is based on the reduction of the colourmetric reporter resazurin. In the presence 
of viable cells Resazurin undergoes an enzymatic reaction where NADH is reduced to NAD, 
converting the blue Resazurin to a pink coloured derivative, Resorufin (Figure 2.2, (Promega, 2013)). 
This colour change can be read using a microplate reader due to Resorufin emitting fluorescence at 590 
nm after excitation at 544 nm. The advantage of using this technique is that it is fast and simple to use, 
and the presence of live or dead cells can easily be distinguished. 
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Figure 2.2. Alamar blue assay reaction. In the presence of viable cells a reduction reaction converts a 
blue coloured Resazurin, to a pink coloured resorufin which emits fluorescence at 590 nm. This allows 
for both a qualitative and quantitative assessment of cell viability (Promega, 2013). 
2.6.1 Optimisation of screening assays 
2.6.1.1 Starting concentration of bacteria 
384-well microtitre plates were divided into three sections containing bacterial suspensions at an OD600 
0.001, 0.005 or 0.01. In each section for mycobacterial experiments, 5 µL of dH2O or 1 mM rifampicin 
(complete inhibition control) was added to each well, and 45 µL of bacterial suspension was added at 
the appropriate concentrations. For Pseudomonas experiments, 50 µL dH2O was used as the complete 
inhibition control. After a period of incubation (see section 2.6.1.2) 5 µL 0.05 % resazurin was added 
to each well, incubated for 4 hours and fluorescence measured at 590 nm using the FLUOstar Omega 
microplate reader. Bacterial growth inhibition was calculated as the percentage fluorescence relative to 
that of the untreated (complete survival) control. 
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2.6.1.2 Incubation time 
Plates were set up as in 2.6.1.1, and incubated for 4, 5, 6 or 7 days for BCG and M. avium, and 4, 7, 24 
or 48 hours for Pseudomonas. Five µL 0.05 % Resazurin was added to each well, incubated for 4 hours 
and fluorescence measured at 590 nm using the FLUOstar Omega microplate reader. The percentage 
inhibition was calculated as described in 2.6.1.1. Once fluorescence was measured, the ‘z’ factor was 
calculated using the following equation: 
 
 
The ‘z’ factor is an indicator of reproducibility. A value between 1 and -1 is the most accurate (-1 being 
below the limit of detection) and the higher the ‘z’ value the higher the data quality (Zhang et al., 
1999). 
 
2.7 Assays of in vitro growth inhibition 
2.7.1 Screening of compounds 
For initial screening of compounds, 5 µL of individual test and control compounds (5-20 µM final 
concentration) were added to 384 well plates in two replicate plates. Forty-five µL of bacterial 
suspension was added to each well and incubated for 1, 5 or 7 days for Pseudomonas, M. avium, and 
M. tuberculosis/BCG respectively.  Five µL 0.05 % Resazurin was then added, incubated for 4 hours 
and fluorescence was measured at 590 nm. Inhibition was calculated as a percentage of growth relative 
          3SD sample + 3SD control 
          mean sample - mean control 
Z= 1-  
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to an untreated control, and compounds exhibiting a greater than 50% inhibition underwent further 
testing. 
2.7.2 Minimum inhibitory concentration (MIC) calculation 
Using 96-well plates, compounds were serially diluted by 8 or 12 halving concentrations in dH2O in 
triplicate, with an initial concentration of 100 µM, 50 µM or 10 µM depending on the experiment. 
Ninety µL of bacterial suspension at an OD600 of 0.001 was added to the wells, and incubated for 1, 5, 
or 7 days for Pseudomonas, M. avium and BCG/M. tuberculosis respectively. Ten µL 0.05 % 
Resazurin was then added, incubated for 4 hours and fluorescence measured at 590 nm. Bacterial 
survival was determined as percentage fluorescence compared to non-treated controls. Further 
experiments were conducted at varying bacterial concentrations, where bacteria were grown to log 
phase, and diluted into 4 concentrations of OD600 0.001, 0.01, 0.1, and 1.0. Assays were performed as 
described above. 
To determine the synergistic effect of compounds in-combination assays adapted from Lechartier et al, 
(2012) were performed by combining serial dilutions of sub-inhibitory concentrations of test 
compounds and standard compounds (Rifampicin and INH). The compounds were added to a 96-well 
plate in a checkerboard pattern and incubated for five and seven days for M. avium and BCG 
respectively. Ten µL 0.05 % Resazurin was then added, incubated for 4 hours and fluorescence 
measured at 590 nm. Bacterial survival was determined as percentage fluorescence compared to non-
treated controls. 
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2.7.3 Iron bound chelators 
Iron chelators were bound in a 2:1 ratio with FeSO4, serially diluted in halving concentrations, and 90 
µL of bacterial suspension at OD600 of 0.001 was added to each appropriate well. The plate was then 
incubated for 7 days and 5 days for BCG and M. avium respectively, 0.05 % Resazurin added, and 
fluorescence measured after 4 hours as described in 2.6.1. 
2.7.4 Non-replicating system for mycobacteria 
The method used was an adaption of that described by Bryk et al (2008). DETANO, a nitric oxide 
adduct, was used to render the bacteria non-replicating by encouraging anaerobic conditions. To 
determine the optimal DETA-NO concentration, bacteria were grown to log phase, diluted to an OD600 
of 0.1, and added to a 96-well plate. Differing concentrations of DETA-NO ranging from 0-100 µM 
(final concentrations) was added over a period of seven days. Bacteria from each well were serially 
diluted and plated onto 7H11 quad plates at days 0, 1, 4, and 7 post-treatment. Plates were incubated at 
37 
o
C in 5 % CO2 for 3 weeks, and counts determined and expressed as CFU/mL. The concentration 
which resulted in similar bacterial numbers at each timepoint was considered optimal for subsequent 
assays.  
For assessment of inhibitors, compounds at a set concentration (see relevant chapter for concentrations) 
were added to 96-well plates. Bacteria were grown to log phase, diluted to an OD600 of 0.1, and added 
to the wells. To enumerate the number of bacteria, 1 in 10 serial dilutions were made and selected 
dilutions were plated onto Middlebrook 7H10 quadrant plates. Plates were incubated at 37 
o
C in a CO2 
incubator for 3 weeks, and bacterial counts determined and expressed as colony forming units per mL 
of culture (CFU/mL). 
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104 (mL) 101 (dilution factor) = # cells/mL 
Average # cells in 
each quadrant 
2.8 Cell culture 
2.8.1 RAW267.4 cells (macrophage cell line) 
Growing and passaging cells: Cells were taken from stocks in liquid nitrogen and grown to 
approximately 80 % confluence in cell culture flasks with 25-30 mL complete DMEM. To passage the 
cells, medium was replaced with 10 mL PBS. The flask was incubated at 37 
o
C in 5 % CO2 for 5 
minutes and the side of the flask was tapped repeatedly to ensure most cells had detached. The cell 
suspension was transferred to a 50 mL falcon tube, 20 mL complete DMEM added and centrifuged at 
1200 rpm for 5 minutes. The supernatant was removed and the cells were resuspended in 5 mL 
complete DMEM, and half the volume transferred to another culture flask containing 25 mL fresh 
complete DMEM. 
Counting cells: To count the cells, the same procedure was undertaken as in passaging to recover the 
cells, however the cell pellet was resuspended in 10 mL complete DMEM. Ten µL of this suspension 
was added to an 1.5 mL eppendorf tube containing 90 µL trypan blue, and a haemocytometer was used 
to count the cells in the mixture.  
Once counted the following equation was used to calculate the number of cells. 
 
2.8.2 THP1 cells 
THP-1 cells are a human leukemic cell line originally cultured from the blood of a boy with acute 
monocytic leukemia (Tsuchiya et al., 1980). Cells were taken from liquid nitrogen stores and grown to 
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approximately 80 % confluence in cell culture flasks. To passage the cells, the entire volume within the 
flask was transferred to a falcon tube and centrifuged for 5 minutes at 1200 rpm. The supernatant was 
poured off, and the pellet was resuspended in 5 mL complete RPMI. Half this volume was transferred 
to another cell culture flask containing 25 mL complete RPMI. Cell numbers were determined as in 
2.8.1. 
2.8.3 THP1 cells infection 
THP1 cells were grown to 80 % confluence, harvested, resuspended and counted as described in 
section 2.8.2. Cells were then seeded at 1 × 10
5
 cells per well of a 96 well microtitre plate in 100 μL of 
culture medium containing 50 ng/mL phorbol myristate acetate (PMA) and allowed to adhere for 48 
hours under standard cell culture conditions (5% CO2, 37 °C). Cells were then infected for 4 hours 
with 10
6 
BCG (± pSMT1), M. avium (± pSMT1), or M. tuberculosis, prepared in RPMI. The media was 
removed and cells washed 3 times with 2 % FBS in PBS. One hundred and eighty µL of complete 
RPMI was then added to the cells. 
2.8.4 Detection of luminescence for pSMT1 strains of bacteria 
After plating and infecting cells as described in section 2.8.3, various compounds were prepared in 
halving dilutions, with an initial starting concentration of 10 µM. The 96 well plates were then 
incubated for up to 7 days at 37
o
C in 5% CO2. Using the FLUOstar Omega microplate reader an 
injection of Decanal substrate was made into each well separately, and a luminescent reading was taken 
after 7 seconds of shaking. To establish the effect of certain compounds over time, experiments were 
conducted over a 7 day period and readings were taken at various points throughout. Survival was 
calculated as percentage luminescence compared to a non-treated control. 
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2.8.5 Determination of intracellular bacterial survival for M. avium, BCG and M. 
tuberculosis 
After plating and infecting cells as described in 2.8.3, compounds were added to the wells in 10 fold 
dilutions in triplicate, using rifampicin-treated and cell-only suspensions as controls. The 96 well plates 
were incubated for up to 7 days (37 °C, 5% CO2), cells were lysed with dH2O, serially diluted and 
lysates plated onto 7H11 agar plates. Counts were obtained after 3 weeks incubation (37 °C, 5% CO2). 
2.8.6 Assay of cell viability 
RAW264.7 and THP1 cells were grown to 80 % confluence, centrifuged, resuspended and counted as 
described in 2.8.1 and 2.8.2 respectively. Cells were then seeded at 1 × 10
5
 cells per well of a 96 well 
microtitre plate in 100 μL of culture medium and allowed to adhere under standard cell culture 
conditions (5% CO2, 37 °C). Compounds were added to the wells in 3 or 5 fold dilutions, and cells and 
media only were used as controls. The plates were incubated for up to 7 days (37 °C, 5% CO2). 
Resazurin was added at a final concentration of 0.05% (w/v) per well and incubated for 4 h before a 
measurement of fluorescence intensity was determined as described in section 2.6.1. The percentage 
cell viability was calculated in relation to the maximum and minimum measurement of fluorescence 
caused by cells only (100% survival) or medium alone (100% inhibition). 
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2.9 In vivo assessment of compound efficacy 
C57BL/6 mice, 6-8 weeks of age were purchased from the Animal Resources Centre (Perth, Australia) 
and maintained in speciﬁc-pathogen-free Biosafety Level 2 and 3 facilities. All experiments were 
approved by the University of Sydney Animal Ethics Committee.  
For M. avium and BCG infected mice, stocks were diluted to 5 × 10
6
 CFU and 20 µL administered 
intra-nasally for a final concentration of 1 × 10
5
 CFU per mouse. For M. tuberculosis infected mice, a 
Middlebrook inhalation exposure apparatus (Glas-col) was used. Bacterial stocks were diluted to 1 × 
10
6
 CFU/mL in PBS and added to a nebuliser for an infection of 100 bacilli per mouse lung (Pinto et 
al., 2004, Bean et al., 1999).  
At four weeks post-infection, INH (10 mg/kg or 100 mg/kg) or PCIH (10 mg/kg or 100 mg/kg) or 
vehicle only (50 % DMSO in PBS) were administered daily via the intra-peritoneal route for 21 days 
(M. avium, BCG) or 28 days (M. tuberculosis). Harvested lungs and spleen were homogenised in 
dH2O, serially diluted and plated onto 7H11 agar plates. Bacterial counts were obtained after 3-4 weeks 
incubation (5% CO2, 37 °C).  
 
2.10 Statistics 
The significance of differences for linear and log-transformed assays was evaluated by one-way 
ANOVA with pair-wise comparison of multi-grouped data sets achieved using the Bonferroni post hoc 
test. Statistics were calculated using Prism software. 
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The MIC90 was determined by calculating the percentage fluorescence relative to a non-treated control. 
This was then graphed, and the MIC90 was the concentration of compound that resulted in less than 10 
% fluorescence. 
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Chapter 3: Activity of Pyridoxal Isonicotinoyl Hydrazone iron 
chelators against pathogenic mycobacteria 
3.1 INTRODUCTION 
Treatment for tuberculosis consists of a 4-6 drug regime, including rifampicin and isoniazid, that 
requires a minimum six month course (W.H.O, 2012). The increase in prevalence of MDR and XDR 
strains has highlighted the urgent need for new therapies to treat M. tuberculosis infection. 
Furthermore, frontline drugs such as INH are less effective against non-replicating forms of 
mycobacteria, which may limit their efficacy against latent TB (Vilcheze and Jacobs, 2007). Strategies 
to improve TB drug therapy include the modification of existing drugs or the development of novel 
antibiotics and a number of promising candidates have been described (Skripconoka et al., 2012, 
Diacon et al., 2012, Gler et al., 2012). There has also been interest in the implementation of nutrient 
supplementation to control TB, either as a stand-alone therapy or as an adjunct treatment for use with 
current drug regimens (Sinclair et al., 2011, Greenstein et al., 2012). 
Iron is an obligate co-factor for over forty enzymes encoded within the mycobacterial genome and is 
required for the function of many proteins that are involved in processes such as fatty acid biosynthesis, 
amino acid biosynthesis, energy generation and DNA synthesis (Yellaboina et al., 2006). The 
importance of iron for mycobacterial growth suggests a potential role for chelation therapy as a 
treatment option. This therapeutic strategy would prevent iron utilisation by bacteria and have anti-
microbial effects due to the requirement of this nutrient for essential metabolic processes (Kalinowski 
et al., 2007). Indeed, the use of iron chelation as a potential therapy for infectious diseases has been 
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well documented, including the in vitro use of chelators to inhibit viral replication and reverse 
transcriptase activity in HIV treatment (Debebe et al., 2007, Traore and Meyer, 2007, Traore and 
Meyer, 2004). Furthermore, in malarial infection, chelation therapy increased parasite clearance rate 
(Pradines et al., 2002, Walcourt et al., 2004, Hershko, 1994). Use of current iron chelators against 
mycobacteria have shown limited effect against mycobacteria (described in section 1.5). For example, 
the first chelator that was clinically approved for iron overload treatment, desferrioxamine (DFO) 
(Bernhardt, 2007) has been assessed for efficacy against mycobacteria.  Although a low-iron 
environment has been shown to inhibit M. avium growth, DFO was not efficacious in this context, 
possibly due to the lack of effective iron chelation efficiency (Gomes et al., 2001). DFO, as a therapy 
for M. tuberculosis infection, was able to prevent effects of excess iron on growth, however had little 
influence on intracellular survival (Cronje et al., 2005), most likely due to its poor membrane 
permeability (Yu et al., 2006, Bernhardt, 2007). In addition, DFO has short plasma half-life of 
approximately 20 minutes, is orally inactive and expensive to produce (Yu et al., 2006, Bernhardt, 
2007), making it unsuitable to treat intracellular, chronic infections with mycobacteria.  
There has been significant progress in the development of new generations of iron chelators, both for 
use in iron overload disease and for their anti-proliferative activity in the inhibition of tumour growth 
(Yu et al., 2006, Richardson et al., 2009, Yu et al., 2009). Compounds that have been developed for 
such purposes include tridentate ligands such as those of the pyridoxal isonicotinoyl hydrazone (PIH) 
class that possess very high affinity for iron and much lower affinity for other essential metals e.g., 
Zn(II), Mg(II), Ca(II) (Richardson and Ponka, 1998a). Notably, the advantages of PIH (Figure 1A) and 
its analogues include: (1) it can be simply prepared by a 1-step synthesis; (2) the compounds possesses 
high membrane permeability; (3) it can be orally administered (Richardson and Ponka, 1998a); and (4) 
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it is neutral at biological pH (Richardson et al., 1990), allowing for penetration through cell membranes 
to reach intracellular iron stores (Richardson and Ponka, 1998b). Analogues of PIH have been designed 
for the treatment of iron overload disease or cancer (Richardson et al., 1995, Sookvanichsilp et al., 
1991). Some of these ligands have shown marked iron chelation activity in vitro and in vivo (Baker et 
al., 1992, Link et al., 2003), while others have been developed into ligands that demonstrate potent 
anti-proliferative effects with minimal toxicity in vivo (Whitnall et al., 2006, Lovejoy et al., 2012, 
Kovacevic et al., 2011). 
PIH is the result of a simple condensation reaction between pyridoxal and the potent anti-mycobacterial 
agent, INH, in which the latter structure is well conserved (Hermes-Lima et al., 2000, Kang et al., 
2006). Considering the structural identity between PIH and INH, in addition to the ability of PIH to 
bind the essential nutrient iron (Richardson and Ponka, 1998a), in this chapter I examined the ability of 
a range of PIH analogues to inhibit the growth of pathogenic mycobacterial strains.  
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3.2  RESULTS 
3.2.1 In vitro inhibition of mycobacterial growth by tridentate iron chelators  
Initially, a screen was conducted on 10 ligands derived from (and including) the compound, PIH (Table 
3.1), to determine if they could effectively reduce mycobacterial growth in culture. The 9 PIH 
analogues shown in Table 3.1 all demonstrate marked structural similarity, being members of the PCIH 
series of chelators (Kalinowski et al., 2008, Becker and Richardson, 1999). Each of the latter have a 
conserved tridentate iron-binding site (aromatic nitrogen, imine nitrogen and carbonyl oxygen) with 
substitutions distal to the coordination sphere (Kalinowski et al., 2008, Becker and Richardson, 1999). 
This group of analogues constitute a series of compounds that all are effective ligands with varying 
lipophilicity, as reflected by their calculated partition coefficient (log Pcalc; Table 3.1). Examination of 
this series enables an assessment of the structure-activity relationships in terms of the role of 
lipophilicity and chelation efficacy in the anti-bacterial efficacy observed. INH was included as a 
positive control due to its potent anti-mycobacterial activity (Vilcheze and Jacobs, 2007) and similarity 
to the isonicotinoyl hydrazone moiety of PIH (Richardson and Ponka, 1998b).  
BCG was exposed to a single chelator dose of 10 µM for 7 days and survival was determined in 
comparison to vehicle-treated bacterial cells (control). Significantly, INH, PIH and PCIH were able to 
markedly and significantly (p<0.01) restrict the growth of BCG at 10 µM, with the two chelators 
leading to almost complete (PIH) and complete growth inhibition (PCIH) (Table 3.1). Calculation of 
the MIC90 for PCIH (0.39 M) and INH (0.39 M) indicated a similar level of inhibitory activity of the 
two compounds (Figure 3.1A). The analogue PC4BBH showed inhibitory activity that was comparable 
to PIH, but less than INH or PCIH. Despite their very similar structures, the other 7 compounds 
Table 3.1. Structure and activity of PIH derivatives against mycobacteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 Data are mean survival ± SEM of triplicate cultures and represent two independent experiments. 
Differences between non-treated and treated bacteria were determined by ANOVA (*p<0.01) 
Compound Structure Log Pcalc 
BCG Survival at 10 µM 
(% of control)
a
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 N
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H
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3
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screened showed limited efficacy, with PCBH, PCHH, PCAH, and PCNH causing less than a 20% 
reduction in BCG growth at 10 µM in comparison to the control (Table 3.1). Remarkably, the slight 
structural change between PCIH and PCBH due to the alteration of the isonicotinoyl nitrogen to a C-H 
led to an almost total loss of anti-mycobacterial activity. This observation indicated the critical 
importance of this structural feature for efficacy. This dramatic alteration was unanticipated, as the 
replacement of the N with the phenyl C-H increased lipophilicity (log Pcalc increases from 0.96 to 2.21; 
Table 3.1), which could potentially enhance membrane permeability relative to PCIH. Indeed, previous 
studies using a human cell line have demonstrated the increased permeability and iron chelation 
efficacy of PCBH over PCIH (Becker and Richardson, 1999). 
Increasing the lipophilicity of PCBH by the synthesis of PCTH, PC3BBH, PC4BBH, and PCTFH (log 
Pcalc: 2.49, 3.05, 3.05 and 3.14, respectively) significantly (p<0.01) improved the anti-mycobacterial 
efficacy relative to PCBH. However, despite the greater lipophilicity of these analogues than PCBH 
and especially PCIH, the anti-mycobacterial activity was considerably less than PCIH (Table 3.1). 
Moreover, there was little correlation between the log Pcalc of these analogues and efficacy at inhibiting 
bacterial growth (r
2
 = 0.46; data not shown), indicating that lipophilicity did not appear to be the 
primary criterion for efficacy. 
Considering the high activity of PCIH against BCG, this agent was also tested against M. avium to 
determine if it displays broad anti-mycobacterial activity (Fig. 3.1B). Interestingly, PCIH also 
effectively restricted the growth of M. avium in culture, being significantly (p<0.01) more effective 
than INH at concentrations less than 1 µM (namely, 0.31 and 0.63 µM), although the MIC90 of both 
compounds was similar (PCIH: 1.25 µM; INH: 2.5 µM; Figure 3.1B). Therefore, PCIH showed potent 
inhibitory activity against both BCG and M. avium. 
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Figure 3.1. Concentration-dependent inhibition of mycobacterial growth by PCIH. BCG (A) and 
M. avium (B) (OD600nm 0.001) were incubated with varying doses of Isoniazid (INH) (black squares) or 
pyridoxylcarboxaldehyde isonicotinoyl hydrazone (PCIH) (white circles) and after a 7 and 5 day 
incubation, respectively, resazurin (0.05%) was added and fluorescence measured. Graphs represent 
percentage survival of bacteria compared to non-treated cells. Data are mean survival ± SEM of 
triplicate cultures and represent two independent experiments. Differences between INH- and PCIH-
treated bacteria were determined by ANOVA (*p<0.01; **p<0.001).  
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These findings were substantiated through the testing of the individual components. Against both BCG 
(Figure 3.2A) and M. avium (Figure 3.2A) the IH molecule that forms the core structure for INH and 
PCIH showed similar levels of activity to INH. The substitution of N for a C atom in Benzoyl 
hydrazide (BH) had a substantial effect with a complete loss of efficacy against both mycobacterial 
strains. This could explain why PCBH and its more lipophilic derivatives were not as efficacious as 
PCIH. 
 
3.2.2 Activity of PCIH against varying bacterial load 
We next determined if PCIH was able to inhibit growth at varying bacterial concentrations, as this is a 
factor that may influence drug efficacy in a clinical setting. PCIH showed no significant difference in 
effectiveness against BCG relative to INH at the lower starting OD600nm of 0.001, 0.01, 0.1; Figure 
3.3A-C). However, notably, at an OD600nm of 1.0, PCIH was able to significantly (p<0.001) inhibit 
BCG growth compared to INH at 10 µM and 1 µM (Figure 3.3D). Testing the effect of PCIH against 
varying bacterial loads of M. avium (Figure 3.3E-H) resulted in a significantly (p<0.01) greater 
reduction in bacterial survival compared to INH, which was most apparent at lower bacterial loads 
(Figure 3.3E-G) and higher concentrations of the agents when bacterial load was increased (Figure 
3.3). However, none of the compounds showed growth inhibition at an OD600nm of 1.0, indicating a 
higher intrinsic resistance to both PCIH and INH by M. avium (Figure 3.3H). Taken together, these 
results indicate that PCIH can restrict the growth of both BCG and M. avium over the full concentration 
ranges, an important property not shared by INH. 
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Figure 3.2. Establishing drug activity through testing of components against mycobacteria. BCG 
(a) and M. avium (b) were exposed to varying doses of compound and after seven and five day 
incubation respectively, 0.05% resazurin added and fluorescence measured. Survival curve was 
calculated as percentage survival compared to non-treated bacteria. Data is represented as mean 
survival ± SEM of triplicate cultures.  
nb. Isonicotinoyl hydrazide (IH), Benzoyl hydrazide (BH) , Pyridoxyl (PYR) 
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Figure 3.3. Concentration-dependent inhibition of mycobacterial growth by PCIH. BCG (A-D) 
and M. avium (E-H) (OD600nm 0.001, 0.01, 0.1 or 1.0) were incubated with varying doses of INH (black 
squares) or PCIH (white circles) and after a 7 and 5 day incubation, respectively, resazurin (0.05%) 
added and fluorescence measured. Graphs represent percentage survival of bacteria compared to non-
treated cells. Data are mean survival ± SEM of triplicate cultures and represent two independent 
experiments. Differences between INH- and PCIH-treated bacteria were determined by ANOVA 
(*p<0.01; **p<0.001).  
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3.2.3 Iron-dependent activity of PCIH 
Despite PCIH showing effectiveness at restricting mycobacterial growth, it was unknown whether 
PCIH was functioning primarily by iron chelation or by direct antimycobacterial activity due to its 
isonicotinoyl hydrazone substructure (Table 3.1). Notably, PCIH has been demonstrated to be an 
effective tridentate iron chelator (Bernhardt et al., 2001), showing marked activity at mobilizing iron 
from mammalian cells (Becker and Richardson, 1999, Richardson et al., 2001). To test the role of iron 
chelation in its activity, PCIH was pre-complexed in a 2:1 ratio with iron to saturate its iron-binding 
site and thus prevent further iron chelation from cells. BCG was then treated with either the free ligand 
or the iron complex, and the MIC90 was calculated. The iron complex of PCIH resulted in a 2-fold 
change of the MIC90 in these experiments (0.31 to 0.63 μM) relative to PCIH alone (data not shown), 
suggesting that the ability of PCIH to complex iron had some effect on its capacity to restrict BCG 
growth. When screened against M. avium, formation of the PCIH–iron complex affected its 
antimycobacterial activity, resulting in an ∼8-fold increase in MIC90 (1.25 to >10 μM; data not shown). 
This observation indicates that iron chelation may play a limited role in the activity of PCIH against 
mycobacteria. Previous studies have demonstrated that PCIH and its iron complex have similar 
partition coefficients (i.e., log P: 1.98 and 1.89, respectively) (Bernhardt et al., 2007), and this suggests 
that they possess comparable ability to permeate the cell membrane. Thus, it is unlikely that the small 
change in the partition coefficient of PCIH relative to its iron complex would contribute to the increase 
in the MIC90 observed upon complexation. This finding supports the suggestion that iron chelation, 
rather than changes in membrane permeability may play some role in the antimycobacterial activity of 
PCIH. 
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3.2.4 Restriction of bacterial growth by PCIH within host cells  
Considering the efficacy of PCIH in mycobacterial culture, we determined if PCIH could restrict 
mycobacterial growth within host THP-1 cells. Both INH and PCIH resulted in a similar trend of dose-
dependent inhibition of BCG growth by day 7 post-infection of THP-1 cells, as determined by 
examination of luminescence emitted by luciferase-expressing BCG within THP-1 cells (Figure 3.4A). 
PCIH was more effective than INH at inhibiting BCG growth at 0.3, 1, and 10 μM, although this did 
not reach statistical significance (Figure 3.4A). Both INH and PCIH displayed a similar level of 
effectiveness when tested at 3 and 5 days postinfection (data not shown). 
When tested against M. avium–infected THP-1 cells, PCIH exhibited a trend of antimycobacterial 
activity similar to that of INH at high drug concentrations (Figure 3.4B). However, PCIH was 
significantly (P < 0.05) more effective than INH at a concentration of 0.3 μM (Figure 3.4B). The 
inhibitory effect of PCIH was independent of any toxic effect on THP-1 cells, as the compound had no 
significant effect on THP-1 viability, irrespective of the inhibitor concentration tested (Figure 3.4C). 
This result was in good correlation with the low antiproliferative activity of PCIH observed in previous 
studies using human cells in vitro (Becker and Richardson, 1999). 
 
3.2.5 Effect of other iron chelators on mycobacterial growth 
Due to the effectiveness of PCIH in vitro, other classes of chelator were studied to determine if they too 
had a similar efficacy. Methyl pyrazinylketone isonicotinoyl hydrazone (MPIH) and its derivatives, as 
described in Kalinowski et al, (2008) were tested. These compounds are more lipophilic and form iron 
 Figure 3.4. Effect of PCIH on intracellular bacteria and host cell viability. THP-1 cells (5x10
5
) 
cells infected with BCG pSMT1 (A) or M. avium pSMT1 (B) at a MOI of 10:1 or un-infected control 
THP-1 cells (C) were treated with INH or PCIH (0.3-10 µM). Luminescence was measured 7 days 
post-infection and bacterial survival was determined relative to non-treated cells. Viability of THP-1 
cells was determined relative to untreated cells by assessment of resazurin reduction. Black bars 
represent INH-treated bacteria while white bars represent PCIH-treated bacteria. Data are mean 
survival ± SEM of triplicate cultures and represent two independent experiments. Differences between 
INH- and PCIH-treated bacteria/cells were determined by ANOVA (*p<0.05).  
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complexes more readily than PCIH (Kalinowski et al., 2008). The most effective compound was MPIH 
which exhibited an MIC90 of 1.3 µM (Figure 3.5), with the remaining compounds displaying an MIC90 
of 2.5 µM or greater. Figure 3.6 shows a study conducted using other types of aroylhydrazones, 311 
and SIH, using N4mT as a non-chelator control (Richardson et al., 1995).  Similarly to the MPIH 
series, none of the compounds exhibited a similar level of efficacy to PCIH, however SIH did have an 
MIC90 of 2.5 µM against BCG (Figure 3.6A). When tested against M. avium no aroylhydrazones tested 
exhibited bacterial growth inhibition (Figure 3.6B). Due to this fact, none of these compounds were 
tested further. 
 
3.2.6 PCIH effectively restricts mycobacterial growth in vivo 
Having determined that PCIH effectively restricted bacterial growth in vitro, we determined if the 
compound also displayed activity in vivo. Mice were infected with M. avium and treated daily with 100 
mg/kg PCIH or INH for 21 days. Although PCIH did appear to decrease the bacterial load in the lung, 
neither INH or PCIH resulted in a significant decrease in M. avium load compared to the vehicle-only 
treated animals (Figure 3.7). However, in the spleen, PCIH showed an approximate 1.5-log reduction in 
M. avium CFU compared to untreated mice (p<0.05) (Figure 3.7). This was similar to the reduction 
observed with INH treatment. Therefore, PCIH retained its activity in an in vivo model of 
mycobacterial infection. 
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Figure 3.5. Inhibition of mycobacterial growth by modified class of chelators. BCG was exposed to 
varying doses of compound and after seven and five day incubation respectively, 0.05% resazurin 
added and fluorescence measured. Survival curve was calculated as percentage survival compared to 
non-treated bacteria..Data is represented as mean survival ± SEM of triplicate cultures.  
  
0
20
40
60
80
100
120
0.0 0.1 1.0 10.0
Drug concentration (uM)
0
20
40
60
80
100
120
140
0.0 0.1 1.0 10.0
INH 311 SIH N4mT
M
y
c
o
b
a
c
te
ri
a
l 
s
u
rv
iv
a
l 
(%
 o
f 
c
o
n
tr
o
l)
A
B
 
Figure 3.6. Bacterial growth inhibition by high iron affinity chelators. BCG (a) and M. avium (b) 
were exposed to varying doses of compound and after seven and five days of incubation respectively, 
0.05% resazurin added and fluorescence measured. The survival curve was calculated as percentage 
survival compared to non-treated bacteria. Data is represented as mean survival ± SEM of duplicate 
samples, and is representative of two independent experiments.  
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Figure 3.7. In vivo efficacy against mycobacterial infection. C57BL/6 mice (n=5) were infected 
intra-nasally with 1x10
5
 CFU M. avium. After 28 days of infection, mice were treated daily for a 
further 21 days with 100 mg/kg of INH or PCIH. The lung and spleen were harvested and bacterial 
load determined. Vehicle-treated, black bars; INH-treated, grey bars; PCIH-treated, white bars. Data 
are mean bacterial survival ± SEM and represent two independent experiments. Differences between 
INH- and PCIH-infected mice compared to untreated animals were determined by ANOVA (*p<0.05). 
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3.2.7 PCIH displays anti-tuberculosis activity 
As PCIH was able to restrict the growth of both BCG and M. avium, we determined if it also displayed 
activity against M. tuberculosis. Similar to that seen in BCG, PCIH showed the same trend of growth 
inhibition compared to INH when tested against mycobacteria grown in culture medium (Figure 3.8A) 
with an MIC90 of 310 nM and 630 nM for INH and PCIH, respectively. PCIH was able to significantly 
(p<0.05) reduce the number of bacteria recovered from M. tuberculosis-infected THP-1 cells compared 
to untreated cells by more than 3-log units (Figure 3.8B). When PCIH was assessed for potency in M. 
tuberculosis-infected mice, a reduction of CFU was observed in the lung and a significant (p<0.05) 
decrease was found in the spleen compared to control mice (Figure 3.8C-D). Further, treatment with 
PCIH caused a similar level of reduction of bacterial load as that found for INH (Figure 3.8C-D). 
Collectively, these data indicate that PCIH displays broad activity against mycobacterial pathogens.  
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Figure 3.8. Efficacy of PCIH against M. tuberculosis. (A) M. tuberculosis was incubated with 
varying doses of compound and after 7 days, resazurin (0.05%) was added and fluorescence measured. 
Graphs represent percentage survival of bacteria compared to non-treated cells. (B) Compounds (10 
M or 1 M) or vehicle alone control (CON) were added to 1 x 105 THP-1 cells previously infected 
with M. tuberculosis at an MOI of 1:1. Cells were lysed 7 days post-infection and bacterial counts 
obtained. (C-D) C57BL/6 mice were aerosol infected with M. tuberculosis and 28 days post infection 
mice were treated daily for 28 days with 100 mg/kg or 10 mg/kg of INH or PCIH, or treated with 
vehicle control (CON). The lung (C) and spleen (D) were harvested and bacterial load determined. 
Data are mean bacterial load ± SEM and represent two independent experiments. Differences between 
INH- and PCIH-infected groups compared to untreated controls were determined by ANOVA 
(*p<0.05). 
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3.3 DISCUSSION 
Despite the marked increase in drug resistance, no new drug has been added to the standard treatment 
regimen for tuberculosis for over 40 years (Ma et al., 2010). This has created an urgent need for 
effective new agents to be developed. Due to the stringent dependence of mycobacteria on iron 
(Yellaboina et al., 2006), this study assessed the ability of iron chelating agents to inhibit mycobaterial 
growth. Of the 9 PIH analogues tested in this study (Table 3.1), PCIH proved to be the most effective 
ligand at inhibiting mycobacterial growth in both in vitro and in vivo models. Hence, despite previous 
studies showing a limited effect of other types of iron chelators in controlling mycobacterial growth 
(Cronje et al., 2005, Gomes et al., 2001), this study has demonstrated that several PIH analogues are 
highly potent against mycobacteria. 
It has been shown that M. avium is highly dependent on iron, with iron supplementation resulting in a 
12-fold increase in bacterial load in vivo (Dhople et al., 1996). This observation could indicate that a 
relatively small reduction in iron levels may have a greater effect on the growth of M. avium compared 
to BCG, and indeed, such a result was observed in this study. PCIH is known to effectively chelate iron 
levels within cells (Richardson et al., 2001, Becker and Richardson, 1999), while its precursor INH is 
not an effective ligand, lacking the tridentate binding sites necessary for marked iron chelation (Ponka 
et al., 1979). Hence, considering the important role of Fe in a variety of essential metabolic processes, 
including DNA synthesis and energy generation (Anderson et al., 2012), depletion of iron levels by 
PCIH would have a profound impact on mycobacterial growth.  
Notably, PCIH has greater membrane permeability when compared to the “gold standard” chelator in 
clinical use, desferrioxamine (DFO) (Becker and Richardson, 1999, Richardson et al., 2001).  This is 
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due to several factors, including that PCIH is: (1) more lipophilic than DFO: (2) it is predominantly 
neutral at physiological pH; (3) it is less than half the molecular weight of DFO; and (4) it mainly 
forms neutral iron complexes that can diffuse readily from cells (Becker and Richardson, 1999, 
Bernhardt et al., 2001, Richardson et al., 2001). In fact, these characteristics of PCIH could contribute 
to its improved microbiocidal efficacy compared to other iron chelators tested against mycobacteria, 
such as DFO and silybin (Cronje et al., 2005). High membrane permeability would permit greater 
access to intracellular bacteria that reside within phagolysosomes (Ehrt and Schnappinger, 2009), 
thereby reducing the effective dose required for bacterial inhibition within host cells. For example, 
previous studies have demonstrated that while DFO could reduce the overall concentration of iron 
available to bacteria grown in culture, it was unable to reduce intracellular bacterial growth, possibly 
due to the limited ability of DFO to permeate cells (Cronje et al., 2005). This is a problem overcome by 
PCIH, which is known to rapidly permeate cells and organelles to bind iron (Becker and Richardson, 
1999, Richardson et al., 2001), and thus, may be a more viable option as a therapy to treat 
mycobacterial infection. The tridentate nature of PCIH (Richardson et al., 1999) may also be a key 
determinant of its anti-mycobacterial activity, as bidentate iron chelators appear to have limited 
efficacy against mycobacteria. 
The enhanced intracellular activity of PCIH may also be due to its greater lipophilicity compared to the 
parent molecule, PIH, due to the absence of the alcohol side chains present in the former ligand 
(Becker and Richardson, 1999). This further suggests that PCIH may be more effective because it 
possesses an appropriate lipophilicity that can more readily enter both host cells and mycobacteria to 
impart its anti-mycobacterial action. However, an argument relying on merely the greater lipophilicity 
of PCIH as the sole determinant of its efficacy does not explain the total lack of activity that was 
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observed with PCBH. Notably, PCBH only differs very slightly in structure to PCIH and due to the 
slightly greater lipophilicity of PCBH relative to PCIH (Table 3.1), it demonstrates greater activity at 
mobilizing cellular iron from human tumor cells in vitro (Becker and Richardson, 1999). Increasing the 
lipophilicity of PCBH by preparing the analogues, PC3BBH, PC4BBH, PCTH and PCTFH (Table 3.1), 
improved the efficacy of these agents over PCBH, but did not lead to an agent as effective as PCIH 
(Table 3.1). This observation indicated that other factors, in addition to appropriate lipophilicity, played 
a role in the activity observed. 
In the current study, the greatest anti-mycobacterial activity was observed with the chelators, PIH and 
PCIH, both of which have the INH moiety conserved within the ligand. Taking into account the 
pronounced loss of activity observed with PCBH (Table 3.1), it is notable that relative to INH, benzoic 
acid hydrazide (which is the analogous hydrazide used to synthesize PCBH) displays little anti-
mycobacterial activity (Quemard et al., 1991). This was validated by testing the components of PIH 
analogs which showed that benzoic acid hydrazide was unable to restrict mycobacterial growth (Figure 
3.2). Thus, hydrolysis of PCBH intracellularly to its components, namely 2-pyridylcarboxaldehyde (2-
PC) and benzoic acid hydrazide would not be expected to lead to an effective anti-tuberculosis agent. 
Considering this, it can be speculated that the efficacy of PCIH relative to INH could be related to the 
ligand acting not only as an iron-depleting agent that blocks growth, but also a lipophilic vehicle for 
INH transport into cells and the mycobacterium. In this case, hydrolysis of PCIH within the cell or the 
mycobacterium may lead to the generation of its components 2-PC and the potent INH moiety (Figure 
3.9). The later agent would lead to bacteriocidal activity via its well described action on mycobacterial 
wall synthesis (Figure 3.9). Hence, by this mechanism, PCIH acts as a lipophilic vehicle which 
facilitates INH entrance into the cell and bacterium, after which INH is liberated. Subsequently, 
 Figure 3.9. Schematic of the possible mechanisms involved in the anti-mycobacterial activity of 
PCIH. (1) PCIH can enter the cell readily due to it being relatively lipophilic; (2) PCIH can bind 
macrophage iron pools depleting them of iron, and in turn, depriving mycobacteria of iron which is 
essential for growth and replication; (3) PCIH may be hydrolyzed in the macrophage liberating the 
starting materials, 2-pyridylcarboxaldehyde (2-PC) and isonicotinic acid hydrazide (INH); (4) INH can 
then diffuse into the phagolysosome to inhibit the mycobacterium synthetic machinery needed for cell 
wall biosynthesis; (5) PCIH may enter the phagolysosome to deplete iron directly from the 
mycobacterium, leading to its iron deprivation; and (6) PCIH may enter the phagolysosome and/or 
mycobacterium itself, and then be hydrolyzed to 2-PC and INH and subsequently the INH then inhibits 
mycobacterial cell wall synthesis. Notably, the phagolysosome is acidic which could favor hydrolysis 
of PCIH. All, or some of these mechanisms may be occurring simultaneously, to effectively prevent 
mycobacterial growth (see text for further details). 
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through well described classical mechanisms, in the presence of the product of the katG gene (Kang et 
al., 2006), INH is activated leading to the inhibition of mycolic acid biosynthesis (Vilcheze and Jacobs, 
2007). Hydrolysis of PIH and its analogues via an acid-catalysed reaction is well described (Richardson 
et al., 1989). Furthermore, it is notable that conditions in the phagolysosome where mycobacteria reside 
are acidic (Geisow et al., 1981) and could facilitate this process (Figure 3.9). 
Examination of the intracellular localisation of effective hexadentate iron chelators (rhodamine B-
conjugated, tripodal 3-hydroxy-4-pyridinone molecules) showed that differential distribution of 
compounds may account for differences in the activity (Nunes et al., 2010). These chelators displayed 
moderate intracellular anti-mycobacterial activity and this may be due to their inability to enter 
compartments within host cells that contain bacteria (Fernandes et al., 2010). Similar factors could also 
be responsible, in part, for the varying activity of the analogues described in the current study. Indeed, 
the fact that lipophilicity was at least one criterion for activity, particularly considering PCBH and its 
more lipophilic derivatives PC3BBH, PC4BBH, PCTH and PCTFH, indicates that cellular 
compartmentalisation may be important to consider. 
Administration of PCIH to mice resulted in a significant reduction in M. tuberculosis growth compared 
to that of untreated controls both in host cells and within mouse spleens (Figure 3.8). While the 
reduction in lung bacterial growth was not significant in this series of experiments for either INH or 
PCIH, there was an approximate a 1-log reduction in CFU numbers compared to control (Figure 3.8). 
A similar result was seen with M. avium, with INH and PCIH displaying the greatest activity in 
bacterial clearance in the spleen (Figure 3.7). This may be due to the relatively short treatment time 
used in our model (21 days) and the difficulty in treating established M. tuberculosis infection in the 
lungs of infected mice. Notably, the changes in bacterial growth observed are similar to that found with 
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other candidate drugs tested against these bacteria (Kanyok et al., 1994). However, other studies have 
shown a more significant lung CFU reduction by INH when administered at similar doses to that 
utilized in the current study (Almeida et al., 2009, Nikonenko et al., 2004). One possible explanation 
may be the extended infection time before treatment used in our study (28 days) compared to that of 
previous studies (14 days) (Fernandes et al., 2010). It is possible that after only 14 days of infection 
bacteria are in a more ‘active’ state, and thus more susceptible to the action of INH (Vilcheze and 
Jacobs, 2007).  
In summary, this chapter demonstrated that PCIH displays potent activity against a range of 
mycobacterial strains, in both in vitro and in vivo models. The pronounced efficacy of PCIH is 
mediated by a novel mechanism involving iron chelation. Moreover, structure-activity relationship 
studies suggest PCIH acts as a lipophilic vehicle for the transport of the intact INH moiety into cells 
and the mycobacterium. These data indicate PCIH should be further evaluated for its potential use to 
control mycobacterial infection in humans. 
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Chapter 4: Novel Metal-Cyclam complexes as a treatment option 
for mycobacterial infection 
4.1     INTRODUCTION 
Drug resistance is an increasing burden for mankind globally. Tuberculosis in particular has shown a 
gradual rise in drug resistance resulting in 3.7 per cent of new cases each year being MDR; of these 
approximately 3 % are classified as XDR (W.H.O, 2012). Despite this, the only drug that has been 
approved for tuberculosis treatment within the last 40 years is Bedaquiline, and even this drug has 
serious safety concerns (Goldenberg, 2013). Therefore there is an urgent need to discover new drugs 
that improve treatment of drug-resistant M. tuberculosis. 
Identifying novel drug scaffolds is a major strategy to develop new antibacterial agents. Poor outcomes 
relating to library screens have been linked to the lack of chemical diversity within these collections 
(Koul et al., 2011). This lack of diversity is in some cases a result of the inclusion of compounds that 
follow the “rule-of-five” (Lipinski, 2004, Koul et al., 2011). This rule suggests that the most 
appropriate antibiotics follow a commonality in structure leading to properties important for a useful 
antibiotic to be created; generally small and lipophilic molecules (Lipinski, 2004). However, an issue 
with this rule is it does not predict if a drug is pharmacologically active, and the bias towards this 
structural formulation restricts the potential scope of chemical structures that are tested for drug 
discovery. Further, most antibiotics do not conform to Lipinski’s rule-of-five (Payne et al., 2007) 
suggesting a broader approach must be taken to identify novel antibacterials.  
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Metal cyclam complexes (MCyCs) are in a new chemical class that has been created on the basis that it 
can potentially function as a target activated compound (Yu et al., 2013b). The premise is that when the 
appended ligand and its biological target meet, it exposes the metal binding site resulting in metal-
catalysed antibiotic activity. Some of these molecules have also shown applications as fluorescent 
sensors to visualise protein binding interactions (Yu et al., 2013b).  Interestingly, MCyCs have been 
developed that are hypothesised to target matrix metalloproteinases (MMPs), zinc-dependant proteases 
that are involved in the regulation of proteolytic activity (Parks and Shapiro, 2001, Yu et al., 2013a). 
MMPs have been shown to be upregulated during TB infection and are involved in destruction of the 
lung matrix (Elkington et al., 2011a). It is this destruction that contributes to the characteristic lung 
lesions seen during infection, as well as the resulting morbidity and mortality (Elkington et al., 2011b, 
Hrabec et al., 2002).  
In this study a panel of MCyCs were tested for their efficacy against various bacterial strains as well as 
their toxicity against host cells. Based on these results, the most effective were studied further to 
determine if they were appropriate for potential use as antibiotics in humans, particularly for the 
treatment of tuberculosis. It was hypothesised that these novel structures would restrict bacterial, and in 
particular mycobacterial growth, without impacting host cell viability. 
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4.2 RESULTS 
4.2.1 Screening of Metal-Cylcam Complexes to determine effectiveness against 
pathogenic bacteria 
To explore the biomedical potential of MCyCs, the activity of 63 compounds against medically-
relevant bacteria was examined. The structures of all compounds are shown in Appendix 1. To do this, 
compounds were tested against three major pathogens; Pseudomonas aeruginosa (gram-negative); 
methicillin-resistant Staphylococcus aureus (MRSA, gram-positive) and mycobacteria. Bacteria were 
treated with a single 50 µM dose of each compound and left for their respective incubation times (see 
Chapter 2). A compound was considered a ‘hit’ if the same compound on two replicate plates caused 
more than 50 per cent bacterial growth inhibition. On comparison of both replicate plates, MRSA had 7 
hits (Fig. 1A), P. aeruginosa CJ2009 had 1 (Figure 4.1B) and P. aeruginosa Bb2009 had 6 hits (Figure 
4.1C). Against M. avium 12 hits appeared in the screen (Figure 4.2A) and 6 against BCG (Figure 4.2B).  
Despite multiple compounds in each of the screens appearing as potential candidates for further study, 
the majority did not have relevant hits on their replicate plate. 
 
4.2.2 Determining cytotoxicity of Metal-Cylcam Complexes 
Before selecting compounds for further testing, the toxicity of compounds against host cells was 
determined. Differentiated THP1 macrophage-like cells  (Tsuchiya et al., 1980) were treated with 3 
doses of compound (50 µM, 5 µM and 0.5 µM) and cell viability measured over 7 days. Only 2 
compounds had an effect on cell viability, compounds C55 and C59 at 50 M, however for all other 
  
Figure 4.1. Screening of compounds. 63 compounds were added to replicate 96-well plates at a 
starting concentration of 50µM. Bacterial strains MRSA (A), CJ2009 (B) and Bb2009 (C) were 
added at an OD600 0.001 and incubated for 24 hours. 0.05% Resazurin was added to each well and 
fluorescence measured. Percentage survival was calculated as percentage growth compared to an 
untreated control. A successful “hit” was when both replicate plates showed more than 50% 
restriction of growth by a single compound (red line). Graphs are representative of 1 replicate plate. 
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Figure 4.2. Screening of compounds against mycobacteria. 63 compounds were added to 
replicate 96-well plates at a starting concentration of 50µM. Bacterial strains M.avium (A) and BCG 
(B) were added at an OD600 0.001 and incubated for 5 and 7 days respectively. 0.05% Resazurin 
was added to each well and fluorescence measured. Percentage survival was calculated as 
percentage growth compared to an untreated control. A successful “hit” was when both replicate 
plates showed more than 50% restriction of growth by a single compound (red line). Graphs are 
representative of 1 replicate plate. 
 
-20
0
20
40
60
80
100
120
0
20
40
60
80
100
120
0 2 4 6 8
Compounds
P
e
rc
e
n
ta
g
e
 b
a
c
te
ri
a
l 
s
u
rv
iv
a
l
A
B
Chapter 4: MCyC results 
69 | P a g e  
 
compounds toxicity was not observed (Figure 4.3). C55 and C59 were non-toxic at lower tested 
concentrations (data not shown). All MCyCs that displayed anti-mycobacterial activity did not exhibit 
toxicity when tested in the mammalian THP-1 cell line, suggesting they were candidates for further 
analysis.  
 
4.2.3 Determining the MIC90 of Metal-Cyclam Complexes 
From the screens conducted, 18 compounds were selected for further testing (greater than 50% 
bacterial growth inhibition in any strain and no cellular toxicity). Bacteria were treated with varying 
doses of compound and the MIC90 calculated as the concentration that inhibited more than 90% 
bacterial growth relative to an untreated control. The majority of compounds tested against CJ2009, 
Bb2009 and MRSA were ineffective at the highest concentration measured (50 µM) (Table 4.1). 
Exceptions included C47 and C48 against CJ2009 and C48 and C53 against MRSA, which all had an 
MIC90 of 50 µM. The results for Bb2009 were expected as none of the compounds displayed complete 
inhibition when tested at 50 M in the initial screen (Figure 4.1C). Further testing on Pseudomonas 
strains was discontinued due to the lack of significant activity observed upon MIC90 calculation. 
The greatest level of anti-bacterial activity was observed against the mycobacteria. Of the 18 
compounds tested, 9 had an MIC90 of 25 µM or less, 6 of which had an MIC90 of less than 10 µM 
(Table 4.1). Compounds C47, C48 and C53 were the most effective at restricting bacterial growth with 
an MIC90 of 1.25 µM against BCG and 1.56-3.13 µM against M. avium (Table 4.1). Compounds were 
also tested against mycobacteria with an OD600 1 to represent a high bacterial load. Bacteria were 
treated with compound at a concentration of 10 µM and growth inhibition measured. Compared to the 
  
 
 
 
 
 
 
Figure 4.3. Cell viability in human cell line. 1x10
5 
THP1 cells were seeded into 96-well plates 
and allowed to adhere for 48 hours. Compounds were added at 50 µM in triplicate and incubated in 
CO2 for 7 days. 0.05% Resazurin was added to each well and fluorescence measured. Cell viability 
was calculated as percentage survival compared to an untreated control. 
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Table 4.1. MIC90 of selected Metal-Cyclam complexes
a
 
 
Drug CJ2009 Bb2009 MRSA BCG M. avium 
1 >50 µM >50 µM >50 µM >50 µM >50 µM 
3 >50 µM >50 µM >50 µM >50 µM >50 µM 
13 >50 µM >50 µM >50 µM >50 µM >50 µM 
14 >50 µM >50 µM >50 µM >50 µM >50 µM 
15 >50 µM >50 µM >50 µM >50 µM >50 µM 
24 >50 µM >50 µM >50 µM >50 µM >50 µM 
25 >50 µM >50 µM >50 µM >50 µM >50 µM 
31 >50 µM >50 µM >50 µM 12.5 µM 12.5 µM 
35 >50 µM >50 µM >50 µM 25 µM 12.5 µM 
38 >50 µM >50 µM >50 µM >50 µM >50 µM 
40 >50 µM >50 µM >50 µM >50 µM 12.5 µM 
44 >50 µM >50 µM >50 µM 6.25 µM 6.25 µM 
45 >50 µM >50 µM >50 µM 3.13 µM 3.13 µM 
46 >50 µM >50 µM >50 µM 3.13 µM 6.25 µM 
47 50 µM >50 µM >50 µM 1.25 µM 3.13 µM 
48 50 µM >50 µM 50 µM 1.25 µM 1.56 µM 
49 >50 µM >50 µM >50 µM 25 µM 25 µM 
53 >50 µM >50 µM 50 µM 1.25 µM 3.13 µM 
 
a 
Data is representative of at least two independent experiments. 
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lower bacterial concentration used for the initial screening (OD600 0.001) the majority of the 
compounds had a markedly reduced efficacy, exhibiting less than 40% growth inhibition at 10 µM 
(Figure 4.4). C48 and C53 however retained some efficacy with 60% and 50% growth inhibition 
respectively against BCG (Figure 4.4A) and more than 90% inhibition was calculated for C48 against 
M. avium (Figure 4.4B).  
The three most effective compounds against BCG (compounds C47, C48 and C53) were tested in vitro 
against an attenuated (H37Ra) and pathogenic clinical (MT103) strain of M. tuberculosis (Pérez et al., 
2001). The efficacy of the compounds against H37Ra was similar to that seen against BCG, with only a 
slight decrease in activity for C47 to an MIC90 of 2.5 M (Table 4.2). There was a 4-fold decrease in 
activity for all compounds against MT103, however results against this strain were variable (Table 4.2). 
Therefore the MCyCs appeared to display similar activity against a range of pathogenic mycobacteria. 
 
4.2.4 Activity of Metal-Cyclam Complexes against intracellular mycobacteria. 
As mycobacteria are intracellular pathogens, and effective drugs should readily enter host cells, it was 
necessary to study the effect of the compounds against bacteria within cells. THP1 cells were infected 
with either BCG or M. avium and treated with a 10 µM dose of 9 effective compounds (MCyCs with an 
MIC90 against BCG and M. avium of 25 µM or less). Against BCG (Figure 4.5A) only C48 showed a 
significant reduction in bacterial survival compared to the untreated control (approximately one log 
reduction), while all other compounds only marginally reduced bacterial loads. M. avium treatment 
resulted in all compounds significantly reducing bacterial load within THP-1 cells, the most effective 
  
 
 
 
 
Figure 4.4. Effect of compounds against high bacterial load. Compounds were diluted to 10µM 
and added to a bacterial suspension of BCG (A) or M. avium (B) at OD600 1. After a seven day 
incubation 0.05% Resazurin was added to each well and fluorescence measured. Data represented 
as mean survival ± SEM of triplicate samples, and is representative of two independent 
experiments.  
  
0 
20 
40 
60 
80 
100 
120 
1 3 13 14 15 24 25 31 35 38 40 44 45 46 47 48 49 53 
0 
20 
40 
60 
80 
100 
120 
1 3 13 14 15 24 25 31 35 38 40 44 45 46 47 48 49 53 
Compound 
P
e
rc
e
n
ta
g
e
 b
a
c
te
ri
a
l 
s
u
rv
iv
a
l 
A 
 
 
 
 
 
B 
  
 
 
 
 
Table 4.2. Comparison of MIC90 values between different strains of M. tuberculosis
a
  
 
Drug BCG H37Ra MT103 
INH 0.3 µM 0.3 µM 0.3 µM 
47 1.25 µM 2.5 µM 5-10 µM 
48 1.25 µM 1.25 µM 2.5-5 µM 
53 1.25 µM 1.25 µM 2.5-5 µM 
 
a 
Data is representative of at least two independent experiments. 
  
  
 
 
 
Figure 4.5. Efficacy of compounds in macrophages. THP1 cells were seeded at 5x10
5 
cells/mL 
into a 96 well plate and left to adhere for 48 hours. Cells were then infected with 1x10
6
 CFU/well of 
BCG (A) and M. avium (B). Compounds were added 4 hours post-infection at a concentration of 10 
µM in triplicate and incubated for up to 7 days. Cells were then lysed, serially diluted and plated out 
onto 7H11 agar plates to obtain bacterial counts. Differences between untreated and compound 
treated bacterial cells were determined by ANOVA (*=p<0.05) 
  
Chapter 4: MCyC results 
71 | P a g e  
 
being C47, C48, and C53 (Figure 4.5B. Importantly, C48 resulted in a 3 log decrease in M. avium 
numbers, which was similar to that observed with rifampicin tested at the same concentration. 
 
4.2.5 Synergistic effect of Metal-Cylcam Complexes with currently approved 
antimycobacterials. 
Treatment for tuberculosis, both susceptible and multi-drug resistant, requires a cocktail of antibiotics. 
Therefore it is necessary to study the effect of any potential compound in combination with other drugs 
from the regimen, both to test for any drug-drug interactions, but also to see if the compounds work 
together synergistically. By collating all the data from the previous experiments, it was determined that 
C47, C48, and C53 were the most effective so were selected for this study. By using a checkerboard 
set up (Lechartier et al., 2012) BCG and M. avium were treated with varying doses of selected 
compounds and either INH or rifampicin, and levels of inhibition measured using the Alamar blue 
assay.  
In combination with INH, C47 and C53 appeared to improve efficacy relative to each compound alone 
against BCG (Figure 4.6a). C47 combined with INH was the most effective combination restricting 
BCG growth by 50 per cent at concentrations of 0.12 µM and 0.3 µM respectively. Both compounds at 
these concentrations independently were unable to restrict growth (Figure 4.6a). No effect was seen in 
M. avium treatment (Figure 4.7a). 
When combined with rifampicin, C47 was the only compound that showed an improved effect against 
BCG (Figure 4.6b). In particular, combining 0.01 µM Rifampicin with 0.12 µM C47 saw the greatest 
 Compound 47 
INH 0 3 0.6 0.12 
0 102.1312 0.039663 101.4093 109.8654 
0.3 108.7311 11.89878 99.14064 53.14789 
0.06 125.0245 0.864645 120.8995 118.9402 
0.012 104.8124 22.52043 120.1777 117.5996 
 
Compound 48 
INH 0 2 0.4 0.08 
0 87.38465 0.967768 107.5967 110.0717 
0.3 83.67223 9.217589 110.5873 115.0216 
0.06 97.28443 33.65769 107.6998 116.0528 
0.012 85.73468 0.967768 120.2808 104.0905 
 
Compound 53 
INH 0 3 0.6 0.12 
0 94.19075 6.536397 120.2808 115.7434 
0.3 75.21616 22.62355 116.7746 118.1152 
0.06 86.14717 4.061451 75.73178 126.2619 
0.012 84.08472 1.380259 113.681 100.8937 
 
 
 
 
Figure 4.6a. Exposure of BCG to compounds in combination with INH. Bacteria (OD600 0.001) 
were treated with compounds serially diluted in a checkerboard layout and incubated for 7 days. 
Resazurin (0.05%) was added and fluorescence measured. Compounds in combination were 
compared to individual treatment results. Effective combinations are also shown in graphical form. 
Results are representative of replicate plates.   
0 
20 
40 
60 
80 
100 
INH 0.012 C53 3 Combination P
e
rc
e
n
ta
g
e
 s
u
rv
iv
a
l 
Compound (µM) 
0 
20 
40 
60 
80 
100 
120 
INH 0.3 C47 0.12 Combination P
e
rc
e
n
ta
g
e
 s
u
rv
iv
a
l 
Compound (µM) 
Compound 47 
RIF 0 3 0.6 0.12 
0 110.2779 22.21106 122.0339 109.1436 
0.05 0.555276 -0.16658 0.761522 0.142785 
0.01 118.2184 0.452154 126.3651 16.64243 
0.002 113.8872 1.483381 94.60324 116.5684 
 
Compound 48 
RIF 0 2 0.4 0.08 
0 95.53135 -1.19781 108.7311 93.46889 
0.05 -0.78532 -0.99157 1.277136 -1.50718 
0.01 20.97358 -0.26971 45.20744 15.81745 
0.002 118.4246 -0.78532 120.3839 129.4587 
 
Compound 53 
RIF 0 3 0.6 0.12 
0 110.4841 -0.06346 122.7558 118.2184 
0.05 0.142785 -0.16658 2.617732 0.142785 
0.01 131.6243 1.380259 130.3868 143.7928 
0.002 108.6279 -0.57907 104.0905 83.25974 
 
 
Figure 4.6b. Exposure of BCG to compounds in combination with Rifampicin. Bacteria (OD600 
0.001) were treated with compounds serially diluted in a checkerboard layout and incubated for 7 
days. Resazurin (0.05%) was added and fluorescence measured. Compounds in combination were 
compared to individual treatment results. Effective combinations are also shown in graphical form. 
Results are representative of replicate plates.   
0 
20 
40 
60 
80 
100 
120 
RIF 0.01 C47 3 Combination P
e
rc
e
n
ta
g
e
 s
u
rv
iv
a
l 
Compound (µM) 
0 
20 
40 
60 
80 
100 
120 
RIF 0.002 C47 3 Combination P
e
rc
e
n
ta
g
e
 s
u
rv
iv
a
l 
Compound (µM) 
0 
20 
40 
60 
80 
100 
120 
RIF 0.01 C47 0.12 Combination P
e
rc
e
n
ta
g
e
 s
u
rv
iv
a
l 
Compound (µM) 
Chapter 4: MCyC results 
72 | P a g e  
 
effect with less than 20% bacterial survival, which compares to each independent compound showing 
no growth restriction (Figure 4.6b). Treatment of M. avium with all combinations of compound and 
rifampicin showed some level of synergy (Figure 4.7b-c). The highest concentration of C48 (2 µM) 
tested in combination resulted in an improvement in growth inhibition for all concentrations of 
rifampicin relative to individual levels (Figure 4.7b). C53 and rifampicin was the most effective 
combination against M. avium resulting in 6 concentration combinations that showed an improvement 
in efficacy compared to their individual counterparts (Figure 4.7c). Of particular promise was that of 
the two lowest concentrations tested (0.006 µM Rifampicin and 0.12 µM 48) in combination which 
resulted in less than 20% bacterial growth. Therefore these two compounds appear to work 
synergistically at low concentrations which is good evidence to support the use of this compound in 
further studies and potentially beneficial to future patients if lower concentrations are required. 
 
4.2.6 Effect of Metal-Cylcam Complexes against non-replicating mycobacteria 
Over a third of the world’s population is latently infected with M. tuberculosis. Current chemotherapies 
are able to efficiently treat active infection with drug-susceptible strains, however a major limitation is 
the inability of current treatments to kill bacteria in a persistent state (Fattorini et al., 2013). Therefore 
this section of the chapter examined the ability of selected MCyCs to restrict the growth of bacteria in a 
non-replicating state.  
The model used in this study was one adapted from Byrk et al, (2008) which forced the bacteria into a 
non-replicating state of growth. DETANO, a nitric oxide adduct, was added to render the bacteria non-
  
 
 
 
 
Compound 47 
INH 0 3 0.6 0.12 
0 121.624 -2.40071 128.5084 123.5305 
10 111.0327 5.860547 137.6169 126.9197 
2 119.188 5.754634 139.5234 129.4616 
0.4 109.8676 2.894969 138.2524 122.1536 
 
Compound 48 
INH 0 2 0.4 0.08 
0 93.45102 -3.8835 109.5499 101.5004 
10 112.3036 5.436893 105.8429 107.4316 
2 108.7026 8.932039 113.4687 121.7299 
0.4 88.89673 20.15887 121.5181 116.8579 
 
Compound 53 
INH 0 3 0.6 0.12 
0 117.917 0.141218 137.1933 114.7396 
10 109.338 9.143866 134.8632 91.7564 
2 108.173 3.318623 139.0997 97.05207 
0.4 95.6752 9.56752 164.9426 85.61342 
 
 
Figure 4.7a. Exposure of M. avium to compounds in combination with INH. Bacteria (OD600 
0.001) were treated with compounds serially diluted in a checkerboard layout and incubated for 5 
days. Resazurin (0.05%) was added and fluorescence measured. Compounds in combination were 
compared to individual treatment results. Results are representative of replicate plates. 
  
 Compound 47 
RIF 0 3 0.6 0.12 
0 66.86673 -3.1421 83.9188 102.6655 
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0.03 111.88 4.801412 110.3972 123.7423 
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Compound 48 
RIF 0 2 0.4 0.08 
0 73.11562 18.46425 124.8014 125.4369 
0.15 68.03177 10.62665 83.49515 61.88879 
0.03 78.4113 8.508385 110.3972 119.7176 
0.006 96.31068 2.789056 112.4095 103.9365 
 
 
 
  
 
Figure 4.7b. Exposure of M. avium to compounds in combination with Rifampicin.  Bacteria 
(OD600 0.001) were treated with compounds serially diluted in a checkerboard layout and incubated 
for 5 days. Resazurin (0.05%) was added and fluorescence measured. Compounds in combination 
were compared to individual treatment results. Effective combinations are also shown in graphical 
form. Results are representative of replicate plates.   
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Figure 4.7c. Exposure of M. avium to compound 53 in combination with Rifampicin. Bacteria 
(OD600 0.001) were treated with compounds serially diluted in a checkerboard layout and incubated 
for 5 days. Resazurin (0.05%) was added and fluorescence measured. Compounds in combination 
were compared to individual treatment results. Effective combinations are also shown in graphical 
form. Results are representative of replicate plates.   
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replicating by encouraging anaerobic conditions. If added to a bacterial population every 24 hours, the 
bacteria remained in a persistent state of growth (Byrk et al, (2008)). 
To determine the optimal conditions for the assay, BCG was treated with varying doses of DETANO 
(0-100 µM) and bacterial CFU were enumerated after 7 days. The three highest concentrations (25 µM, 
50 µM and 100 µM) all caused a reduction in bacterial CFU of more than one log by day 7 (Figure 
4.8A). Non-replicating conditions however was observed when using 10 µM DETANO, and this 
concentration was used in subsequent experiments. In order to simplify the assay, a 5-day timepoint 
was also examined using a DETANO concentration of 10 µM. As seen in Figure 4.8B, over the 5 day 
time period the bacteria were in a non-replicating state of growth and displayed an approximate 2 log 
difference compared with the non-treated control. This was similar to that seen with the day 7 
timepoint (Figure 4.8A) and thus was considered suitable for the subsequent studies. 
To assess killing in this model, 10 µM INH was used as a ‘non-killing’ control as it does not kill 
bacteria that are not actively replicating (Wang et al., 1998), and 10 µM rifampicin was used as the 
‘killing’ control, as it can kill bacteria in a non-replicating state (Figueiredo et al., 2009). Results for 
the rifampicin and INH were as expected against BCG (Figure 4.9A) and M. avium (Figure 4.9B). INH 
did not show any growth inhibition in this model of persistence over the five days (Figure 4.9), whilst 
rifampicin decreased bacterial growth by 5.5 and 3 logs for BCG (Figure 4.9A) and M. avium (Figure 
4.9B) respectively.  
The only MCyC tested in this study was C48. This was due to the fact that it was the most efficacious 
as a single agent of all compounds from previous experiments. In this model C48 was shown to reduce 
bacterial growth of BCG by approximately 3.5 logs after 5 days (Figure 4.9A) and resulted in 0.5 log 
  
  
 
 
Figure 4.8. Optimisation of dosage and incubation time for a non-replicating model of 
infection. (A) BCG (OD600 0.01) was treated with varying doses of DETANO (0-100 µM) every 24 
hours and incubated for 7 days. Bacterial colonies were enumerated over the 7 day timepoint and 
persistence determined as the concentration that neither reduced bacterial concentrations nor 
allowed replication. (B) Experimentation was repeated using 10 µM DETANO over a 5 day 
timepoint and bacterial colonies enumerated over the time period. All results are CFU/mL ± SEM. 
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Figure 4.9. Testing compound 48 in a non-replicating model. DETANO treated (10 µM) BCG 
(A) and M. avium (B) (OD600 0.01) was incubated with 10 µM Rifampicin, INH or 48 for 5 days. 
Bacterial culture was plated out and colonies enumerated to determine absolute bacterial numbers. 
The compound was effective if bacterial growth was less than the starting concentration. All results 
are CFU/mL ± SEM.  
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reduction in M. avium (Figure 4.9B)  However, DETANO-treated controls for both strains did not enter 
a non-replicating state, exhibiting a similar pattern of growth to the non-treated bacterial cultures. This 
was observed after repeated testing. This meant that any effect seen by the MCyCs tested was most 
likely due to activity against dividing cells, indicating this assay was unreliable using these strains. 
In order to examine the influence of compounds in a more reliable model of non-replicating 
persistence, M. tuberculosis H37Ra was treated with 50 µM DETANO as done in other studies 
(Hussain et al., 2009, Voskuil et al., 2003) and validated in our laboratory (D. Quan, unpublished 
observations). A 10 µM dose of each compound was administered and bacterial counts obtained after a 
five day incubation. When comparing day 0 counts with those obtained on day 4 both via absorbance 
(Figure 4.10A) and bacterial counts (Figure 4.10B), the DETANO treated control were in a non-
replicating state with a consistent absorbance (Figure 4.10A) and significantly less bacterial growth 
compared to the untreated control (Figure 4.10B). As shown previously (Bryk et al., 2008) rifampicin 
was effective at reducing bacterial numbers in this model, while INH-treated bacteria did not result in a 
significant decrease in CFU over the 4-day period (Figure 4.10B). C48 showed little effect on 
persistent cells and displayed a similar pattern of growth restriction to INH. The 1-log reduction by 
both INH and C48 could be attributed to their killing of actively replicating bacteria that may still be 
present in the assay. None-the-less, these results indicate that C48 did not appear to be active against 
non-replicating M. tuberculosis.  
 
 
 
  
 
  
 
Figure 4.10. Effect of compound 48 against non-replicating bacteria. DETANO treated (50 µM) 
H37Ra (OD600 0.01) was incubated with 10 µM Rifampicin, INH or 48 for 5 days. (A) Absorbance 
was measured before and after treatment to determine changes in bacteria growth over time. (B) 
Bacterial culture was plated out and colonies enumerated to determine absolute bacterial numbers. 
The compound was effective if bacterial growth was less than the starting concentration. Difference 
between DETANO treated and untreated cells determine by ANOVA (*=p<0.05). All results are 
CFU/mL ± SEM. 
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4.3 DISCUSSION 
In this chapter a library of cyclam-containing compounds were tested for antibacterial activity 
(Appendix 1). This compound library was composed of metal-cyclam complexes (Yu et al., 2013b), 
cyclam-peptide, cyclam-amino acid complexes (Yu et al., 2011) and potential MMP inhibitors (Yu et 
al., 2013a).  Of the 63 compounds tested, there were a number of efficacious and relatively non-toxic 
individuals that demonstrated specific action towards mycobacteria, as seen by the greatly reduced 
MIC90 of some compounds against mycobacterial strains compared to the same compound against the 
representative gram positive and gram negative strains tested here (Table 4.1).  
One class of compounds in this screen were predicted MMP inhibitors. The major chemical moiety, 
Marimastat, is an orally active, potent broad spectrum inhibitor of MMPs (Failes and Hambley, 2007, 
Underwood et al., 2003b). Initial experimentation showed the ability of Marimastat to effectively 
inhibit multiple MMP subtypes in a range of 3-260 nM and early clinical trials revealed little toxicity 
and pharmacologically active levels in blood serum after oral treatment (Rasmussen and McCann, 
1997). Previous studies have looked at the use of MMP inhibitors as potential treatment options for M. 
tuberculosis infection. One particular inhibitor, BB-94, showed a reduction in bacterial CFU as well as 
a decrease in leukocyte recruitment, a major source of MMPs, leading to a reduction in disseminated 
infection (Izzo et al., 2004). Other studies have looked at the inhibitory effects of Vitamin D used as 
MMP inhibitors (Nursyam et al., 2006, Coussens et al., 2009, Martineau et al., 2007). Results indicated 
a reduction in time to sputum smear conversion (Nursyam et al., 2006) as well lower levels of lung 
cavitation (Martineau et al., 2007). These studies suggest that targeting MMPs could be a valid way to 
improve disease pathology and severity.  
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The addition of the cyclam molecule, which individually shows limited effect on bacterial growth (as 
seen in initial screen; Figure 4.1 and 4.2), potentially adds a metal binding site which enhances the 
effect of Marimastat against bacterial cells. Despite the theory suggesting that MMP inhibitors should 
be a useful antibacterials, none of the Marimastat derivatives in this study showed effectiveness at the 
concentrations tested (Figure 4.1 and 4.2) and C59, a cyclam-marimistat complex (Appendix 1) was 
the most toxic to tissue cells of all compounds tested with more than 90 per cent reduction in cell 
viability (Figure 4.3). Therefore, these compounds were not considered appropriate for use as 
antibacterials. 
Of the 18 compounds that successfully inhibited bacterial growth during the initial screening phase, 
three contained a cyclen molecule instead of a cyclam (Appendix 1). A cyclen is shorter by two carbon 
atoms (Appendix 1). Compounds containing this molecule have been associated with peptide cleavage 
(Chei et al., 2010, Kim et al., 2009) and most importantly, have been looked at with regards to 
Alzheimer’s disease (Wu et al., 2008, Chei et al., 2010). It is selective for peptides and for the 
treatment of Alzheimer’s disease targets Abeta protein found in the brain, and degrades it preventing 
plaque formation (Wu et al., 2008). As yet there is no evidence of cyclens being used as antibiotic 
therapies. 
C31, C35 and C40 contained cyclen structures with a metal co-factor (Appendix 1). Whilst they 
appeared to work to a certain degree against bacterial cultures, their effect within cells was limited. One 
thing to note was that they were more active against M. avium than BCG (Table 4.1 and Figure 4.5). 
This could be due to these compounds targeting a specific peptide within the cell wall of M. avium that 
is less abundant in BCG. It could also be related to bacterial growth, in that M. avium grows at a faster 
rate than BCG so the effect of the cyclen is more rapid. When toxicity of the compounds was tested 
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C55 was the only other compound to show a reduction in cell viability at 50 µM (Figure 4.3). This 
compound was the cyclen molecule which may suggest that some of the effect seen in the MIC90 study 
could be a general toxicity, however his toxicity was not apparent in the cyclen-containing compounds. 
The most active compounds from the screen contained a napthalimide structure (Appendix 1). They 
were created for the purpose of being able to visualise the binding of a biological event such as protein-
protein interactions (Yu et al., 2013b). Napthalimides have been primarily used as markers (Grabchev 
et al., 2012) however one study did look at the use of napthalimide derivatives against gram positive 
and gram negative bacteria as well as fungi (Lv et al., 2014). Its suggested mode of action was 
targeting DNA polymerase, and results indicated a somewhat broad effect with some MICs in a range 
lower than that of the reference drugs. In particular, it seemed effective at restricting the growth of E. 
coli (16 µg/mL) to a much greater extent than for any other strain tested (Lv et al., 2014). 
In this study, the compounds containing the napthalimide were far superior to the others tested. 
Compounds C44, C45, C46 and C49 all contained one napthalimide with the addition of a biotin 
molecule in all except C49 (Appendix 1). Interestingly, the compounds that were the most effective 
contained two napthalimide molecules surrounding a cyclam moiety. These were compound C47, C48 
and C53, and in all tests these compounds were superior. 
C47, C48 and C53 did display a level of broader specificity as they were able to inhibit MRSA and P. 
aeruginosa growth at 50 µM (Table 4.1). However activity against mycobacteria was in the low 
micromolar range, indicating that these compounds may be acting against a specific target in 
mycobacteria. This could suggest that the compounds are targeting a specific gene or protein within the 
cell wall. The mycobacterial cell wall is  more complex than that of gram positive and negative 
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bacteria, and is composed of long fatty-acid chains and mycolic acids covalently bound to an 
arabinogalactan-peptidoglycan co-polymer (Song et al., 2008). These are more complex structures than 
the lipopolysaccharides found in the cell wall of gram negative bacteria such as P. aeruginosa.  
(Kocincova and Lam, 2011). The result seen in this study could indicate that the compounds are acting 
in a targeted manner, however further studies would need to be conducted to confirm this. This may 
include sequencing the genome of spontaneous drug-resistant mutants (Andries et al., 2005, Makarov et 
al., 2009) or affinity purification of compound-target complexes using mycobacterial cell walls or 
lysates (Terstappen et al., 2007). 
C47, C48 and C53 differ solely by the metal iron within a cyclam moiety (Appendix 1). C48, the most 
effective in this study, contained a copper ion and thus this metal may be in part responsible for the 
activity of the compound. Copper has been shown to be a highly effective molecule against different 
bacterial strains including M. tuberculosis (Mehtar et al., 2008). It appears to encourage the disruption 
of the cell membrane and subsequent cell death and DNA damage (Grass et al., 2011). In one study, the 
addition of copper to INH improved efficacy two-fold (Maccari et al., 2004). In another, copper 
treatment alone was highly ineffective against mycobacteria, however it improved the efficacy of 
ethambutol when in combination (Kozak et al., 1998).  
The likelihood of the copper adding to the mechanism of action is enhanced by the fact that C53 was 
not as effective. This compound is not complexed with a metal ion, having only the cyclam shell.  It 
has a 3-fold higher MIC90 against M. avium (Table 4.1) and is not as effective as C48 in restricting 
growth of bacteria at a high concentration (Figure 4.4). It is of interest to note that this compound 
showed a marked difference to compound C48 when tested against M. avium, with an MIC90 of 3.13 
µM compared to 1.56 µM for C48, and approximately 10-fold reduction in activity against high 
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bacterial load. When in combination however, compound C53 was able to improve the activity of 
rifampicin at all concentrations tested (Figure 4.7c), a property not shared by compound C48. This 
indicates that against M. avium compound C53 may be more beneficial when used in a combination 
therapy regimen.  
C47 differed from the other molecules by the inclusion of a zinc ion. Whist it was highly effective, it 
had a 3-fold higher MIC90 compared to C48 against M. avium (Table 4.1) and was unable to restrict 
bacterial growth at a high concentration (Figure 4.4). Previous studies using zinc supplementation of 
current regimens have failed to show any significant impact on morbidity and mortality outcomes 
relative to placebo or normal treatment (Haider et al., 2011, Das et al., 2012). In a study specifically 
looking at the use of oral zinc in tuberculosis patients co-infected with HIV, the authors could not 
recommend zinc as a pharmacological supplement (Green et al., 2005). As zinc appears to add no 
benefit it is unusual that it is less effective than the parent molecule C53 against M. tuberculosis. It is 
possible that inclusion of the zinc molecule interferes with target binding in M. tuberculosis and thus 
alters activity relative to C53.  
One potential benefit of C47 could be an enhanced activity in vivo. Zinc is essential for immunological 
processes such as the production of cytokines, phagocytosis and intracellular killing (Prasad, 2009). In 
an in vivo setting, the drug could be effective at restricting bacterial growth and assist in ‘boosting’ the 
host immune response. We obtained ethics approval for testing these compounds in mice, however we 
were unable to obtain non-particulate samples at the concentration range to be tested (100mg/kg and 10 
mg/kg). This was irrespective of the vehicle used (combinations of PBS, FBS and DMSO) and was 
also evident at a concentration of 1 mg/kg. Therefore we were unable to deliver these compounds to 
mice in order to determine their in vivo efficacy. However, future studies into these compounds should 
Chapter 4: MCyC results 
80 | P a g e  
 
examine their activity in vivo to determine whether their ability to restrict bacterial growth and affect 
the immune system could benefit in a clinical setting. 
The MCyCs described in this chapter were effective against actively replicating bacteria however did 
not show efficacy against non-replicating bacteria (Figure 4.10). This suggests that the drug target of 
C48 could be a gene that is present or upregulated only during active infection, such as a gene involved 
in replication, cell wall biosynthesis or energy metabolism. Rifampicin is effective against non-
replicating bacteria (Figueiredo et al., 2009) and in this study C47 improved the effect of rifampicin 
(Figure 4.6b). Testing this particular compound in combination with rifampicin in vivo could uncover a 
potentially beneficial partnership. 
The inhibitors described in this chapter display a number of properties that are attractive from a 
medicinal chemistry perspective. They are small and have low lipophilicity, allowing addition of 
functionality in the optimization process. These are also novel anti-mycobacterials; they bear no 
resemblance to known drugs and are distinct from anti-TB compounds identified using small molecule 
libraries (Ballell et al., 2013). Although this chapter explored the biological effects of these 
compounds, there is scope for further modification of structure. The design of the lead compounds 
incorporated four key elements: a macrocycle (cyclam), a linker (‘click’-derived triazole), the pendant 
group (naphthalimide) and a metal ion. C47 and C48 are the zinc(II) and copper(II) complexes of the 
free amine form(perchlorate counterion); C53 is the ammonium salt (trifluoroacetate counterion) 
(Figure 4.11). To explore and expand the potential of these compounds, each of the four structural 
components can be varied in turn. Variations in the pendant group in particular could be employed to 
alter lipophilicity and improve host cell penetration (see Figure 4.5).  
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Figure 4.11. Structure of lead MCyCs inhibitors. The zinc(II) (C47) and copper(II) (C48) MCyCs and 
the ammonium salt C53. 
 
In conclusion this study has uncovered 3 potent compounds against mycobacterial species, both in 
culture and within host cells. The options to manipulate these compounds to improve their efficacy are 
numerous, and as they are relatively non-toxic they have potential to be used in future treatment 
regimens against pathogenic mycobacteria. 
 
!
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Chapter 5: Discovery of new antibacterials against lung 
pathogens 
5.1 INTRODUCTION 
In 2011, respiratory disease accounted for approximately 8% of deaths in Australia (ABS, 2013), the 
third largest cause of mortality after neoplasia and circulatory disease (ABS, 2013). The two most 
common causes of respiratory disease include influenza and pneumonia, both of which are caused by 
infectious agents. This suggests that the development of new strategies and treatments to combat lung 
pathogens could lead to a reduction in mortality nationwide. 
Two medically important pathogens of the lung include Mycobacterium tuberculosis and Pseudomonas 
aeruginosa. Tuberculosis is the leading cause of mortality worldwide by a single bacterial pathogen. 
Despite the availability of effective medication, drug resistance is on the rise with multiple-drug 
resistant strains resulting in approximately 4% of newly diagnosed cases globally and as much as 20% 
in recurring disease states (W.H.O, 2012). P. aeruginosa is the main causative agent of chronicity and 
mortality in Cystic Fibrosis (CF) (Lopes et al., 2012, Folkesson et al., 2012). CF is an autosomal 
recessive genetic disorder primarily affecting Caucasians. Despite the availability of potent 
antimicrobials, the use of broad-spectrum antibiotics in hospital settings has led to an emergence of 
problematic drug resistance in this pathogen (Gorgani et al., 2009). Resistance to commonly used 
antibiotics has been increasing by 2 to 4.6 per cent each year, and resistance of pathogens to 
compounds such as the last-line carbapenems is more than 40 per cent (Xu et al., 2013). Both these 
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pathogens are becoming more difficult to treat with current therapies with slow progress made to 
develop new treatment options. Therefore the discovery of new anti-bacterials is urgently required.  
In recent years, the process of discovering a new antibiotic has been largely target-based and genetics-
driven. Whilst the theoretical principle is valid, the strategy has not been very successful due to a lack 
of correlation between inhibition of enzyme activity and that of whole bacteria (Payne et al., 2007). 
Large scale screening programs have largely been made up of small molecule ‘corporate’ chemical 
libraries that are relatively limited in diversity (Payne et al., 2007). However, the properties of 
antibiotics are somewhat distinct from those found in such libraries (Payne et al., 2007), and there is a 
need to develop and/or test novel compounds that may not necessarily fit the typical medicinal 
chemistry profile.  
A number of antibiotics in current circulation have multiple targets within a cell, for example INH is a 
pro-drug requiring activation by genes within the bacterial cell to function accordingly. It is for this 
reason that whole-cell screens are being actively pursued within the field of M. tuberculosis drug 
discovery, and most inhibitors in the later stages of development of the drug pipeline have been derived 
from screens conducted on the whole bacterial cell (Barry et al., 2009, Koul et al., 2011). Delamanid, 
currently in phase III clinical trials, was discovered through screening a number of nitro-dihydro-
imidazooxazole compounds against M. tuberculosis and PA824, currently in phase II clinical trials, was 
discovered by screening a series of bicyclic nitroimidazofurans against whole bacteria (Stover et al., 
2000b). This approach allows for the discovery of drugs that directly kill the organism or inhibit its 
growth (Ymele-Leki et al., 2012), and overcomes the problem of trying to translate specific activity of 
a gene or enzyme to its effect on the entire organism.  
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High-throughput screening allows for thousands of compounds to be tested in a relatively short period 
of time, ultimately speeding up the potential discovery of a new treatment. In this study, a selection of 
diverse compounds (natural products and synthetic derivatives) were examined for antibacterial 
properties and toxicity to determine if any were able to successfully restrict growth of selected bacterial 
pathogens of the lung and had the potential to be future treatment options.  
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5.2 RESULTS  
5.2.1 Selection of appropriate Pseudomonas aeruginosa strains for screening 
Due to the large number of P. aeruginosa strains that infect cystic fibrosis patients, it was necessary to 
determine the appropriate strain(s) to be used for the most informative antibiotic testing. Epidemic 
strains AES-1M, AD-2009 and CJ2009, non-epidemic strains 17-2009 and Bb2009, together with the 
lab strain PAO1, were chosen to represent a more general pathogenic Pseudomonas population 
(Harmer et al., 2012). All strains except the PAO1 were chronic isolates, selected due to having more 
acquired resistance then non-chronic isolates (Hare and Cordwell, 2010). Bacterial strains were then 
subjected to varying doses of compounds representing different antibiotic classes in order to determine 
the MIC90. All clinical strains typically displayed resistance that was greater than that observed for 
PAO1 (Table 5.1). All epidemic strains displayed greater resistance to norfloxacin, gentamicin, 
tobramycin and collistin, with a MIC90 ranging from 2 to 32 times greater than that for PAO1 (Table 
5.1). Rifampicin and tetracycline were the only two antibiotics in which PAO1 was more resistant than 
the clinical strains (Table 5.1). The non-epidemic strains appeared to have similar levels of resistance 
to all tested antibiotics with the exception of ciprofloxacin and polymyxin B in which Bb2009 was 
more resistant by approximately 2 and 8 times respectively (Table 5.1).  
While there were some differences between epidemic strains, we selected strains CJ2009 for further 
analysis, as this strain was determined to be more amenable for genetic manipulation (Dr Gabriella 
Scandurra, personal correspondence), which would potentially facilitate the identification of targets any 
of any compounds of interest identified in subsequent screens. Of the non-epidemic strains Bb2009 was 
comparatively more resistant to all other strains tested and was also selected for additional study. 
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5.2.2 Optimisation of culture conditions for compound screening 
5.2.2.1  Pseudomonas aeruginosa 
The goal of this chapter was to identify anti-bacterial agents from novel compound libraries (described 
in detail on page 86). Initial optimisation sought to determine the ideal conditions for screening in 384-
well plates, in order to maximise the number of compounds that could be screened. The lab strain 
PAO1 and epidemic strain AES-1R were initially used, as these strains are commonly used in the 
laboratory of our collaborator Dr Jim Manos (Infectious Diseases and Immunology, University of 
Sydney). Bacteria were added at different concentrations to 384 well plates (50µL), and left for 4, 7, 24 
or 48 hours. After each incubation resazurin was added to the wells, fluorescence measured at 
ex544/em590 and z-factor calculated. As shown in Table 5.2, the most appropriate conditions were a 
bacterial concentration of OD600 0.001 with one day incubation, which displayed a z-factor of 0.79 and 
0.93 for PAO1 and AES-1R respectively. The higher the z-factor value, the higher the quality of data 
those conditions will produce (Zhang et al., 1999), therefore these conditions were selected on the basis 
of being the highest z-factor of the conditions tested (see 2.6.1 for further information on ‘z’ factor). 
After initial testing, it was necessary to determine if the conditions were also appropriate for the 
selected strains from Table 5.1. CJ2009 and Bb2009 were added at OD600 0.001 to the wells of a 384-
well plate, incubated for 24 hours, resazurin added and fluorescence measured. As shown in Table 
5.2B, CJ2009 had a calculated z factor of 0.68 and Bb2009 had a z factor of 0.81. Therefore these 
conditions were appropriate for screening. 
  
 
Table 5.2. Optimisation of P. aeruginosa conditions for compound screening. The values shown 
are Z-values. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Strain Conditions Z factor 
CJ2009 OD600 0.001  
24 hours 
0.686875 
Bb2009 
0.812283 
 
 
 
 
 
A 
Strain 
Bacterial 
concentration 
Incubation time (hours) 
4 7 24 48 
PAO-1 
0.001 0.684345 0.587224 0.792348 -0.94608 
0.005 0.682513 0.707595 0.776249 -1.63942 
0.01 0.762894 0.5008 0.76305 -0.42682 
AES-1R 
0.001 0.65108 0.661194 0.932552 -0.65614 
0.005 0.446265 0.820282 0.812932 0.566818 
0.01 0.719872 0.838072 0.661307 -0.07574 
 
 
B 
 
 
 
 
 
 
 
B 
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5.2.2.2 Mycobacteria 
Mycobacteria can be fastidious when grown in 384 well plates due to the reduced volume of nutrient 
broth (7H9 medium) and their slow growing time. Therefore the optimum conditions for screening 
needed to be determined. Firstly, the most appropriate media and method of dispensing was elucidated. 
7H9s is a specialised medium containing toloxypol as a detergent in place of tween 80, and assists 
growth of mycobacteria when growing in plates (correspondence with Dr N. West, University of 
Queensland). In the initial optimisation experiments M. bovis BCG and M. avium were diluted to an 
OD600 0.001 and dispensed into wells either by an automated multichannel pipette or dispenser to 
determine which method resulted in the least level of variance. Plates containing bacteria were 
incubated for five days, after which resazurin was added and fluorescence measured. As shown in 
Figure 5.1, bacteria dispensed via the automated multichannel pipette exhibited the highest 
fluorescence reading in all conditions. Using 7H9 medium, the difference in fluorescence units between 
the multichannel and dispenser varied from 800 against M. avium to 2500 against BCG (Figure 5.1). 
The values of fluorescence were less using 7H9s medium, and the control values were higher (965 
compared to 739 for BCG; Figure 5.1) indicating this medium was not as useful for screening methods. 
Subsequent experiments were carried out by diluting bacteria in 7H9 medium and dispensing solutions 
using an automated multichannel pipette. 
The optimal screening conditions for both BCG and M. avium were then determined. This was done by 
incubating various concentrations of bacteria for 4, 5, 6 and 7 days, Resazurin then added to each well, 
fluorescence measured and the z-factor calculated. As shown in Table 5.3, the optimal condition for 
both mycobacterial strains was an OD600 0.01 after incubating for 6 days, where the z-factor was 0.97 
 Strain Media Dispensing method 
Mean fluorescence ± 
SEM 
(A) BCG 7H9 multichannel 12077 ± 129 
 
dispenser 9508 ± 122 
 
control 739 ± 12 
7H9s multichannel 10177 ± 82 
 
dispenser 9957 ± 98 
 
control 965 ± 174 
(B) M. avium 7H9 multichannel 7856 ± 75 
 
dispenser 7009 ± 84 
 
control 793 ± 9 
7H9s multichannel 6310 ± 97 
 
dispenser 5059 ± 97 
 
control 878 ± 7 
 
  
 
 
 
 
 
Figure 5.1. Optimising conditions for use in mycobacterial High-Throughput screen. M. bovis 
BCG (A) and M avium (B) was grown and diluted to OD600 0.001 in control media (7H9) or 
specialised growth media (7H9s). Bacteria were dispensed into 384 well plates either via an 
automated multichannel pipette or robotic dispenser. Control wells contained TDW only. After five 
days, resazurin was added and fluorescence measured. Optimal conditions were determined as that 
exhibiting the greatest fluorescence level compared to control, with the least error.  
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for M. avium and 0.67 for BCG, indicating these conditions allow for an effective comparison between 
bacterial presence and that in which a drug may effectively restrict growth.  
 
5.2.3 Screening of compound libraries to determine potential pharmaceutical 
targets 
We obtained a library of 1920 compounds from the Queensland Compound Library for screening 
against the pathogens of interest. Approximately 10% of the compounds were natural products sourced 
from the Eskitis Institute for Cell and Molecular Therapies, Griffith University, and had been used in 
previous anti-microbial screens (Professor Ron Quinn, personal correspondence). The compounds 
spanned a diverse set of compounds including various alkaloids, modified peptides, sesqui- and tri-
terpenes and polyketides. The remaining compounds are a structurally diverse set of synthesized small 
molecules provided by CSIRO Materials Science and Engineering. To reduce any bias in the screen the 
compounds were coded (provided as sequential numbers) and thus compound identity and structure of 
compounds was not disclosed. This information was provided once any ‘hits’ were identified. 
Compounds at a final concentration of 50 µM were added to individual wells of a 384-well plate on 
replicate plates. P. aeruginosa was added at OD600 0.001, incubated for 24 hours, resazurin added and 
fluorescence measured. Mycobacteria was added at OD600 0.01 and incubated for 6 days. A compound 
was considered effective if it showed more than 50 % bacterial growth reduction compared to non–
treated controls on both replicate plates.  
  
 
 
Table 5.3. Optimisation of mycobacterial strains for high throughput screening. The values 
shown are Z-values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
strain 
bacterial 
concentration 
Incubation time (days) 
4 5 6 7 
M. avium 
0.001 -0.18295 0.126353 0.506048   
0.005 0.273328 0.401568 0.733727   
0.01 0.585773 0.465752 0.969292   
BCG 
0.001  -0.41659 -0.00631 -0.04007 
0.005  0.270119 0.583213 0.556431 
0.01   0.442121 0.670283 0.666705 
Chapter 5: HTS results 
89 | P a g e  
 
As shown in Figure 5.2, there were six hits in total out of 1920 for the two strains of P. aeruginosa 
tested; four for CJ2009 (Figure 5.2A) and two for Bb2009 (Figure 5.2B). The two compound ‘hits’ for 
Bb2009 were also identified in CJ2009 (468620 and 465895), while compounds 465697 and 296405 
displayed no activity against Bb2009, further highlighting the high antimicrobial resistance of this 
strain (see Table 5.1). Due to the overlap, the success rate for this screen was only 0.2 %. Compounds 
46820 and 465895 displayed almost complete inhibition of growth at 50 M, while 465697 and 296405 
displayed an intermediate level of inhibition with bacterial survival of 44.9 % for 465697 and 31.9 % 
for 296405 (Figure 5.2A).  
The same compounds against M. avium yielded 0.1 % success, with only 2 ‘hits’. Despite a number of 
compounds having a survival level below threshold, this was not replicated in both plates, therefore 
only compounds 467142 and 296385 were considered true anti-M. avium compounds (Figure 5.3). 
Only M. avium 104 was screened against the entire library as the mycobacterial representative due to 
the optimisation results for the 384-well plate format being more reliable in this strain compared to 
BCG (data not shown).  
 
5.2.4 Determination of activity of anti-bacterial compounds   
5.2.4.1 Compounds inhibiting growth of Pseudomonas  
To determine the effectiveness of the compounds identified in section 5.2.3 the MIC90 was calculated. 
The four compounds selected from the screen in Figure 5.2 were serially diluted with a starting 
concentration of 50 µM and tested against the relevant strains of Pseudomonas CJ2009 and Bb2009. 
  
 
 
 
Figure 5.2a. Screening of compounds against P. aeruginosa CJ2009. Compounds were aliquoted 
into single wells on replicate 384 well plates and strain CJ2009 culture added at OD600 0.001. 
Resazurin (0.05%) was added 24 hours post-treatment and fluorescence measured. Bacterial 
survival was calculated as a percentage compared to untreated control. A successful “hit” was when 
both replicate plates showed more than 50% restriction of growth by a single compound (red line). 
Graphs are replicate plates. 
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Figure 5.2b. Screening of compounds against P. aeruginosa Bb2009. Compounds were aliquoted 
into single wells on replicate 384 well plates and strain Bb2009 culture added at OD600 0.001. 
Resazurin (0.05%) was added 24 hours post-treatment and fluorescence measured. Bacterial 
survival was calculated as a percentage compared to untreated control. A successful “hit” was when 
both replicate plates showed more than 50% restriction of growth by a single compound (red line). 
Graphs are replicate plates. 
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Figure 5.3. Screening of compounds against M. avium. Compounds were aliquoted into single 
wells on replicate 384 well plates and M. avium culture added at OD600 0.01. Resazurin (0.05%) 
was added 24 hours post-treatment and fluorescence measured. Bacterial survival was calculated as 
a percentage compared to untreated control. A successful “hit” was when both replicate plates 
showed more than 50% restriction of growth by a single compound (red line). Graphs are replicate 
plates. 
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Polymyxin B was used as a control due to the susceptibility of Pseudomonas isolates to this antibiotic 
compared to others tested (Table 5.1). Figure 5.4A shows the survival curves for the four compounds 
against CJ2009. Both 468620 and 465895 displayed strong anti-Pseudomonas activity with MIC90 of 
3.13 µM and 6.25 µM respectively (Figure 5.4C), while compounds 4655697 and 296405 were not 
active at the concentrations tested (Figure 5.4A,C). Against Bb2009 (Figure 5.4B) both 468620 and 
465895 maintained their activity, both displaying an MIC90 of 6.25 µM (Figure 5.4C). Due to their 
efficacy compound 468620 and 465895 were selected for further analysis.  
5.2.4.2 Compounds inhibiting growth of M. avium 
Active compounds from the M. avium screen in Figure 5.3 were serially diluted from a starting 
concentration of 50 µM to determine the MIC90. Figure 5.5A shows the survival curve of the two 
compounds against M. avium. Compound 296385 had an MIC90 of 12.5 µM, and compound 467142 
had an MIC90 of 25 µM (Figure 5.5B). As these compounds were effective within the range tested 
indicating some level of activity against M. avium they were both selected for further study. 
 
5.2.5 Determining the efficacy of compounds against patient sputum samples 
As the CF lung is infected by an array of bacteria, broad spectrum antibiotics would be useful during 
treatment. Therefore, the effective compounds against P. aeruginosa were tested against sputum 
samples obtained from the RPA Respiratory Clinic and prepared for culturing as previously described 
(Hu et al., 2013). No bacterial typing was conducted on the samples as they were tested immediately 
   
 
 
 
 
 
 
Figure 5.4. MIC90 of selected compounds against P. aeruginosa strains. Compounds were 
serially diluted in 96 well plates and CJ2009 (A) and Bb2009 (B) were added at OD600 0.001. 
Resazurin was added 24 hours post-treatment and fluorescence measured. Survival was calculated 
as a percentage compared to an untreated control. MIC90 (C) was calculated as the lowest 
concentration that restricted more than 90% bacterial growth. Data are representative of two 
independent experiments.  
Compound CJ2009 Bb2009 
468620 3.13 µM 6.25 µM 
465895 6.25 µM 6.25 µM 
465697 >50 µM  
296405 >50 µM  
PolB 1.56 µM 12.5 µM 
 
 
 
 
 
 
 
 
 
 
C 
  
 
 
 
 
 
 
 
 
Figure 5.5. MIC90 of selected compounds against M.avium. (A) Compounds were serially diluted 
in 96 well plates and bacteria were added at OD600 0.001. Resazurin was added 5 days post-
treatment and fluorescence measured. Survival was calculated as a percentage compared to an 
untreated control. MIC90 (B) was calculated as the lowest concentration that restricted more than 
90% bacterial growth. Data are representative of two independent experiments. 
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after collection, so the bacterial population was unknown. However it was assumed the bacterial 
makeup was that of the common CF lung pathogens (Foundation, 2012). 
Experimentation was carried out as for other MIC studies. Four patient samples were cultured 
overnight and added to wells containing serial dilutions of the two most effective compounds, 468620 
and 465895 (50 µM starting concentration). Compound 465895 was active against all four samples 
(MIC90 range of 3.13 to 12.5 µM; Figure 5.6) and in 3 of the samples displayed inhibition greater than 
Polymyxin B (Figure 5.6A, C-D). Compound 468620 was also effective however its inhibitory action 
was less than compound 465895 (MIC90 range of 6.25 to >50µM; Figure 5.6). These results suggest 
these compounds may have activity as broad spectrum agents against CF pathogens. 
 
5.2.6 Testing the toxicity of compounds to determine viability as a treatment 
Many compounds derived from screening programs display generalised toxicity against both microbial 
and mammalian cells, and are thus unsuitable for further development (Payne et al., 2007). The toxicity 
of the compounds was next assessed in a murine macrophage-like RAW267.4 cell line (Ralph and 
Nakoinz, 1977) and the human monocytic THP1 cell line (Tsuchiya et al., 1980). Compounds were 
serially diluted 1 in 5 from a starting concentration of 25 µM and 7 days post-treatment cell viability 
determined. Compound 465895 was toxic at all concentrations except 0.2 µM when tested against 
RAW267.4 cells (Figure 5.7A), and against THP1 cells caused an almost complete reduction in cell 
viability at the two highest concentrations but was non-toxic at concentrations lower than 5 µM (Figure 
5.7B). Compound 468620 exhibited approximately a 20 per cent reduction in cell viability at 25 µM 
and 10 per cent reduction at 5 µM in both cell types, however was non-toxic at lower concentrations 
 Figure 5.6. Effect of compounds against patient sputum samples. Sputum samples collected 
from CF patients were cultured overnight, exposed to compound for 24 hours and resazurin (0.05%) 
added. The legend corresponds to compounds 468620 (620) and 465895 (895). Fluorescence 
measured and survival calculated as a percentage compared to an untreated control. (A-D) 
represents different patient samples and is representative of two independent experiments. 
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(Figure 5.7). Treatment with 296385 caused almost complete cell death at 25 µM in both cell types 
(Figure 5.8). A 15% of RAW267.4 cell viability (Figure 5.8A) and 30% reduction of THP1 cell 
viability (Figure 5.8B) was seen for compound 296385, with no toxicity observed at the lowest 
concentrations for both cell lines. For compound 467142, treatment of RAW267.4 cells at 
concentrations greater than 1 µM caused almost complete cell death, with no effect seen at the two 
lowest concentrations (Figure 5.8A). Against THP1 cells, a similar effect was seen (Figure 5.8B), 
however at 5 µM there was only 40 per cent reduction in cell viability as opposed to >95% in 
RAW267.4 cells. Therefore these compounds displayed a generalised pattern of toxicity against the 
mammalian cells tested at concentrations greater than 1 µM. 
 
 
 
 
 
 
 
 
 Figure 5.7. Toxicity of compounds effective against P. aeruginosa. One x10
5 
RAW264.7 cells 
(A) or THP1 cells (B) were seeded into 96 well plates. Compounds were serially diluted and added 
to the wells, resazurin was added 7 days post-treatment and fluorescence measured. Toxicity was 
calculated as percentage cell viability compared to an untreated control.
 
 
 
 
 
 
  
Figure 5.8. Toxicity of compounds effective against M.avium. One x10
5 
RAW264.7 cells (A) or 
THP1 cells (B) were seeded into 96 well plates. Compounds were serially diluted and added to the 
cells, Resazurin was added 7 days post-treatment and fluorescence measured. Toxicity was 
calculated as percentage cell viability compared to an untreated control. 
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5.3 DISCUSSION  
High throughput screening is rapidly becoming a useful and efficient tool in the search for new 
compounds against various diseases. It allows researchers to test a large number of compounds in a 
relatively short amount of time increasing the likelihood of finding a new compound for therapeutic 
use. This study sought to discover new antimicrobial compounds that were effective against highly 
resistant, difficult to treat bacterial species. 
Initial experiments were undertaken to identify strains of resistant P. aeruginosa. In early infection, P. 
aeruginosa can be successfully treated with antibiotics (Hare and Cordwell, 2010) however during 
chronic infection the bacteria are typically unresponsive to chemotherapy (Eberl and Tummler, 2004). 
Due to an increase in bacterial resistance it was necessary to focus on chronic isolates as compounds 
that were efficacious against such strains would be more important clinically. Screening of the 
compound libraries against both M. avium and P. aeruginosa resulted in 8 potential candidates from an 
original compound number of 1920. This compares favourably with other studies; for example a review 
of the screening program at GSK concluded that 14 HTS (approximately 260 000-530 000 compounds 
per screen) was required to obtain one lead compound, however highly stringent gating criteria were 
placed on compounds progressing through the GSK screening program (Payne et al., 2007). Against M. 
tuberculosis, a similar success rate to that in this study (0.4 per cent) was achieved from 20 000 novel 
small molecules when tested at a single concentration of 25 µM (Stanley et al., 2012). Other studies 
can have higher success rates such as one against Naegleria (Debnath et al., 2012), identifying 1.6 per 
cent from 910 compounds. While the success rate of HTS studies is dependent on the makeup of the 
compound library used, the current study indicates the results presented in this chapter agree with 
previous studies identifying anti-bacterial compounds within diverse compound libraries.  
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 In the screens presented in this chapter there were two compounds, 468620 and 465895, that restricted 
the growth of the two different strains of P. aeruginosa studied. This indicates that these particular 
compounds are broad spectrum or highly active, particularly due to the fact that Bb2009 was the most 
resistant non-epidemic isolate when tested for antibiotic sensitivity (Table 5.1). Their effect against 
patient sputum samples indicates they could have broad spectrum activity due to the variety of bacteria 
in CF sputum that is being restricted in this assay. Whilst the sample populations were not 
characterised in this study it is known that the lung environment of a CF patient can include bacteria 
such as Haemophilus influenzae, Staphylococcis aureus, and Burkholdaria cepacia (Foundation, 2012). 
Patients eventually succumb to the P. aeruginosa infection in the chronic stages of disease, however 
early stages of disease have a wide variety of infecting pathogens. Testing of the compounds in this 
assay may reflect how these compounds may behave in an in vivo setting within the lung. However as 
the sputum samples were cultured overnight before being treated, there is the possibility that some 
bacteria are out-competing other species and the compounds may be active against a restrictive set of 
CF pathogens. Testing the compounds against individual cultures of bacteria found in the CF lung 
would be a more accurate way of determining whether they are broad spectrum antibiotics. 
Alternatively, culturing sputum samples and then analysing the sample to determine the bacterial 
population could also be performed. 
Testing of the MIC90 showed that compounds 465697 and 296405 that were identified in the initial 
screen were no longer effective when re-assayed for the determination of the MIC (Figure 5.4). This 
could be due to the fact that in the screening assays compounds 465697 and 296405 only displayed an 
intermediate level of inhibition in the initial screen (Figure 5.2a). Despite appearing as ‘hits’ on both 
replicate plates, the fact that neither compound completely restricted bacterial growth at 50 µM could 
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account for the loss of activity in subsequent experiments, possible due to the compounds being 
unstable compared to the other hits identified in this study. Decoding of compounds identified 465697 
as a small molecule with a molecular weight of 143.16. It has a nitrate group, which when in a cellular 
environment could potentially be cleaved from the core structure resulting in a compound that is too 
simple to function as an antimicrobial. Compound 296405 was identified as Mispyric acid which 
inhibits DNA polymerase β. A DNA polymerase β is found in mammalian cells and is involved in base 
excision repair (Mizushina et al., 2005). Inhibitors have previously been developed to target this 
protein as a potential treatment for cancer (Barakat et al., 2012). This compound may have shown 
limited activity against bacteria due to the lack of a specific target within in a bacterial cell, and instead 
displaying generalised toxicity. Additionally, there are two carboxylic acid groups which could 
deprotonate, thus making passage through the cell membrane difficult and preventing the compound 
from directly acting on the bacteria. 
Compound 467142 was effective against M. avium at 25 M yet displayed toxicity at 5 M against 
mammalian cells. The compound has a nucleotide-like structure (Table 5.4). Currently, nucleotide 
analogs have been used in the treatment of herpesvirus and hepatitis B. For example Famciclovir, 
which is a prodrug for penciclovir, is activated by viral thymadine kinase and inhibits viral DNA 
polymerase (Mubareka et al., 2010). The prodrug is also able to rapidly diffuse into both viral and host 
cells (Mubareka et al., 2010). Compound 467142 may work in a similar manner and its relative lack of 
effectiveness could be due to related compounds displaying activity primarily against viral DNA. As a 
nucleotide analog it may also readily diffuse into cells and affect host DNA synthesis or repair, thus 
accounting for the toxicity. 
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Compound 296385, or Lissoclinotoxin F, is predicted to be an inhibitor of the PI3-K/AKT/mTOR 
cellular signally pathway (Davis et al., 2003). It has previously been tested for biological activity 
against tumour cell lines and microbes, showing some effect against fungus and marine bacteria (Liu et 
al., 2005). The most interesting result was against the tumour cell line HL60, which restricted cell 
proliferation at 0.23 µM (Oda et al., 2007). If such a low concentration is required to restrict tumour 
cell growth, this could account for the toxicity levels seen at concentrations greater than 1 µM is this 
study. As this compound may target cell signalling pathways absent from or poorly conserved from 
bacterial cells, this may be a reason for the lack of strong activity against M. avium (Figure 5.5).  
Analysis of compound 465895 indicates it is a steroid analog. It has a long fatty acid chain which, 
because of the lipophilic nature of this structure, could penetrate cells with no specificity to a particular 
cell type, mammalian or microbial. The steroid-like structure independent of the fatty acid chain has 
been studied as an aromatase inhibitor in the treatment of breast cancer, exhibiting an IC50 of 0.45-0.75 
µM (Varela et al., 2013, Amaral et al., 2013). If such a low dose is required for the inhibition of breast 
cancer cells, the concentrations tested in this study could account for the toxicity observed against 
THP1 cells, resulting is a very low selectivity index (Table 5.4). Whilst the fatty acid structure may 
help with cell penetration, the effect of the steroid moiety could negatively affecting host cells. 
The final compound, 468620, contains a metal binding site. Metal complexes have been used in the 
treatment of cancer, such as the chemotherapy cisplatin, although the metal is generally platinum 
(Bruijnincx and Sadler, 2008). 468620 contains cobalt which although found naturally in vitamin B can 
have various toxic effects such as cardiomyopathy, haematological, neurological, reproductive and 
dermatological effects (Paustenbach et al., 2013). Experimental studies have shown that cobalt can 
interfere with DNA repair and can cause DNA cross-linking, damage and sister-chromatid exchange 
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(Jomova and Valko, 2011). The resulting toxicity in this study could be explained by the effect of 
cobalt. Despite the compound having an MIC90 relatively similar to the MIC calculated against 
mammalian cells, and the selectivity index is low (Table 5.4). The activity of the compound could also 
be non-specific which would account for the similar level of bacterial and cellular toxicity in this study.  
This study showed that whilst high-throughput screening results in a greater number of potential 
compounds in a short period of time, larger screens may be required to potentially identify compounds 
of interest (Payne et al., 2007). Despite most of the selected compounds exhibiting useful levels of 
efficacy in this study, the selectivity index (SI) calculated for all compounds was less than 1. 
Compounds with a SI of more than 1000 are considered promising candidates for further clinical drug 
development (Haagsma et al., 2009) therefore through this fact alone no compound was selected for 
further study. None-the-less, this chapter has identified a subset of novel structures that display some 
anti-bacterial activity, and future work may involve ‘decoupling’ toxicity from their anti-microbial 
effect for potential use in humans.  
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Chapter 6:  General discussion 
Of thousands of drug candidates tested every year in research labs and pharmaceutical companies, only 
a fraction are approved for clinical development (CISCRP, 2013). Of those that do reach late clinical 
trial stage, on average only 1 in 6 make it to market (DiMasi et al., 2010). In addition to project 
attrition, time is a key challenge for market entry. It can take approximately 7 years to get a candidate 
drug through the trial phases, and in the case of cancer and neuropharmacologic drugs, it can take up to 
nine years from the start of human trials to market approval (Kaitin, 2010). 
December 2012 was a milestone for tuberculosis treatment with the first new drug being approved by 
the FDA in over 40 years (Goldenberg, 2013). Bedaquiline, an ATP-synthase inhibitor, is highly 
efficacious, with results indicating that culture conversion is more rapid (in 14 days) and more 
prevalent than the current therapeutic combination of rifampicin, INH, ethambutol and pyrazinamide 
(Diacon et al., 2013). However, it has serious toxicity concerns, including unexplained mortality and 
risk of QT prolongation (Chahine et al., 2013), underscoring the need to maintain the pipeline of new 
compounds.   
Drug susceptible tuberculosis generally requires a 6-8 month treatment regimen. During this treatment 
course, patients can experience acute renal failure, thrombocytopenia, paresthesia, hepatitis, angina, 
and various gastrointestinal, nervous, cardiovascular and musculoskeletal problems. Drug resistant 
disease however, requires a 20 month regimen using less efficacious drugs with a higher toxicity 
profile (Zumla et al., 2013b). With the level of worldwide MDR cases increasing (W.H.O, 2012), it is 
important to develop new drugs that are highly efficacious, can reduce treatment length and are 
relatively non-toxic. 
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Recently, drug discovery has been target driven, which although valid in theory has resulted in less 
success in finding a lead compound due to the lack of correlation between enzyme inhibition and whole 
cell bacterial inhibition (Payne et al., 2007). Never-the-less, new approaches have been sought to 
overcome these problems. There are a number of ways in which drug development can occur. These 
can include; old compounds being re-synthesised with altered side chains to improve their potency or 
change their target site to improve target specificity; the development of new compounds with a 
specific target, for example ones that target a particular gene, protein or pathway within a pathogen; 
and high-throughput screening of a range of compounds, whether novel, for a different indication, or 
natural (Payne et al., 2007, Koul et al., 2011). The methods chosen by the researcher are dependent on 
available materials and the level of specificity desired for each compound tested. In this study all 
methods of drug discovery described above were utilised.  
 
6.1 Iron chelation and mycobacteria 
The use of iron chelators in chapter 3 fit two criteria for drug discovery. Iron is an obligate cofactor for 
over 40 genes encoded within the M. tuberculosis genome (Yellaboina et al., 2006) suggesting that 
targeting this growth determinant of the pathogen could affect its viability and hence the infective 
potential. The group of PIH derivatives tested are more potent than the commonly used DFO for 
clinical treatment; these derivatives have a high affinity for iron (Becker and Richardson, 1999) and are 
orally active (Yu et al., 2006), making them a desired class of compound to test against a pathogen that 
so heavily relies on iron for growth. As seen from this study, these compounds were effective and 
relatively safe when delivered to mammalian cells (Chapter 3). When tested in vivo these compounds 
significantly reduced bacterial CFU for both M. avium and M. tuberculosis, however there was no 
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significant difference compared to INH in this model, and thus the clinical potential for these 
compounds to ‘supersede’ the use of INH is uncertain, particularly as both ING and PCIH appear to 
share the same target (Chapter 3). Recently, new compounds have been discovered that target other 
steps in the biosynthetic pathway for mycolic acid production (Stanley et al., 2013) or directly target 
inhA (Encinas et al., 2014) may be beneficial to treat INH-resistant strains. However, it was shown in 
Chapter 3 that PCIH could inhibit growth at high bacterial loads, a result not observed with INH 
treated cells, and was more effective against M. avium. This suggests that PCIH is not simply acting in 
a similar fashion to INH, but may function as a lipophilic vehicle to penetrate both mycobacterial and 
mammalian cells and release INH intracellularly. Future studies may involve the development of 
derivatives with improved uptake into mammalian cells, which may improve the clinical benefit of 
these molecules. Indeed, as INH is a relatively simple compound that is inexpensive and exhibits a 
tolerable safety profile, derivatives with improved therapeutic potential (i.e. require less drug for 
efficacy) could become important components of new anti-tuberculosis treatment regimes.  
 
6.2 A novel class of mycobacterial inhibitors 
The second study (Chapter 4) looked at the antibacterial effect of metal-cyclam moieties; novel 
compounds that were varied in both structure and application. Lack of chemical diversity in potential 
antibiotics has led to poor outcomes in drug development (Koul et al., 2011). This lack of diversity is in 
part a result of the need for compounds to follow the “rule-of-five” (Lipinski, 2004, Koul et al., 2011). 
This rule suggests that antibiotics should have structures that lead to known properties in currently 
effective therapies (Lipinski, 2004), however, this rule does not predict if a drug is pharmacologically 
active. It also encourages bias towards particular structures which can limit the availability of certain 
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molecules during testing and may cause potentially effective compounds to be neglected on the basis of 
structure. This study is an example that compounds not fitting the “rule-of-five” model can be active 
against bacteria as is commonly seen with other antibiotics (Payne 2007);  for example the effective 
compounds described had a molecular mass around 1000 daltons, where the rule of 5 states compounds 
should have a molecular mass less than 500 daltons. This further highlights the necessity to ‘cast the 
net wide’ to find new targets to treat pathogenic bacteria. As these structures appear to be novel 
antimicrobials, it is possible they may be active against drug-resistant strains of M. tuberculosis; future 
studies using such strains would further validate the clinical potential of these compounds.  
The three most efficacious compounds could not be tested in vivo due to low solubility at the 
concentrations required for dose response testing in mice, irrespective of the delivery vehicle 
employed. Additional modifications may improve compound solubility and allow in vivo assessment of 
these compounds (see chapter 4.3). Such in vivo characterisation is critical for evaluating the potential 
of these compounds as antibacterials for use in humans. These in vivo studies would need to assess the 
pharmacokinetics, safety and efficacy of compounds against drug-sensitive and drug-resistant strains of 
M. tuberculosis, as has been detailed for other novel candidates (Pethe et al., 2013). Similarly, as a 
subset of these compounds display some efficacy against drug-resistant clinical Pseudomonas isolates, 
murine models of P. aeruginosa infection could also be employed (Ueda et al., 2005) to determine if 
these compounds display broad-spectrum activity. 
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6.3 Discovery of new drugs from diverse compound libraries 
High-throughput screening allows otherwise unconsidered molecules to be tested rapidly against the 
pathogen of interest. This could reveal potent compounds against the bacterium of interest or permit a 
good starting point for future modification of anti-bacterial scaffolds (Cooper, 2013). Chemical 
modifications on a compound of interest could include the elimination of toxic side-chains, the addition 
of components to increase substrate range, or the addition of components that could be involved in 
glycosylation, methylation or phosphorylation (Schmidt, 2004). The modification of compounds to 
develop new, more effective anti-bacterials is both cost-effective and faster than traditional methods 
(Schwarz and Kehrenberg, 2006), hence appropriate for use in this study.   
In the final study (Chapter 5) various compounds, both synthetic and natural, were screened resulting in 
6 successful ‘hits’. Unfortunately these yielded disappointing results due to compound toxicity and 
very low selectivity index scores (SI<1). The MIC90 of 4 of the identified compounds were at a level 
(6.25-25 µM) that modifications to ‘decouple’ toxicity from antibacterial activity could be investigated; 
however any resultant activity would need to be in the low µM to nM range to warrant additional 
assessment (Payne 2007).   
One positive outcome of the screen described in Chapter 5 was the identification of compounds that 
inhibited either P. aeruginosa or M. avium, however no overlapping activity was identified. As a gram 
negative bacterium, P. aeruginosa has a distinct lipid bilayer characterised by the attachment of 
lipopolysaccharide to the outer membrane (Lam et al., 2011). M. avium, like other mycobacterial 
species, has a complex cell wall with long fatty acid chains and mycolic acid (Song et al., 2008). As the 
compounds in this screen did not overlap between species, it is tempting to speculate that these 
compounds may target diverse structures in the cell wall; identification of the true target of the 
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compounds would clarify this, however at this stage the relatively weak antibacterial activity and 
toxicity of these compounds does not warrant further investigation. None the less, this observation has 
parallels with results observed in Chapter 4, with different metal cyclam complexes having quite 
distinct activity against different strain of mycobacteria, further highlighting the potential complexity 
of the mode of action of novel inhibitors.   
One issue with the screening performed in Chapter 5 was the relatively low success rate of finding 
active compounds (approximately 0.3 per cent). In a whole-cell assay against M. tuberculosis using 
20,000 small molecules, the success rate was 0.4 per cent (Stanley et al., 2012), similar to that observed 
in our study. Cleary the relatively small subset of compounds used in our library may have limited the 
number of active compounds obtained, however it is possible the conditions used for the screen may 
not be optimal for identifying compounds of interest. There is growing interest in developing screening 
models that more accurately ‘mimic’ the conditions encountered by pathogenic mycobacteria within 
the host. These include the screening of non-replicating bacteria (Mak et al., 2012) or high-content 
imaging of M. tuberculosis-infected macrophages (Christophe et al., 2010). In the case of P. 
aeruginosa, the development of a specialised medium to mimic the CF lung environment (Fung et al., 
2010) has meant that potentially screens could be performed on bacteria that more closely represent 
those found in a clinical setting. Results therefore would be more reminiscent of actual treatment 
outcomes. Such strategies may accelerate the identification of compounds for potential use in humans.  
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6.4 Concluding remarks 
Despite the promise of some of the compounds identified here, this study is only the very first step in 
the drug development process. The treatment of P. aeruginosa is relatively straightforward in that any 
new compound simply needs to be novel and efficacious in order to combat the increasing resistance 
seen particularly in hospital settings. M. tuberculosis is a more complicated in that there are many 
criteria that new drugs for tuberculosis need to fulfil, including the ability to treat MDR-TB and XDR-
TB cases, shortening treatment duration from the 6-8 months, reducing pill numbers, lowering 
frequency of pill intake, and drug-drug interactions, particularly in the case of HIV medications (Koul 
et al., 2011). These criteria have been established as the most important in the drug discovery field. 
However other factors that must be considered include the potential patients to be treated, the countries 
in which these drugs are to be implemented and possible future resistance. To combat resistance 
controls need to be put in place to restrict usage of new drugs so that overprescribing and 
monotherapeutic treatment is prevented. This requires education and assistance by country leaders, 
health departments, international organisations and advocate groups. The WHO carefully monitors 
drug usage however it is unable to regulate individual countries, so must rely on leaders to implement 
the strategies they put in place without jeopardising the new compound. The private sector is the most 
difficult to control, as people can afford treatment so this section of the health industry is less likely to 
regulate usage. To try and combat this, the WHO has started to encourage Public-Private Mix, whereby 
private companies and individuals are encouraged to send tuberculosis patients to the public sector. In 
the countries where this has been implemented there has been cooperation between the public and 
private sector, so there is hope that any future drug can be protected, at least in this case, from 
inappropriate use (W.H.O, 2007, Yesudian and Raviglione, 2009). 
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Possible areas that could be utilised for guidance of tuberculosis drug development are those of HIV 
and malaria. These two prominent infectious agents had reached a critical level of resistance such that 
there needed to be urgent reforms in their drug development and implementation. Similarly to TB, HIV 
and malaria have experienced high levels of resistance. In the case of malaria, countries such as Kenya 
were experiencing over 25% treatment failures in their studies indicating an urgent need for new drugs 
to be developed (Amin et al., 2007). A new regimen was developed and the first recommendation made 
by the WHO was in 2001 (W.H.O, 2001). It took a further three years before this new combination 
therapy was adapted into country policy (Sipilanyambe et al., 2008). Tuberculosis, while a global 
problem, is not yet at the stage of malaria or HIV in that susceptible tuberculosis, if treated 
appropriately, has more than a 95 per cent success rate (Zumla et al., 2013a). It is therefore crucial that 
studies such as those conducted throughout this thesis be consistently undertaken to increase the 
number of potential candidate drugs that may one day assist in the decline and hopeful eradication of 
this life threatening disease. 
A
p
p
en
d
ix
 
1
0
6
 |
 P
a
g
e
 
 A
p
p
e
n
d
ix
 1
: 
C
o
m
p
o
u
n
d
 s
tr
u
c
tu
re
s
 a
n
d
 r
e
la
te
d
 d
a
ta
 o
f 
m
e
ta
l-
c
y
c
la
m
 c
o
m
p
o
u
n
d
s
. 
 
 
 
M
IC
9
0
 
C
o
m
p
o
u
n
d
 
C
o
m
p
o
u
n
d
 S
tr
u
c
tu
re
 
M
o
le
c
u
la
r 
W
e
ig
h
t 
M
. 
a
v
iu
m
 
M
. 
b
o
v
is
 
B
C
G
 
M
R
S
A
 
P
. 
A
a
 
C
J
2
0
0
9
 
1
 
 
6
9
1
.0
2
1
4
4
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
2
 
 
6
8
6
.1
6
8
8
4
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
3
 
 
7
0
1
.8
6
3
0
8
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
0
7
 |
 P
a
g
e
 
 
4
 
 
8
2
0
.1
3
5
4
2
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
5
 
 
8
0
6
.2
7
5
1
8
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
6
 
 
8
1
2
.9
6
1
7
8
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
7
 
 
7
3
3
.0
5
6
5
8
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
0
8
 |
 P
a
g
e
 
 
8
 
 
7
1
0
.1
8
8
7
0
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
9
 
 
7
3
4
.8
9
0
5
8
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
1
0
 
 
7
8
1
.0
9
9
3
8
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
1
1
 
 
7
6
7
.2
3
9
1
4
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
0
9
 |
 P
a
g
e
 
 
1
2
 
 
7
7
3
.9
2
5
7
4
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
1
3
 
 
8
7
1
.2
4
3
5
2
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
1
4
 
 
8
4
8
.3
7
5
6
4
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
1
5
 
 
8
6
4
.0
6
9
8
8
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
1
0
 |
 P
a
g
e
 
 
1
6
 
 
1
5
3
6
.2
0
4
6
8
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
1
7
 
 
7
3
7
.2
3
4
7
6
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
1
8
 
 
7
4
3
.9
2
1
3
6
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
1
9
 
 
9
3
1
.3
1
8
7
0
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
1
1
 |
 P
a
g
e
 
 
2
0
 
 
9
0
8
.4
5
0
8
2
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
2
1
 
 
9
4
2
.1
6
0
3
4
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
2
2
 
 
2
3
8
.3
7
2
3
4
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
2
3
 
 
5
3
2
.8
6
1
4
0
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
1
2
 |
 P
a
g
e
 
 
2
4
 
 
6
3
3
.3
5
9
8
6
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
2
5
 
 
5
0
2
.6
5
3
5
4
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
2
6
 
 
4
5
7
.9
1
8
9
6
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
2
7
 
 
1
3
6
7
.2
7
7
8
2
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
1
3
 |
 P
a
g
e
 
 
2
8
 
 
1
1
9
5
.6
9
0
3
3
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
2
9
 
 
1
6
8
0
.7
6
5
4
2
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
3
0
 
 
1
3
2
1
.2
0
9
3
8
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
3
1
 
 
1
1
4
9
.6
2
1
8
9
 
1
2
.5
 µ
M
 
1
2
.5
 µ
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
1
4
 |
 P
a
g
e
 
 
3
2
 
 
1
4
0
6
.3
1
3
8
6
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
3
3
 
 
1
2
7
0
.7
5
6
9
3
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
3
4
 
 
1
3
7
8
.2
6
0
7
0
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
3
5
 
 
1
2
0
6
.6
7
3
2
1
 
1
2
.5
 µ
M
 
2
5
 µ
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
1
5
 |
 P
a
g
e
 
 
3
6
 
 
1
4
6
6
.3
6
9
1
2
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
3
7
 
 
1
1
9
8
.7
7
3
5
6
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
3
8
 
 
1
8
0
2
.8
9
3
3
6
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
3
9
 
 
1
4
0
2
.2
8
5
4
0
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
1
6
 |
 P
a
g
e
 
 
4
0
 
 
1
1
3
4
.6
8
9
8
4
 
1
2
.5
 µ
M
 
5
0
 µ
M
 
>
5
0
 
M
 
>
5
0
 
M
 
4
1
 
 
9
0
6
.8
6
0
1
7
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
4
2
 
 
8
8
1
.2
8
3
1
6
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
4
3
 
 
9
6
1
.1
0
9
9
5
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
1
7
 |
 P
a
g
e
 
 
4
4
 
 
1
2
4
7
.1
9
3
5
1
 
6
.2
5
 µ
M
 
6
.2
5
 µ
M
 
>
5
0
 
M
 
>
5
0
 
M
 
4
5
 
 
1
2
6
5
.4
1
2
7
3
 
6
.2
5
 µ
M
 
6
.2
5
 µ
M
 
>
5
0
 
M
 
>
5
0
 
M
 
4
6
 
 
1
1
6
7
.5
7
0
6
6
 
3
.1
3
 µ
M
 
6
.2
5
 µ
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
1
8
 |
 P
a
g
e
 
 
4
7
 
 
1
0
9
1
.2
2
6
4
0
 
1
.5
6
 µ
M
 
3
.1
3
 µ
M
 
>
5
0
 
M
 
>
5
0
 
M
 
4
8
 
 
1
0
8
9
.3
9
2
4
0
 
0
.7
8
 µ
M
 
1
.5
6
 µ
M
 
5
0
 µ
M
 
>
5
0
 
M
 
4
9
 
 
7
6
8
.9
0
8
3
4
 
2
5
 µ
M
 
2
5
 µ
M
 
>
5
0
 
M
 
>
5
0
 
M
 
5
0
 
 
9
8
0
.9
1
5
5
7
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
1
9
 |
 P
a
g
e
 
 
5
1
 
 
9
3
7
.3
2
3
2
8
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
5
2
 
 
9
5
7
.1
7
2
5
6
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
5
3
 
 
1
0
8
2
.0
1
4
8
2
 
3
.1
3
 µ
M
 
3
.1
3
 µ
M
 
5
0
 µ
M
 
>
5
0
 
M
 
5
4
 (
c
y
c
la
m
) 
 
2
0
0
.3
2
4
3
6
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
2
0
 |
 P
a
g
e
 
 
5
5
 (
c
y
c
le
n
) 
 
1
7
2
.2
7
1
2
0
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
5
6
 
 
4
2
5
.5
2
2
4
0
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
5
7
 
 
3
8
5
.4
5
8
5
4
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
5
8
 
 
4
0
0
.4
7
3
1
8
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
5
9
 
 
9
3
9
.1
9
2
9
8
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
A
p
p
en
d
ix
 
1
2
1
 |
 P
a
g
e
 
 
6
0
 
 
7
3
5
.8
7
2
8
2
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
6
1
 
 
3
0
4
.1
3
8
7
0
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
6
2
 
 
2
6
6
.2
5
4
8
0
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
6
3
 (
b
io
ti
n
) 
 
2
4
4
.3
1
0
6
4
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
>
5
0
 
M
 
a
 P
. 
a
er
u
g
in
o
sa
. 
 
Bibliography 
122 | P a g e  
 
Bibliography  
ABS. 2013. 3303.0 - Causes of Death, Australia, 2011 [Online]. Available: 
http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3303.0Main+Features12011?OpenDocu
ment [Accessed]. 
ABUBAKAR, I., LAUNDY, M. T., FRENCH, C. E. & SHINGADIA, D. 2008. Epidemiology and 
treatment outcome of childhood tuberculosis in England and Wales: 1999-2006. Arch Dis 
Child, 93, 1017-21. 
ALMEIDA, D., NUERMBERGER, E., TASNEEN, R., ROSENTHAL, I., TYAGI, S., WILLIAMS, 
K., PELOQUIN, C. & GROSSET, J. 2009. Paradoxical effect of isoniazid on the activity of 
rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents 
Chemother, 53, 4178-84. 
ALVAREZ-LERMA, F., GRAU, S. & FERRANDEZ, O. 2009. Characteristics of doripenem: a new 
broad-spectrum antibiotic. Drug Des Devel Ther, 3, 173-90. 
AMARAL, C., VARELA, C., AZEVEDO, M., DA SILVA, E. T., ROLEIRA, F. M. F., CHEN, S., 
CORREIA-DA-SILVA, G. & TEIXEIRA, N. 2013. Effects of steroidal aromatase inhibitors on 
sensitive and resistant breast cancer cells: Aromatase inhibition and autophagy. The Journal of 
Steroid Biochemistry and Molecular Biology, 135, 51-59. 
AMIN, A. A., ZUROVAC, D., KANGWANA, B. B., GREENFIELD, J., OTIENO, D. N., 
AKHWALE, W. S. & SNOW, R. W. 2007. The challenges of changing national malaria drug 
policy to artemisinin-based combinations in Kenya. Malar J, 6, 72. 
ANDERSEN, D. H. 1949. Therapy and prognosis of fibrocystic disease of the pancreas. Pediatrics, 3, 
406-17. 
ANDERSEN DH, H. R. 1946. Celiac syndrome: V. genetics of cystic fibrosis of the pancreas with a 
consideration of etiology. American Journal of Diseases of Children, 72, 62-80. 
ANDERSON, C. P., SHEN, M., EISENSTEIN, R. S. & LEIBOLD, E. A. 2012. Mammalian iron 
metabolism and its control by iron regulatory proteins. Biochim Biophys Acta, 1823, 1468-83. 
ANDRIES, K., VERHASSELT, P., GUILLEMONT, J., GOHLMANN, H. W., NEEFS, J. M., 
WINKLER, H., VAN GESTEL, J., TIMMERMAN, P., ZHU, M., LEE, E., WILLIAMS, P., DE 
CHAFFOY, D., HUITRIC, E., HOFFNER, S., CAMBAU, E., TRUFFOT-PERNOT, C., 
LOUNIS, N. & JARLIER, V. 2005. A diarylquinoline drug active on the ATP synthase of 
Mycobacterium tuberculosis. Science, 307, 223-7. 
ARLEHAMN, C. S., SIDNEY, J., HENDERSON, R., GREENBAUM, J. A., JAMES, E. A., 
MOUTAFTSI, M., COLER, R., MCKINNEY, D. M., PARK, D., TAPLITZ, R., KWOK, W. 
W., GREY, H., PETERS, B. & SETTE, A. 2012. Dissecting mechanisms of immunodominance 
to the common tuberculosis antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and 
Rv1038c (EsxJ). J Immunol, 188, 5020-31. 
ASAY, L. D. 1965. Cystic Fibrosis. Calif Med, 102, 292-300. 
Bibliography 
123 | P a g e  
 
ASSAEL, B. M., PRESSLER, T., BILTON, D., FAYON, M., FISCHER, R., CHIRON, R., LAROSA, 
M., KNOOP, C., MCELVANEY, N., LEWIS, S. A., BRESNIK, M., MONTGOMERY, A. B. 
& OERMANN, C. M. 2012. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: 
A comparative efficacy trial. J Cyst Fibros. 
BAKER, E., RICHARDSON, D., GROSS, S. & PONKA, P. 1992. Evaluation of the iron chelation 
potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using 
the hepatocyte in culture. Hepatology, 15, 492-501. 
BALGANESH, T. S., ALZARI, P. M. & COLE, S. T. 2008. Rising standards for tuberculosis drug 
development. Trends Pharmacol Sci, 29, 576-81. 
BALLELL, L., BATES, R. H., YOUNG, R. J., ALVAREZ-GOMEZ, D., ALVAREZ-RUIZ, E., 
BARROSO, V., BLANCO, D., CRESPO, B., ESCRIBANO, J., GONZALEZ, R., LOZANO, 
S., HUSS, S., SANTOS-VILLAREJO, A., MARTIN-PLAZA, J. J., MENDOZA, A., 
REBOLLO-LOPEZ, M. J., REMUINAN-BLANCO, M., LAVANDERA, J. L., PEREZ-
HERRAN, E., GAMO-BENITO, F. J., GARCIA-BUSTOS, J. F., BARROS, D., CASTRO, J. P. 
& CAMMACK, N. 2013. Fueling open-source drug discovery: 177 small-molecule leads 
against tuberculosis. ChemMedChem, 8, 313-21. 
BANFI, E., SCIALINO, G. & MONTI-BRAGADIN, C. 2003. Development of a microdilution method 
to evaluate Mycobacterium tuberculosis drug susceptibility. J Antimicrob Chemother, 52, 796-
800. 
BARAKAT, K. H., GAJEWSKI, M. M. & TUSZYNSKI, J. A. 2012. DNA polymerase beta (pol beta) 
inhibitors: a comprehensive overview. Drug Discov Today, 17, 913-20. 
BARRY, C. E., 3RD, BOSHOFF, H. I., DARTOIS, V., DICK, T., EHRT, S., FLYNN, J., 
SCHNAPPINGER, D., WILKINSON, R. J. & YOUNG, D. 2009. The spectrum of latent 
tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol, 7, 845-55. 
BEAN, A. G., ROACH, D. R., BRISCOE, H., FRANCE, M. P., KORNER, H., SEDGWICK, J. D. & 
BRITTON, W. J. 1999. Structural deficiencies in granuloma formation in TNF gene-targeted 
mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, 
which is not compensated for by lymphotoxin. J Immunol, 162, 3504-11. 
BECKER, E. & RICHARDSON, D. R. 1999. Development of novel aroylhydrazone ligands for iron 
chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J Lab Clin Med, 
134, 510-21. 
BEHR, M. A. 2013. Evolution of Mycobacterium tuberculosis. Adv Exp Med Biol, 783, 81-91. 
BEHR, M. A., WILSON, M. A., GILL, W. P., SALAMON, H., SCHOOLNIK, G. K., RANE, S. & 
SMALL, P. M. 1999. Comparative genomics of BCG vaccines by whole-genome DNA 
microarray. Science, 284, 1520-3. 
BEKER, L. T., RUSSEK-COHEN, E. & FINK, R. J. 2001. Stature as a prognostic factor in cystic 
fibrosis survival. J Am Diet Assoc, 101, 438-42. 
BERMUDEZ, L. E. & SANGARI, F. J. 2001. Cellular and molecular mechanisms of internalization of 
mycobacteria by host cells. Microbes Infect, 3, 37-42. 
Bibliography 
124 | P a g e  
 
BERNHARDT, P. V. 2007. Coordination chemistry and biology of chelators for the treatment of iron 
overload disorders. Dalton Trans, 3214-20. 
BERNHARDT, P. V., CHIN, P. & RICHARDSON, D. R. 2001. Unprecedented oxidation of a 
biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification 
of diacylhydrazine ligands with high iron chelation efficacy. J Biol Inorg Chem, 6, 801-9. 
BERNHARDT, P. V., CHIN, P., SHARPE, P. C. & RICHARDSON, D. R. 2007. Hydrazone chelators 
for the treatment of iron overload disorders: iron coordination chemistry and biological activity. 
Dalton Trans, 3232-44. 
BEZUIDENHOUT, J., ROBERTS, T., MULLER, L., VAN HELDEN, P. & WALZL, G. 2009. Pleural 
tuberculosis in patients with early HIV infection is associated with increased TNF-alpha 
expression and necrosis in granulomas. PLoS One, 4, e4228. 
BIELECKI, P., GLIK, J., KAWECKI, M. & MARTINS DOS SANTOS, V. A. 2008. Towards 
understanding Pseudomonas aeruginosa burn wound infections by profiling gene expression. 
Biotechnol Lett, 30, 777-90. 
BONFIOLI, A. A., DE MIRANDA, S. S., CAMPOS, W. R. & OREFICE, F. 2005. Tuberculosis. 
Semin Ophthalmol, 20, 169-75. 
BOSE, M. 2008. Natural reservoir, zoonotic tuberculosis & interface with human tuberculosis: an 
unsolved question. Indian J Med Res, 128, 4-6. 
BOTTGER, E. C. & SPRINGER, B. 2008. Tuberculosis: drug resistance, fitness, and strategies for 
global control. Eur J Pediatr, 167, 141-8. 
BREWER, T. F. 2000. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis 
of the literature. Clin Infect Dis, 31 Suppl 3, S64-7. 
BROTO, P. M., G.; VANDYCKE, C. 1984. Molecular Structures: Perception, Autocorrelation 
Descriptor and SAR Studies. System of Atomic Contributions for the Calculation of the n-
Octanol/Water Partition Coefficients. Eur. J. Med. Chem. Chim. Theor. , 19, 71−78. 
BRUIJNINCX, P. C. & SADLER, P. J. 2008. New trends for metal complexes with anticancer activity. 
Curr Opin Chem Biol, 12, 197-206. 
BRUSILOW, S. W. 1970. Cystic fibrosis in adults. Annu Rev Med, 21, 99-104. 
BRYK, R., GOLD, B., VENUGOPAL, A., SINGH, J., SAMY, R., PUPEK, K., CAO, H., POPESCU, 
C., GURNEY, M., HOTHA, S., CHERIAN, J., RHEE, K., LY, L., CONVERSE, P. J., EHRT, 
S., VANDAL, O., JIANG, X., SCHNEIDER, J., LIN, G. & NATHAN, C. 2008. Selective 
killing of nonreplicating mycobacteria. Cell Host Microbe, 3, 137-45. 
BURNS, J. L., JONAS, M., CHI, E. Y., CLARK, D. K., BERGER, A. & GRIFFITH, A. 1996. 
Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia. Infect Immun, 
64, 4054-9. 
BYERS, B. R. & ARCENEAUX, J. E. 1998. Microbial iron transport: iron acquisition by pathogenic 
microorganisms. Met Ions Biol Syst, 35, 37-66. 
Bibliography 
125 | P a g e  
 
C.D.C 2007. Extensively drug-resistant tuberculosis--United States, 1993-2006. MMWR Morb Mortal 
Wkly Rep, 56, 250-3. 
CHAHINE, E. B., KARAOUI, L. R. & MANSOUR, H. 2013. Bedaquiline: A Novel Diarylquinoline 
for Multidrug-Resistant Tuberculosis. Ann Pharmacother. 
CHAN, E. D. & ISEMAN, M. D. 2002. Current medical treatment for tuberculosis. Bmj, 325, 1282-6. 
CHAN, E. D., STRAND, M. J. & ISEMAN, M. D. 2009. Multidrug-resistant tuberculosis (TB) 
resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy 
has a better prognosis than extensively drug-resistant TB. Clin Infect Dis, 48, e50-2. 
CHEI, W. S., LEE, J. W., KIM, J. B. & SUH, J. 2010. Cell-penetration by Co(III)cyclen-based peptide-
cleaving catalysts selective for pathogenic proteins of amyloidoses. Bioorg Med Chem, 18, 
5248-53. 
CHRISTOPHE, T., EWANN, F., JEON, H. K., CECHETTO, J. & BRODIN, P. 2010. High-content 
imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for 
tuberculosis drug discovery. Future Med Chem, 2, 1283-93. 
CISCRP. 2013. Clinical Trial Facts & Figures: General Information About Clinical Trials; 
The Drug Development Process: [Online]. Boston. Available: 
http://www.ciscrp.org/professional/facts_pat.html#2 [Accessed]. 
COLLINS, H. L. 2003. The role of iron in infections with intracellular bacteria. Immunol Lett, 85, 193-
5. 
CONNELL, T. G., RANGAKA, M. X., CURTIS, N. & WILKINSON, R. J. 2006. QuantiFERON-TB 
Gold: state of the art for the diagnosis of tuberculosis infection? Expert Rev Mol Diagn, 6, 663-
77. 
CONTI, A. A., LIPPI, D. & GENSINI, G. F. 2004. Tuberculosis: a long fight against it and its current 
resurgence. Monaldi Arch Chest Dis, 61, 71-4. 
COOPER, C. B. 2013. Development of Mycobacterium tuberculosis Whole Cell Screening Hits as 
Potential Antituberculosis Agents. J Med Chem, 56, 7755-60. 
COUSSENS, A., TIMMS, P. M., BOUCHER, B. J., VENTON, T. R., ASHCROFT, A. T., 
SKOLIMOWSKA, K. H., NEWTON, S. M., WILKINSON, K. A., DAVIDSON, R. N., 
GRIFFITHS, C. J., WILKINSON, R. J. & MARTINEAU, A. R. 2009. 1alpha,25-
dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium 
tuberculosis infection. Immunology, 127, 539-48. 
COX, H. S., MORROW, M. & DEUTSCHMANN, P. W. 2008. Long term efficacy of DOTS regimens 
for tuberculosis: systematic review. BMJ, 336, 484-7. 
CRICHTON, R. R., WILMET, S., LEGSSYER, R. & WARD, R. J. 2002. Molecular and cellular 
mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem, 91, 9-18. 
CRONJE, L. & BORNMAN, L. 2005. Iron overload and tuberculosis: a case for iron chelation therapy. 
Int J Tuberc Lung Dis, 9, 2-9. 
Bibliography 
126 | P a g e  
 
CRONJE, L., EDMONDSON, N., EISENACH, K. D. & BORNMAN, L. 2005. Iron and iron chelating 
agents modulate Mycobacterium tuberculosis growth and monocyte-macrophage viability and 
effector functions. FEMS Immunol Med Microbiol, 45, 103-12. 
DAS, R. R., SINGH, M. & SHAFIQ, N. 2012. Short-term therapeutic role of zinc in children < 5 years 
of age hospitalised for severe acute lower respiratory tract infection. Paediatr Respir Rev, 13, 
184-91. 
DAVIES, P. D. O. (ed.) 1998. Clinical Tuberculosis, London: Chapman & Hall Medical. 
DAVIS, R. A., SANDOVAL, I. T., CONCEPCION, G. P., MOREIRA DA ROCHA, R. & IRELAND, 
C. M. 2003. Lissoclinotoxins E and F, novel cytotoxic alkaloids from a Philippine didemnid 
ascidian. Tetrahedron, 59, 2855-2859. 
DE MONYE, C., KARCHER, D. S., BOELAERT, J. R. & GORDEUK, V. R. 1999. Bone marrow 
macrophage iron grade and survival of HIV-seropositive patients. Aids, 13, 375-80. 
DE SOUZA, M. V. 2006. Promising drugs against tuberculosis. Recent Pat Antiinfect Drug Discov, 1, 
33-44. 
DE VOSS, J. J., RUTTER, K., SCHROEDER, B. G., SU, H., ZHU, Y. & BARRY, C. E., 3RD 2000. 
The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for 
growth in macrophages. Proc Natl Acad Sci U S A, 97, 1252-7. 
DEBEBE, Z., AMMOSOVA, T., JEREBTSOVA, M., KURANTSIN-MILLS, J., NIU, X., CHARLES, 
S., RICHARDSON, D. R., RAY, P. E., GORDEUK, V. R. & NEKHAI, S. 2007. Iron chelators 
ICL670 and 311 inhibit HIV-1 transcription. Virology, 367, 324-33. 
DEBNATH, A., TUNAC, J. B., GALINDO-GOMEZ, S., SILVA-OLIVARES, A., SHIBAYAMA, M. 
& MCKERROW, J. H. 2012. Corifungin, a new drug lead against Naegleria, identified from a 
high-throughput screen. Antimicrob Agents Chemother, 56, 5450-7. 
DERIEMER, K., GARCIA-GARCIA, L., BOBADILLA-DEL-VALLE, M., PALACIOS-MARTINEZ, 
M., MARTINEZ-GAMBOA, A., SMALL, P. M., SIFUENTES-OSORNIO, J. & PONCE-DE-
LEON, A. 2005. Does DOTS work in populations with drug-resistant tuberculosis? Lancet, 
365, 1239-45. 
DHOPLE, A. M., IBANEZ, M. A. & POIRIER, T. C. 1996. Role of iron in the pathogenesis of 
Mycobacterium avium infection in mice. Microbios, 87, 77-87. 
DIACON, A. H., DAWSON, R., HANEKOM, M., NARUNSKY, K., VENTER, A., HITTEL, N., 
GEITER, L. J., WELLS, C. D., PACCALY, A. J. & DONALD, P. R. 2011. Early bactericidal 
activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J 
Tuberc Lung Dis, 15, 949-54. 
DIACON, A. H., DAWSON, R., VON GROOTE-BIDLINGMAIER, F., SYMONS, G., VENTER, A., 
DONALD, P. R., CONRADIE, A., ERONDU, N., GINSBERG, A. M., EGIZI, E., WINTER, 
H., BECKER, P. & MENDEL, C. M. 2013. Randomized dose-ranging study of the 14-day early 
bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-
positive pulmonary tuberculosis. Antimicrob Agents Chemother, 57, 2199-203. 
Bibliography 
127 | P a g e  
 
DIACON, A. H., DAWSON, R., VON GROOTE-BIDLINGMAIER, F., SYMONS, G., VENTER, A., 
DONALD, P. R., VAN NIEKERK, C., EVERITT, D., WINTER, H., BECKER, P., MENDEL, 
C. M. & SPIGELMAN, M. K. 2012. 14-day bactericidal activity of PA-824, bedaquiline, 
pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet, 380, 986-93. 
DIMASI, J. A., FELDMAN, L., SECKLER, A. & WILSON, A. 2010. Trends in risks associated with 
new drug development: success rates for investigational drugs. Clin Pharmacol Ther, 87, 272-7. 
DYE, C., ESPINAL, M. A., WATT, C. J., MBIAGA, C. & WILLIAMS, B. G. 2002a. Worldwide 
incidence of multidrug-resistant tuberculosis. J Infect Dis, 185, 1197-202. 
DYE, C., WILLIAMS, B. G., ESPINAL, M. A. & RAVIGLIONE, M. C. 2002b. Erasing the world's 
slow stain: strategies to beat multidrug-resistant tuberculosis. Science, 295, 2042-6. 
EBERL, L. & TUMMLER, B. 2004. Pseudomonas aeruginosa and Burkholderia cepacia in cystic 
fibrosis: genome evolution, interactions and adaptation. Int J Med Microbiol, 294, 123-31. 
EHRT, S. & SCHNAPPINGER, D. 2009. Mycobacterial survival strategies in the phagosome: defence 
against host stresses. Cell Microbiol, 11, 1170-8. 
ELKINGTON, P., SHIOMI, T., BREEN, R., NUTTALL, R. K., UGARTE-GIL, C. A., WALKER, N. 
F., SARAIVA, L., PEDERSEN, B., MAURI, F., LIPMAN, M., EDWARDS, D. R., 
ROBERTSON, B. D., D'ARMIENTO, J. & FRIEDLAND, J. S. 2011a. MMP-1 drives 
immunopathology in human tuberculosis and transgenic mice. J Clin Invest, 121, 1827-33. 
ELKINGTON, P. T., UGARTE-GIL, C. A. & FRIEDLAND, J. S. 2011b. Matrix metalloproteinases in 
tuberculosis. Eur Respir J, 38, 456-64. 
ENCINAS, L., O'KEEFE, H., NEU, M., REMUINAN, M. J., PATEL, A. M., GUARDIA, A., DAVIE, 
C. P., PEREZ-MACIAS, N., YANG, H., CONVERY, M. A., MESSER, J. A., PEREZ-
HERRAN, E., CENTRELLA, P. A., ALVAREZ-GOMEZ, D., CLARK, M. A., HUSS, S., 
O'DONOVAN, G. K., ORTEGA-MURO, F., MCDOWELL, W., CASTANEDA, P., ARICO-
MUENDEL, C. C., PAJK, S., RULLAS, J., ANGULO-BARTUREN, I., ALVAREZ-RUIZ, E., 
MENDOZA-LOSANA, A., PAGES, L. B., CASTRO-PICHEL, J. & EVINDAR, G. 2014. 
Encoded library technology as a source of hits for the discovery and lead optimization of a 
potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA. 
J Med Chem. 
ESPINAL, M. & FARMER, P. 2009. The Cambridge Declaration: towards clinical trials for drug-
resistant tuberculosis. Int J Tuberc Lung Dis, 13, 1-2. 
ESPINAL, M. A. 2003. The global situation of MDR-TB. Tuberculosis (Edinb), 83, 44-51. 
ESPINAL, M. A. & DYE, C. 2005. Can DOTS control multidrug-resistant tuberculosis? Lancet, 365, 
1206-9. 
FAILES, T. W. & HAMBLEY, T. W. 2007. Towards bioreductively activated prodrugs: Fe(III) 
complexes of hydroxamic acids and the MMP inhibitor marimastat. J Inorg Biochem, 101, 396-
403. 
FARMER, P. & KIM, J. Y. 1998. Community based approaches to the control of multidrug resistant 
tuberculosis: introducing "DOTS-plus". Bmj, 317, 671-4. 
Bibliography 
128 | P a g e  
 
FATTORINI, L., PICCARO, G., MUSTAZZOLU, A. & GIANNONI, F. 2013. Targeting Dormant 
Bacilli to Fight Tuberculosis. Mediterr J Hematol Infect Dis, 5, e2013072. 
FERNANDES, S. S., NUNES, A., GOMES, A. R., DE CASTRO, B., HIDER, R. C., RANGEL, M., 
APPELBERG, R. & GOMES, M. S. 2010. Identification of a new hexadentate iron chelator 
capable of restricting the intramacrophagic growth of Mycobacterium avium. Microbes Infect, 
12, 287-94. 
FERNANDEZ-OLMOS, A., GARCIA-CASTILLO, M., MAIZ, L., LAMAS, A., BAQUERO, F. & 
CANTON, R. 2012. In vitro prevention of Pseudomonas aeruginosa early biofilm formation 
with antibiotics used in cystic fibrosis patients. Int J Antimicrob Agents, 40, 173-6. 
FIGUEIREDO, R., MOITEIRO, C., MEDEIROS, M. A., DA SILVA, P. A., RAMOS, D., SPIES, F., 
RIBEIRO, M. O., LOURENCO, M. C., JUNIOR, I. N., GASPAR, M. M., CRUZ, M. E., 
CURTO, M. J., FRANZBLAU, S. G., OROZCO, H., AGUILAR, D., HERNANDEZ-PANDO, 
R. & COSTA, M. C. 2009. Synthesis and evaluation of rifabutin analogs against 
Mycobacterium avium and H(37)Rv, MDR and NRP Mycobacterium tuberculosis. Bioorg Med 
Chem, 17, 503-11. 
FLYNN, J. L. & CHAN, J. 2001. Immunology of tuberculosis. Annu Rev Immunol, 19, 93-129. 
FOLKESSON, A., JELSBAK, L., YANG, L., JOHANSEN, H. K., CIOFU, O., HOIBY, N. & MOLIN, 
S. 2012. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary 
perspective. Nat Rev Microbiol, 10, 841-51. 
FOUNDATION, C. F. 2012. Cystic Fibrosis Foundation Patient Registry 2011 Annual Data Report. In: 
FOUNDATION, C. F. (ed.). Bethesda, Maryland. 
FREDERIKSEN, B., PRESSLER, T., HANSEN, A., KOCH, C. & HOIBY, N. 2006. Effect of 
aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. 
Acta Paediatr, 95, 1070-4. 
FUNG, C., NAUGHTON, S., TURNBULL, L., TINGPEJ, P., ROSE, B., ARTHUR, J., HU, H., 
HARMER, C., HARBOUR, C., HASSETT, D. J., WHITCHURCH, C. B. & MANOS, J. 2010. 
Gene expression of Pseudomonas aeruginosa in a mucin-containing synthetic growth medium 
mimicking cystic fibrosis lung sputum. J Med Microbiol, 59, 1089-100. 
GANDHI, N. R., MOLL, A., STURM, A. W., PAWINSKI, R., GOVENDER, T., LALLOO, U., 
ZELLER, K., ANDREWS, J. & FRIEDLAND, G. 2006. Extensively drug-resistant tuberculosis 
as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South 
Africa. Lancet, 368, 1575-80. 
GEISOW, M. J., D'ARCY HART, P. & YOUNG, M. R. 1981. Temporal changes of lysosome and 
phagosome pH during phagolysosome formation in macrophages: studies by fluorescence 
spectroscopy. J Cell Biol, 89, 645-52. 
GERBERRY, D. J. 2009. Tradeoff between BCG vaccination and the ability to detect and treat latent 
tuberculosis. J Theor Biol. 
GHOSE, A. K. & CRIPPEN, G. M. 1987. Atomic physicochemical parameters for three-dimensional-
structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and 
hydrophobic interactions. J Chem Inf Comput Sci, 27, 21-35. 
Bibliography 
129 | P a g e  
 
GLER, M. T., SKRIPCONOKA, V., SANCHEZ-GARAVITO, E., XIAO, H., CABRERA-RIVERO, J. 
L., VARGAS-VASQUEZ, D. E., GAO, M., AWAD, M., PARK, S. K., SHIM, T. S., SUH, G. 
Y., DANILOVITS, M., OGATA, H., KURVE, A., CHANG, J., SUZUKI, K., TUPASI, T., 
KOH, W. J., SEAWORTH, B., GEITER, L. J. & WELLS, C. D. 2012. Delamanid for 
multidrug-resistant pulmonary tuberculosis. N Engl J Med, 366, 2151-60. 
GOLDENBERG, M. M. 2013. Pharmaceutical approval update. P T, 38, 150-2. 
GOMES, M. S., BOELAERT, J. R. & APPELBERG, R. 2001. Role of iron in experimental 
Mycobacterium avium infection. J Clin Virol, 20, 117-22. 
GORGANI, N., AHLBRAND, S., PATTERSON, A. & POURMAND, N. 2009. Detection of point 
mutations associated with antibiotic resistance in Pseudomonas aeruginosa. Int J Antimicrob 
Agents, 34, 414-8. 
GOSS, C. H. & RATJEN, F. 2013. Update in cystic fibrosis 2012. Am J Respir Crit Care Med, 187, 
915-9. 
GRABCHEV, I., STANEVA, D. & BETCHEVA, R. 2012. Fluorescent dendrimers as sensors for 
biologically important metal cations. Curr Med Chem, 19, 4976-83. 
GRASS, G., RENSING, C. & SOLIOZ, M. 2011. Metallic copper as an antimicrobial surface. Appl 
Environ Microbiol, 77, 1541-7. 
GREEN, J. A., LEWIN, S. R., WIGHTMAN, F., LEE, M., RAVINDRAN, T. S. & PATON, N. I. 
2005. A randomised controlled trial of oral zinc on the immune response to tuberculosis in 
HIV-infected patients. Int J Tuberc Lung Dis, 9, 1378-84. 
GREENSTEIN, R. J., SU, L. & BROWN, S. T. 2012. Vitamins A & D inhibit the growth of 
mycobacteria in radiometric culture. PLoS One, 7, e29631. 
HAAGSMA, A. C., ABDILLAHI-IBRAHIM, R., WAGNER, M. J., KRAB, K., VERGAUWEN, K., 
GUILLEMONT, J., ANDRIES, K., LILL, H., KOUL, A. & BALD, D. 2009. Selectivity of 
TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic 
homologue. Antimicrob Agents Chemother, 53, 1290-2. 
HAIDER, B. A., LASSI, Z. S., AHMED, A. & BHUTTA, Z. A. 2011. Zinc supplementation as an 
adjunct to antibiotics in the treatment of pneumonia in children 2 to 59 months of age. 
Cochrane Database Syst Rev, CD007368. 
HARE, N. J. & CORDWELL, S. J. 2010. Proteomics of bacterial pathogens: Pseudomonas aeruginosa 
infections in cystic fibrosis - a case study. Proteomics Clin Appl, 4, 228-48. 
HARMER, C. J., TRICCAS, J. A., HU, H., ROSE, B., BYE, P., ELKINS, M. & MANOS, J. 2012. 
Pseudomonas aeruginosa strains from the chronically infected cystic fibrosis lung display 
increased invasiveness of A549 epithelial cells over time. Microb Pathog, 53, 37-43. 
HARRISON, F. 2007. Microbial ecology of the cystic fibrosis lung. Microbiology, 153, 917-23. 
HAWGOOD, B. J. 2007. Albert Calmette (1863-1933) and Camille Guerin (1872-1961): the C and G 
of BCG vaccine. J Med Biogr, 15, 139-46. 
Bibliography 
130 | P a g e  
 
HERMES-LIMA, M., PONKA, P. & SCHULMAN, H. M. 2000. The iron chelator pyridoxal 
isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by 
ferric iron plus ascorbate. Biochim Biophys Acta, 1523, 154-60. 
HERSHKO, C. 1994. Control of disease by selective iron depletion: a novel therapeutic strategy 
utilizing iron chelators. Baillieres Clin Haematol, 7, 965-1000. 
HJELTE, L., PETRINI, B., KALLENIUS, G. & STRANDVIK, B. 1990. Prospective study of 
mycobacterial infections in patients with cystic fibrosis. Thorax, 45, 397-400. 
HOFT, D. F. 2008. Tuberculosis vaccine development: goals, immunological design, and evaluation. 
Lancet, 372, 164-75. 
HONAKER, R. W., STEWART, A., SCHITTONE, S., IZZO, A., KLEIN, M. R. & VOSKUIL, M. I. 
2008. Mycobacterium bovis BCG vaccine strains lack narK2 and narX induction and exhibit 
altered phenotypes during dormancy. Infect Immun, 76, 2587-93. 
HRABEC, E., STREK, M., ZIEBA, M., KWIATKOWSKA, S. & HRABEC, Z. 2002. Circulation level 
of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. The 
International Journal of Tuberculosis and Lung Disease, 6, 713-719. 
HU, H., HARMER, C., ANUJ, S., WAINWRIGHT, C. E., MANOS, J., CHENEY, J., HARBOUR, C., 
ZABLOTSKA, I., TURNBULL, L., WHITCHURCH, C. B., GRIMWOOD, K. & ROSE, B. 
2013. Type 3 secretion system effector genotype and secretion phenotype of longitudinally 
collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis 
following newborn screening. Clin Microbiol Infect, 19, 266-72. 
HURLEY, M. N., CAMARA, M. & SMYTH, A. R. 2012. Novel approaches to the treatment of 
Pseudomonas aeruginosa infections in cystic fibrosis. Eur Respir J, 40, 1014-23. 
HUSSAIN, S., MALIK, M., SHI, L., GENNARO, M. L. & DRLICA, K. 2009. In vitro model of 
mycobacterial growth arrest using nitric oxide with limited air. Antimicrob Agents Chemother, 
53, 157-61. 
HWANG, S. S., KIM, H. R., KIM, H. J., KIM, M. J., LEE, S. M., YOO, C. G., KIM, Y. W., HAN, S. 
K., SHIM, Y. S. & YIM, J. J. 2009. Impact of resistance to first-line and injectable drugs on 
treatment outcomes in MDR-TB. Eur Respir J, 33, 581-5. 
I.U.T.L.D 1998. Guidelines for surveillance of drug resistance in tuberculosis. WHO Geneva/IUATLD 
Paris. International Union Against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis, 2, 
72-89. 
ISEMAN, M. D. 2002. Tuberculosis therapy: past, present and future. Eur Respir J Suppl, 36, 87s-94s. 
IZZO, A. A., IZZO, L. S., KASIMOS, J. & MAJKA, S. 2004. A matrix metalloproteinase inhibitor 
promotes granuloma formation during the early phase of Mycobacterium tuberculosis 
pulmonary infection. Tuberculosis, 84, 387-396. 
JASSAL, M. & BISHAI, W. R. 2009. Extensively drug-resistant tuberculosis. Lancet Infect Dis, 9, 19-
30. 
Bibliography 
131 | P a g e  
 
JENSEN, T., PEDERSEN, S. S., GARNE, S., HEILMANN, C., HOIBY, N. & KOCH, C. 1987. 
Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung 
infection. J Antimicrob Chemother, 19, 831-8. 
JIH, K. Y. & HWANG, T. C. 2013. Vx-770 potentiates CFTR function by promoting decoupling 
between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci U S A, 110, 4404-9. 
JOHNSON, R., STREICHER, E. M., LOUW, G. E., WARREN, R. M., VAN HELDEN, P. D. & 
VICTOR, T. C. 2006. Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol, 8, 
97-111. 
JOMOVA, K. & VALKO, M. 2011. Advances in metal-induced oxidative stress and human disease. 
Toxicology, 283, 65-87. 
KAITIN, K. I. 2010. Deconstructing the drug development process: the new face of innovation. Clin 
Pharmacol Ther, 87, 356-61. 
KALINOWSKI, D. S., SHARPE, P. C., BERNHARDT, P. V. & RICHARDSON, D. R. 2008. 
Structure-activity relationships of novel iron chelators for the treatment of iron overload 
disease: the methyl pyrazinylketone isonicotinoyl hydrazone series. J Med Chem, 51, 331-44. 
KALINOWSKI, D. S., YU, Y., SHARPE, P. C., ISLAM, M., LIAO, Y. T., LOVEJOY, D. B., 
KUMAR, N., BERNHARDT, P. V. & RICHARDSON, D. R. 2007. Design, synthesis, and 
characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine 
thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J Med 
Chem, 50, 3716-29. 
KANG, S. K., LEE, J. H., LEE, Y. C. & KIM, C. H. 2006. Catalase-peroxidase of Mycobacterium 
bovis BCG converts isoniazid to isonicotinamide, but not to isonicotinic acid: differentiation 
parameter between enzymes of Mycobacterium bovis BCG and Mycobacterium tuberculosis. 
Biochim Biophys Acta, 1760, 724-9. 
KANYOK, T. P., REDDY, M. V., CHINNASWAMY, J., DANZIGER, L. H. & GANGADHARAM, 
P. R. 1994. In vivo activity of paromomycin against susceptible and multidrug-resistant 
Mycobacterium tuberculosis and M. avium complex strains. Antimicrob Agents Chemother, 38, 
170-3. 
KEREM, B., ROMMENS, J. M., BUCHANAN, J. A., MARKIEWICZ, D., COX, T. K., 
CHAKRAVARTI, A., BUCHWALD, M. & TSUI, L. C. 1989. Identification of the cystic 
fibrosis gene: genetic analysis. Science, 245, 1073-80. 
KERR, K. G. & SNELLING, A. M. 2009. Pseudomonas aeruginosa: a formidable and ever-present 
adversary. J Hosp Infect, 73, 338-44. 
KILBY, J. M., GILLIGAN, P. H., YANKASKAS, J. R., HIGHSMITH, W. E., JR., EDWARDS, L. J. 
& KNOWLES, M. R. 1992. Nontuberculous mycobacteria in adult patients with cystic fibrosis. 
Chest, 102, 70-5. 
KIM, H. M., JANG, B., CHEON, Y. E., SUH, M. P. & SUH, J. 2009. Proteolytic activity of Co(III) 
complex of 1-oxa-4,7,10-triazacyclododecane: a new catalytic center for peptide-cleavage 
agents. J Biol Inorg Chem, 14, 151-7. 
Bibliography 
132 | P a g e  
 
KING, J. D., KOCINCOVA, D., WESTMAN, E. L. & LAM, J. S. 2009. Review: Lipopolysaccharide 
biosynthesis in Pseudomonas aeruginosa. Innate Immun, 15, 261-312. 
KOCH, R. 1882. Die aetiologie der tuberculose. Berliner Klinische Wochenschrift 19, 221-230. 
KOCINCOVA, D. & LAM, J. S. 2011. Structural diversity of the core oligosaccharide domain of 
Pseudomonas aeruginosa lipopolysaccharide. Biochemistry (Mosc), 76, 755-60. 
KOUL, A., ARNOULT, E., LOUNIS, N., GUILLEMONT, J. & ANDRIES, K. 2011. The challenge of 
new drug discovery for tuberculosis. Nature, 469, 483-90. 
KOVACEVIC, Z., CHIKHANI, S., LOVEJOY, D. B. & RICHARDSON, D. R. 2011. Novel 
thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis 
suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic 
cancer. Mol Pharmacol, 80, 598-609. 
KOZAK, S. F., INDERLIED, C. B., HSU, H. Y., HELLER, K. B. & SADUN, A. A. 1998. The Role of 
Copper on Ethambutol’s Antimicrobial Action and Implications for Ethambutol-induced Optic 
Neuropathy. Diagn Microbiol Infect Dis, 30, 83-87. 
KUMAR, D., WATSON, J. M., CHARLETT, A., NICHOLAS, S. & DARBYSHIRE, J. H. 1997. 
Tuberculosis in England and Wales in 1993: results of a national survey. Public Health 
Laboratory Service/British Thoracic Society/Department of Health Collaborative Group. 
Thorax, 52, 1060-7. 
LAM, J., VAUGHAN, S. & PARKINS, M. D. 2013. Tobramycin Inhalation Powder (TIP): An 
Efficient Treatment Strategy for the Management of Chronic Infection in Cystic Fibrosis. Clin 
Med Insights Circ Respir Pulm Med, 7, 61-77. 
LAM, J. S., TAYLOR, V. L., ISLAM, S. T., HAO, Y. & KOCINCOVA, D. 2011. Genetic and 
Functional Diversity of Pseudomonas aeruginosa Lipopolysaccharide. Front Microbiol, 2, 118. 
LANDS, L. C. & STANOJEVIC, S. 2013. Oral non-steroidal anti-inflammatory drug therapy for lung 
disease in cystic fibrosis. Cochrane Database Syst Rev, 6, CD001505. 
LECHARTIER, B., HARTKOORN, R. C. & COLE, S. T. 2012. In vitro combination studies of 
benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob 
Agents Chemother, 56, 5790-3. 
LINK, G., PONKA, P., KONIJN, A. M., BREUER, W., CABANTCHIK, Z. I. & HERSHKO, C. 2003. 
Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and 
deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Blood, 101, 4172-9. 
LIPINSKI, C. A. 2004. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery 
Today: Technologies, 1, 337-341. 
LIU, H., FUJIWARA, T., NISHIKAWA, T., MISHIMA, Y., NAGAI, H., SHIDA, T., TACHIBANA, 
K., KOBAYASHI, H., MANGINDAAN, R. E. P. & NAMIKOSHI, M. 2005. Lissoclibadins 1–
3, three new polysulfur alkaloids, from the ascidian Lissoclinum cf. badium. Tetrahedron, 61, 
8611-8615. 
LIU, J., TRAN, V., LEUNG, A. S., ALEXANDER, D. C. & ZHU, B. 2009. BCG vaccines: their 
mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin, 5, 70-8. 
Bibliography 
133 | P a g e  
 
LODDENKEMPER, R., SAGEBIEL, D. & BRENDEL, A. 2002. Strategies against multidrug-resistant 
tuberculosis. Eur Respir J Suppl, 36, 66s-77s. 
LOPES, A. J., MAFORT, T. T., DE SA FERREIRA, A., SANTOS DE CASTRO, M. C., CASSIA DE 
FIRMIDA, M. & DE ANDRADE MARQUES, E. 2012. Is the type of chronic pulmonary 
infection a determinant of lung function outcomes in adult patients with cystic fibrosis? 
Monaldi Arch Chest Dis, 77, 122-8. 
LOUNIS, N., TRUFFOT-PERNOT, C., GROSSET, J., GORDEUK, V. R. & BOELAERT, J. R. 2001. 
Iron and Mycobacterium tuberculosis infection. J Clin Virol, 20, 123-6. 
LOVEJOY, D. B., SHARP, D. M., SEEBACHER, N., OBEIDY, P., PRICHARD, T., STEFANI, C., 
BASHA, M. T., SHARPE, P. C., JANSSON, P. J., KALINOWSKI, D. S., BERNHARDT, P. 
V. & RICHARDSON, D. R. 2012. Novel second-generation di-2-pyridylketone 
thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent 
activity against lung cancer xenografts after oral and intravenous administration in vivo. J Med 
Chem, 55, 7230-44. 
LUMB, R., BASTIAN, I., GILPIN, C., JELFS, P., KEEHNER, T. & SIEVERS, A. 2008. Tuberculosis 
in Australia: bacteriologically confirmed cases and drug resistance, 2006 a report of the 
Australian Mycobacterium Reference Laboratory Network. Commun Dis Intell, 32, 12-7. 
LV, J.-S., PENG, X.-M., KISHORE, B. & ZHOU, C.-H. 2014. 1,2,3-Triazole-derived naphthalimides 
as a novel type of potential antimicrobial agents: Synthesis, antimicrobial activity, interaction 
with calf thymus DNA and human serum albumin. Bioorg Med Chem Lett, 24, 308-313. 
LYCZAK, J. B., CANNON, C. L. & PIER, G. B. 2002. Lung infections associated with cystic fibrosis. 
Clin Microbiol Rev, 15, 194-222. 
MA, Z., LIENHARDT, C., MCILLERON, H., NUNN, A. J. & WANG, X. 2010. Global tuberculosis 
drug development pipeline: the need and the reality. Lancet, 375, 2100-9. 
MAARTENS, G. & WILKINSON, R. J. 2007. Tuberculosis. Lancet, 370, 2030-43. 
MACCARI, R., OTTANÀ, R., BOTTARI, B., ROTONDO, E. & VIGORITA, M. G. 2004. In vitro 
advanced antimycobacterial screening of cobalt(II) and copper(II) complexes of fluorinated 
isonicotinoylhydrazones. Bioorg Med Chem Lett, 14, 5731-5733. 
MADARIAGA, M. G., LALLOO, U. G. & SWINDELLS, S. 2008. Extensively drug-resistant 
tuberculosis. Am J Med, 121, 835-44. 
MAK, P. A., RAO, S. P., PING TAN, M., LIN, X., CHYBA, J., TAY, J., NG, S. H., TAN, B. H., 
CHERIAN, J., DURAISWAMY, J., BIFANI, P., LIM, V., LEE, B. H., LING MA, N., BEER, 
D., THAYALAN, P., KUHEN, K., CHATTERJEE, A., SUPEK, F., GLYNNE, R., ZHENG, J., 
BOSHOFF, H. I., BARRY, C. E., 3RD, DICK, T., PETHE, K. & CAMACHO, L. R. 2012. A 
high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating 
Mycobacterium tuberculosis. ACS Chem Biol, 7, 1190-7. 
MAKAROV, V., MANINA, G., MIKUSOVA, K., MOLLMANN, U., RYABOVA, O., SAINT-
JOANIS, B., DHAR, N., PASCA, M. R., BURONI, S., LUCARELLI, A. P., MILANO, A., DE 
ROSSI, E., BELANOVA, M., BOBOVSKA, A., DIANISKOVA, P., KORDULAKOVA, J., 
SALA, C., FULLAM, E., SCHNEIDER, P., MCKINNEY, J. D., BRODIN, P., CHRISTOPHE, 
Bibliography 
134 | P a g e  
 
T., WADDELL, S., BUTCHER, P., ALBRETHSEN, J., ROSENKRANDS, I., BROSCH, R., 
NANDI, V., BHARATH, S., GAONKAR, S., SHANDIL, R. K., BALASUBRAMANIAN, V., 
BALGANESH, T., TYAGI, S., GROSSET, J., RICCARDI, G. & COLE, S. T. 2009. 
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science, 
324, 801-4. 
MAKAROV, V., RIABOVA, O. B., YUSCHENKO, A., URLYAPOVA, N., DAUDOVA, A., 
ZIPFEL, P. F. & MOLLMANN, U. 2006. Synthesis and antileprosy activity of some 
dialkyldithiocarbamates. J Antimicrob Chemother, 57, 1134-8. 
MARTINEAU, A. R., HONECKER, F. U., WILKINSON, R. J. & GRIFFITHS, C. J. 2007. Vitamin D 
in the treatment of pulmonary tuberculosis. The Journal of Steroid Biochemistry and Molecular 
Biology, 103, 793-798. 
MATSUMOTO, M., HASHIZUME, H., TOMISHIGE, T., KAWASAKI, M., TSUBOUCHI, H., 
SASAKI, H., SHIMOKAWA, Y. & KOMATSU, M. 2006. OPC-67683, a nitro-dihydro-
imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS 
Med, 3, e466. 
MATTHEWS, L. W., DOERSHUK, C. F., WISE, M., EDDY, G., NUDELMAN, H. & SPECTOR, S. 
1964. A Therapeutic Regimen for Patients with Cystic Fibrosis. J Pediatr, 65, 558-75. 
MEHTAR, S., WIID, I. & TODOROV, S. D. 2008. The antimicrobial activity of copper and copper 
alloys against nosocomial pathogens and Mycobacterium tuberculosis isolated from healthcare 
facilities in the Western Cape: an in-vitro study. J Hosp Infect, 68, 45-51. 
MIZUSHINA, Y., TAKIKAWA, H., IMAMURA, Y., SASAKI, M., MORI, K. & YOSHIDA, H. 
2005. Inhibitory effect of mispyric acid on mammalian DNA polymerases. Biosci Biotechnol 
Biochem, 69, 1534-8. 
MOSKOWITZ, S. M., SILVA, S. J., MAYER-HAMBLETT, N., PASTA, D. J., MINK, D. R., 
MABIE, J. A., KONSTAN, M. W. & WAGENER, J. S. 2008. Shifting patterns of inhaled 
antibiotic use in cystic fibrosis. Pediatr Pulmonol, 43, 874-81. 
MOUTON, J. W., DEN HOLLANDER, J. G. & HORREVORTS, A. M. 1993. Emergence of antibiotic 
resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J 
Antimicrob Chemother, 31, 919-26. 
MUBAREKA, S., LEUNG, V., AOKI, F. Y. & VINH, D. C. 2010. Famciclovir: a focus on efficacy 
and safety. Expert Opin Drug Saf, 9, 643-58. 
MURRAY, P. R., ROSENTHAL, K. S. & PFALLER, M. A. 2005. Medical Microbiology, United 
States of America, Elsevier Mosby. 
NIKONENKO, B. V., SAMALA, R., EINCK, L. & NACY, C. A. 2004. Rapid, simple in vivo screen 
for new drugs active against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 48, 
4550-5. 
NOEL, S., DHOOGHE, B. & LEAL, T. 2012. PDE5 Inhibitors as Potential Tools in the Treatment of 
Cystic Fibrosis. Front Pharmacol, 3, 167. 
Bibliography 
135 | P a g e  
 
NUNES, A., PODINOVSKAIA, M., LEITE, A., GAMEIRO, P., ZHOU, T., MA, Y., KONG, X., 
SCHAIBLE, U. E., HIDER, R. C. & RANGEL, M. 2010. Fluorescent 3-hydroxy-4-pyridinone 
hexadentate iron chelators: intracellular distribution and the relevance to antimycobacterial 
properties. J Biol Inorg Chem, 15, 861-77. 
NURSYAM, E. W., AMIN, Z. & RUMENDE, C. M. 2006. The effect of vitamin D as supplementary 
treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med 
Indones, 38, 3-5. 
O'CARROLL, M. R., SYRMIS, M. W., WAINWRIGHT, C. E., GREER, R. M., MITCHELL, P., 
COULTER, C., SLOOTS, T. P., NISSEN, M. D. & BELL, S. C. 2004. Clonal strains of 
Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J, 24, 101-6. 
ODA, T., KAMOSHITA, K., MARUYAMA, S., MASUDA, K., NISHIMOTO, M., XU, J., UKAI, K., 
MANGINDAAN, R. E. & NAMIKOSHI, M. 2007. Cytotoxicity of lissoclibadins and 
lissoclinotoxins, isolated from a tropical ascidian Lissoclinum cf. badium, against human solid-
tumor-derived cell lines. Biol Pharm Bull, 30, 385-7. 
ORENSTEIN, D. M., WINNIE, G. B. & ALTMAN, H. 2002. Cystic fibrosis: a 2002 update. J Pediatr, 
140, 156-64. 
PARKS, W. C. & SHAPIRO, S. D. 2001. Matrix metalloproteinases in lung biology. Respir Res, 2, 10-
9. 
PAUSTENBACH, D. J., TVERMOES, B. E., UNICE, K. M., FINLEY, B. L. & KERGER, B. D. 2013. 
A review of the health hazards posed by cobalt. Crit Rev Toxicol, 43, 316-62. 
PAYNE, D. J., GWYNN, M. N., HOLMES, D. J. & POMPLIANO, D. L. 2007. Drugs for bad bugs: 
confronting the challenges of antibacterial discovery. Nat Rev Drug Discov, 6, 29-40. 
PÉREZ, E., SAMPER, S., BORDAS, Y., GUILHOT, C., GICQUEL, B. & MARTÍN, C. 2001. An 
essential role for phoP in Mycobacterium tuberculosis virulence. Molecular Microbiology, 41, 
179-187. 
PETHE, K., BIFANI, P., JANG, J., KANG, S., PARK, S., AHN, S., JIRICEK, J., JUNG, J., JEON, H. 
K., CECHETTO, J., CHRISTOPHE, T., LEE, H., KEMPF, M., JACKSON, M., LENAERTS, 
A. J., PHAM, H., JONES, V., SEO, M. J., KIM, Y. M., SEO, M., SEO, J. J., PARK, D., KO, 
Y., CHOI, I., KIM, R., KIM, S. Y., LIM, S., YIM, S. A., NAM, J., KANG, H., KWON, H., 
OH, C. T., CHO, Y., JANG, Y., KIM, J., CHUA, A., TAN, B. H., NANJUNDAPPA, M. B., 
RAO, S. P., BARNES, W. S., WINTJENS, R., WALKER, J. R., ALONSO, S., LEE, S., OH, 
S., OH, T., NEHRBASS, U., HAN, S. J., NO, Z., LEE, J., BRODIN, P., CHO, S. N. & NAM, 
K. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat 
Med, 19, 1157-60. 
PINTO, R., SAUNDERS, B. M., CAMACHO, L. R., BRITTON, W. J., GICQUEL, B. & TRICCAS, J. 
A. 2004. Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation 
provides greater protective immunity against tuberculosis than the existing bacille Calmette-
Guerin vaccine. J Infect Dis, 189, 105-12. 
PITT, T. L. 1986. Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic 
fibrosis. J R Soc Med, 79 Suppl 12, 13-8. 
Bibliography 
136 | P a g e  
 
PONKA, P., BOROVA, J., NEUWIRT, J. & FUCHS, O. 1979. Mobilization of iron from reticulocytes. 
Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett, 
97, 317-21. 
PRADINES, B., ROLAIN, J. M., RAMIANDRASOA, F., FUSAI, T., MOSNIER, J., ROGIER, C., 
DARIES, W., BARET, E., KUNESCH, G., LE BRAS, J. & PARZY, D. 2002. Iron chelators as 
antimalarial agents: in vitro activity of dicatecholate against Plasmodium falciparum. J 
Antimicrob Chemother, 50, 177-87. 
PRASAD, A. S. 2009. Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin 
Clin Nutr Metab Care, 12, 646-52. 
PROMEGA. 2013. CellTiter-Blue® Cell Viability Assay Instructions for use of Products [Online]. 
Available: 
http://au.promega.com/~/media/Files/Resources/Protocols/Technical%20Bulletins/101/CellTite
r-Blue%20Cell%20Viability%20Assay%20Protocol.pdf [Accessed]. 
PROUST, A. J., ABRAHAMS, E. W., BRESLIN, A. B. X. & ROBERTSON, D. G. 1982. Treatment of 
Tuberculosis, Canberra, Australian Government Publishing Service. 
PUZO, G. 1990. The carbohydrate- and lipid-containing cell wall of mycobacteria, phenolic 
glycolipids: structure and immunological properties. Crit Rev Microbiol, 17, 305-27. 
QUEMARD, A., LACAVE, C. & LANEELLE, G. 1991. Isoniazid inhibition of mycolic acid synthesis 
by cell extracts of sensitive and resistant strains of Mycobacterium aurum. Antimicrob Agents 
Chemother, 35, 1035-9. 
RALPH, P. & NAKOINZ, I. 1977. Antibody-dependent killing of erythrocyte and tumor targets by 
macrophage-related cell lines: enhancement by PPD and LPS. J Immunol, 119, 950-54. 
RASMUSSEN, H. S. & MCCANN, P. P. 1997. Matrix Metalloproteinase Inhibition as a Novel 
Anticancer Strategy: A Review with Special Focus on Batimastat and Marimastat. 
Pharmacology & Therapeutics, 75, 69-75. 
REEVES, E. P., MOLLOY, K., POHL, K. & MCELVANEY, N. G. 2012. Hypertonic saline in 
treatment of pulmonary disease in cystic fibrosis. ScientificWorldJournal, 2012, 465230. 
RICHARDSON, D., VITOLO, L. W., BAKER, E. & WEBB, J. 1989. Pyridoxal isonicotinoyl 
hydrazone and analogues. Study of their stability in acidic, neutral and basic aqueous solutions 
by ultraviolet-visible spectrophotometry. Biol Met, 2, 69-76. 
RICHARDSON, D. R., BECKER, E. & BERNHARDT, P. V. 1999. The biologically active iron 
chelators 2-pyridylcarboxaldehyde isonicotinoylhydrazone, 2-pyridylcarboxaldehyde 
benzoylhydrazone monohydrate and 2-furaldehyde isonicotinoylhydrazone. Acta Crystallogr C, 
55 ( Pt 12), 2102-5. 
RICHARDSON, D. R., KALINOWSKI, D. S., LAU, S., JANSSON, P. J. & LOVEJOY, D. B. 2008. 
Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. 
Biochim Biophys Acta. 
Bibliography 
137 | P a g e  
 
RICHARDSON, D. R., KALINOWSKI, D. S., LAU, S., JANSSON, P. J. & LOVEJOY, D. B. 2009. 
Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. 
Biochim Biophys Acta, 1790, 702-17. 
RICHARDSON, D. R., MOURALIAN, C., PONKA, P. & BECKER, E. 2001. Development of 
potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize 
mitochondrial iron. Biochim Biophys Acta, 1536, 133-40. 
RICHARDSON, D. R. & PONKA, P. 1998a. Orally effective iron chelators for the treatment of iron 
overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its 
analogs. J Lab Clin Med, 132, 351-2. 
RICHARDSON, D. R. & PONKA, P. 1998b. Pyridoxal isonicotinoyl hydrazone and its analogs: 
potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab 
Clin Med, 131, 306-15. 
RICHARDSON, D. R., TRAN, E. H. & PONKA, P. 1995. The potential of iron chelators of the 
pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood, 86, 4295-
306. 
RICHARDSON, D. R., WIS VITOLO, L. M., HEFTER, G. T., MAY, P. M., CLARE, B. W., WEBB, 
J. & WILAIRAT, P. 1990. Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part I. 
Ionisation characteristics of the ligands and their relevance to biological properties. Inorganica 
Chimica Acta, 170, 165-170. 
RIORDAN, J. R., ROMMENS, J. M., KEREM, B., ALON, N., ROZMAHEL, R., GRZELCZAK, Z., 
ZIELENSKI, J., LOK, S., PLAVSIC, N., CHOU, J. L. & ET AL. 1989. Identification of the 
cystic fibrosis gene: cloning and characterization of complementary DNA. Science, 245, 1066-
73. 
RITZ, N., HANEKOM, W. A., ROBINS-BROWNE, R., BRITTON, W. J. & CURTIS, N. 2008. 
Influence of BCG vaccine strain on the immune response and protection against tuberculosis. 
FEMS Microbiol Rev, 32, 821-41. 
ROGALL, T., WOLTERS, J., FLOHR, T. & BOTTGER, E. C. 1990. Towards a phylogeny and 
definition of species at the molecular level within the genus Mycobacterium. Int J Syst 
Bacteriol, 40, 323-30. 
ROSS, J. D. & HORNE, N. W. 1976. Modern Drug Treatment in Tuberculosis, London, The Chest, 
Heart and Stroke Association. 
RUSSELL, D. G., CARDONA, P. J., KIM, M. J., ALLAIN, S. & ALTARE, F. 2009. Foamy 
macrophages and the progression of the human tuberculosis granuloma. Nat Immunol, 10, 943-
8. 
RYAN, G., SINGH, M. & DWAN, K. 2011. Inhaled antibiotics for long-term therapy in cystic fibrosis. 
Cochrane Database Syst Rev, CD001021. 
SAIMAN, L. 2004. Microbiology of early CF lung disease. Paediatr Respir Rev, 5 Suppl A, S367-9. 
SAKULA, A. 1983. Robert koch: centenary of the discovery of the tubercle bacillus, 1882. Can Vet J, 
24, 127-31. 
Bibliography 
138 | P a g e  
 
SANCHEZ, C. J., JR., MENDE, K., BECKIUS, M. L., AKERS, K. S., ROMANO, D. R., WENKE, J. 
C. & MURRAY, C. K. 2013. Biofilm formation by clinical isolates and the implications in 
chronic infections. BMC Infect Dis, 13, 47. 
SANGARI, F. J., PARKER, A. & BERMUDEZ, L. E. 1999. Mycobacterium avium interaction with 
macrophages and intestinal epithelial cells. Front Biosci, 4, D582-8. 
SCHMIDT, F. R. 2004. The challenge of multidrug resistance: actual strategies in the development of 
novel antibacterials. Appl Microbiol Biotechnol, 63, 335-43. 
SCHWARZ, S. & KEHRENBERG, C. 2006. Old dogs that learn new tricks: Modified antimicrobial 
agents that escape pre-existing resistance mechanisms. Int J Med Microbiol, 296, Supplement 2, 
45-49. 
SHINNICK, T. M. & GOOD, R. C. 1994. Mycobacterial taxonomy. Eur J Clin Microbiol Infect Dis, 
13, 884-901. 
SHOFF, S. M., TLUCZEK, A., LAXOVA, A., FARRELL, P. M. & LAI, H. J. 2013. Nutritional status 
is associated with health-related quality of life in children with cystic fibrosis aged 9–
19&#xa0;years. Journal of Cystic Fibrosis. 
SILBY, M. W., WINSTANLEY, C., GODFREY, S. A., LEVY, S. B. & JACKSON, R. W. 2011. 
Pseudomonas genomes: diverse and adaptable. FEMS Microbiol Rev, 35, 652-80. 
SINCLAIR, D., ABBA, K., GROBLER, L. & SUDARSANAM, T. D. 2011. Nutritional supplements 
for people being treated for active tuberculosis. Cochrane Database Syst Rev, CD006086. 
SIPILANYAMBE, N., SIMON, J. L., CHANDA, P., OLUMESE, P., SNOW, R. W. & HAMER, D. H. 
2008. From chloroquine to artemether-lumefantrine: the process of drug policy change in 
Zambia. Malar J, 7, 25. 
SKRIPCONOKA, V., DANILOVITS, M., PEHME, L., TOMSON, T., SKENDERS, G., KUMMIK, 
T., CIRULE, A., LEIMANE, V., KURVE, A., LEVINA, K., GEITER, L. J., MANISSERO, D. 
& WELLS, C. D. 2012. Delamanid Improves Outcomes and Reduces Mortality for Multidrug-
Resistant Tuberculosis. Eur Respir J. 
SKRIPCONOKA, V., DANILOVITS, M., PEHME, L., TOMSON, T., SKENDERS, G., KUMMIK, 
T., CIRULE, A., LEIMANE, V., KURVE, A., LEVINA, K., GEITER, L. J., MANISSERO, D. 
& WELLS, C. D. 2013. Delamanid improves outcomes and reduces mortality in multidrug-
resistant tuberculosis. Eur Respir J, 41, 1393-400. 
SMITH, A. L. 2002. Inhaled antibiotic therapy: What drug? What dose? What regimen? What 
formulation? J Cyst Fibros, 1, 189-93. 
SNEWIN, V. A., GARES, M. P., GAORA, P. O., HASAN, Z., BROWN, I. N. & YOUNG, D. B. 1999. 
Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect 
Immun, 67, 4586-93. 
SONG, H., SANDIE, R., WANG, Y., ANDRADE-NAVARRO, M. A. & NIEDERWEIS, M. 2008. 
Identification of outer membrane proteins of Mycobacterium tuberculosis. Tuberculosis 
(Edinb), 88, 526-44. 
Bibliography 
139 | P a g e  
 
SOOKVANICHSILP, N., NAKORNCHAI, S. & WEERAPRADIST, W. 1991. Toxicological study of 
pyridoxal isonicotinoyl hydrazone: acute and subchronic toxicity. Drug Chem Toxicol, 14, 395-
403. 
SOTGIU, G., FERRARA, G., MATTEELLI, A., RICHARDSON, M. D., CENTIS, R., RUESCH-
GERDES, S., TOUNGOUSSOVA, O., ZELLWEGER, J. P., SPANEVELLO, A., CIRILLO, 
D., LANGE, C. & MIGLIORI, G. B. 2009. Epidemiology and clinical management of XDR-
TB: a systematic review by TBNET. Eur Respir J, 33, 871-81. 
SOW, F. B., FLORENCE, W. C., SATOSKAR, A. R., SCHLESINGER, L. S., ZWILLING, B. S. & 
LAFUSE, W. P. 2007. Expression and localization of hepcidin in macrophages: a role in host 
defense against tuberculosis. J Leukoc Biol, 82, 934-45. 
STAHL, D. A. & URBANCE, J. W. 1990. The division between fast- and slow-growing species 
corresponds to natural relationships among the mycobacteria. J Bacteriol, 172, 116-24. 
STANIER, R. Y., PALLERONI, N. J. & DOUDOROFF, M. 1966. The aerobic pseudomonads: a 
taxonomic study. J Gen Microbiol, 43, 159-271. 
STANLEY, S. A., GRANT, S. S., KAWATE, T., IWASE, N., SHIMIZU, M., WIVAGG, C., SILVIS, 
M., KAZYANSKAYA, E., AQUADRO, J., GOLAS, A., FITZGERALD, M., DAI, H., 
ZHANG, L. & HUNG, D. T. 2012. Identification of novel inhibitors of M. tuberculosis growth 
using whole cell based high-throughput screening. ACS Chem Biol, 7, 1377-84. 
STANLEY, S. A., KAWATE, T., IWASE, N., SHIMIZU, M., CLATWORTHY, A. E., 
KAZYANSKAYA, E., SACCHETTINI, J. C., IOERGER, T. R., SIDDIQI, N. A., MINAMI, 
S., AQUADRO, J. A., GRANT, S. S., RUBIN, E. J. & HUNG, D. T. 2013. Diarylcoumarins 
inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32. 
Proc Natl Acad Sci U S A, 110, 11565-70. 
STEINKAMP, G. & VON DER HARDT, H. 1994. Improvement of nutritional status and lung function 
after long-term nocturnal gastrostomy feedings in cystic fibrosis. J Pediatr, 124, 244-9. 
STOVER, C. K., PHAM, X. Q., ERWIN, A. L., MIZOGUCHI, S. D., WARRENER, P., HICKEY, M. 
J., BRINKMAN, F. S., HUFNAGLE, W. O., KOWALIK, D. J., LAGROU, M., GARBER, R. 
L., GOLTRY, L., TOLENTINO, E., WESTBROCK-WADMAN, S., YUAN, Y., BRODY, L. 
L., COULTER, S. N., FOLGER, K. R., KAS, A., LARBIG, K., LIM, R., SMITH, K., 
SPENCER, D., WONG, G. K., WU, Z., PAULSEN, I. T., REIZER, J., SAIER, M. H., 
HANCOCK, R. E., LORY, S. & OLSON, M. V. 2000a. Complete genome sequence of 
Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature, 406, 959-64. 
STOVER, C. K., WARRENER, P., VANDEVANTER, D. R., SHERMAN, D. R., ARAIN, T. M., 
LANGHORNE, M. H., ANDERSON, S. W., TOWELL, J. A., YUAN, Y., MCMURRAY, D. 
N., KREISWIRTH, B. N., BARRY, C. E. & BAKER, W. R. 2000b. A small-molecule 
nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 405, 962-6. 
TALBOT, G. H., BRADLEY, J., EDWARDS, J. E., JR., GILBERT, D., SCHELD, M. & BARTLETT, 
J. G. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial 
Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis, 42, 657-
68. 
Bibliography 
140 | P a g e  
 
TAYLOR, G. M., STEWART, G. R., COOKE, M., CHAPLIN, S., LADVA, S., KIRKUP, J., 
PALMER, S. & YOUNG, D. B. 2003. Koch's bacillus - a look at the first isolate of 
Mycobacterium tuberculosis from a modern perspective. Microbiology, 149, 3213-20. 
TAYLOR, J. P., BERGMIRE-SWEAT, D. & SUAREZ, L. 1999. Epidemiology of drug-resistant 
tuberculosis in Texas. Am J Epidemiol, 149, 359-65. 
TERSTAPPEN, G. C., SCHLUPEN, C., RAGGIASCHI, R. & GAVIRAGHI, G. 2007. Target 
deconvolution strategies in drug discovery. Nat Rev Drug Discov, 6, 891-903. 
TINGPEJ, P., ELKINS, M., ROSE, B., HU, H., MORIARTY, C., MANOS, J., BARRAS, B., BYE, P. 
& HARBOUR, C. 2010. Clinical profile of adult cystic fibrosis patients with frequent epidemic 
clones of Pseudomonas aeruginosa. Respirology, 15, 923-9. 
TORRENS, J. K., DAWKINS, P., CONWAY, S. P. & MOYA, E. 1998. Non-tuberculous 
mycobacteria in cystic fibrosis. Thorax, 53, 182-5. 
TRAORE, H. N. & MEYER, D. 2004. The effect of iron overload on in vitro HIV-1 infection. J Clin 
Virol, 31 Suppl 1, S92-8. 
TRAORE, H. N. & MEYER, D. 2007. Necrosis of host cells and survival of pathogens following iron 
overload in an in vitro model of co-infection with human immunodeficiency virus (HIV) and 
Mycobacterium tuberculosis. Int J Antimicrob Agents, 29, 465-70. 
TSUCHIYA, S., YAMABE, M., YAMAGUCHI, Y., KOBAYASHI, Y., KONNO, T. & TADA, K. 
1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-
1). Int J Cancer, 26, 171-6. 
TSUKAMURA, M. 1981. A review of the methods of identification and differentiation of 
mycobacteria. Rev Infect Dis, 3, 841-61. 
UEDA, Y., KANAZAWA, K., EGUCHI, K., TAKEMOTO, K., ERIGUCHI, Y. & SUNAGAWA, M. 
2005. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum 
parenteral carbapenem. Antimicrob Agents Chemother, 49, 4185-96. 
ULRICH, M., HERBERT, S., BERGER, J., BELLON, G., LOUIS, D., MUNKER, G. & DORING, G. 
1998. Localization of Staphylococcus aureus in infected airways of patients with cystic fibrosis 
and in a cell culture model of S. aureus adherence. Am J Respir Cell Mol Biol, 19, 83-91. 
UNDERWOOD, B. R., WHITE, V. L., BAKER, T., LAW, M. & MOORE-GILLON, J. C. 2003a. 
Contact tracing and population screening for tuberculosis--who should be assessed? J Public 
Health Med, 25, 59-61. 
UNDERWOOD, C. K., MIN, D., LYONS, J. G. & HAMBLEY, T. W. 2003b. The interaction of metal 
ions and Marimastat with matrix metalloproteinase 9. J Inorg Biochem, 95, 165-70. 
VANKEERBERGHEN, A., CUPPENS, H. & CASSIMAN, J. J. 2002. The cystic fibrosis 
transmembrane conductance regulator: an intriguing protein with pleiotropic functions. J Cyst 
Fibros, 1, 13-29. 
VARELA, C. L., AMARAL, C., CORREIA-DA-SILVA, G., CARVALHO, R. A., TEIXEIRA, N. A., 
COSTA, S. C., ROLEIRA, F. M. F. & TAVARES-DA-SILVA, E. J. 2013. Design, synthesis 
Bibliography 
141 | P a g e  
 
and biochemical studies of new 7α-allylandrostanes as aromatase inhibitors. Steroids, 78, 662-
669. 
VILCHEZE, C. & JACOBS, W. R., JR. 2007. The mechanism of isoniazid killing: clarity through the 
scope of genetics. Annu Rev Microbiol, 61, 35-50. 
VISWANADHAN, V. N., GHOSE, A. K., REVANKAR, G. R. & ROBINS, R. K. 1989. Atomic 
physicochemical parameters for three dimensional structure directed quantitative structure-
activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and 
their application for an automated superposition of certain naturally occurring nucleoside 
antibiotics. J Chem Inf Comput Sci, 29, 163-172. 
VOSKUIL, M. I., SCHNAPPINGER, D., VISCONTI, K. C., HARRELL, M. I., DOLGANOV, G. M., 
SHERMAN, D. R. & SCHOOLNIK, G. K. 2003. Inhibition of respiration by nitric oxide 
induces a Mycobacterium tuberculosis dormancy program. J Exp Med, 198, 705-13. 
W.H.O 2001. Antimalarial drug combination therapy, in Report of a WHO Technical Consultation. In: 
GEYER, M. (ed.). Geneva: World Health Organisation. 
W.H.O 2007. Public-Pirvate mix for TB Care and Control: A Tool for National Situation Assessment. 
Geneva: World Health Organisation. 
W.H.O 2009. Global Tuberculosis Control: Epidemiology, strategy, financing. Switzerland: World 
Health Organisation. 
W.H.O 2012. Global Tuberculosis Report 2012. Geneva: World Health Organisation. 
WAGNER, D., MASER, J., LAI, B., CAI, Z., BARRY, C. E., 3RD, HONER ZU BENTRUP, K., 
RUSSELL, D. G. & BERMUDEZ, L. E. 2005. Elemental analysis of Mycobacterium avium-, 
Mycobacterium tuberculosis-, and Mycobacterium smegmatis-containing phagosomes indicates 
pathogen-induced microenvironments within the host cell's endosomal system. J Immunol, 174, 
1491-500. 
WALCOURT, A., LOYEVSKY, M., LOVEJOY, D. B., GORDEUK, V. R. & RICHARDSON, D. R. 
2004. Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity 
against chloroquine-resistant and -sensitive parasites. Int J Biochem Cell Biol, 36, 401-7. 
WANG, J. Y., BURGER, R. M. & DRLICA, K. 1998. Role of superoxide in catalase-peroxidase-
mediated isoniazid action against mycobacteria. Antimicrob Agents Chemother, 42, 709-11. 
WHITE, H., MORTON, A. M., CONWAY, S. P. & PECKHAM, D. G. 2013. Enteral tube feeding in 
adults with cystic fibrosis; patient choice and impact on long term outcomes. Journal of Cystic 
Fibrosis. 
WHITEFORD, M. L., WILKINSON, J. D., MCCOLL, J. H., CONLON, F. M., MICHIE, J. R., 
EVANS, T. J. & PATON, J. Y. 1995. Outcome of Burkholderia (Pseudomonas) cepacia 
colonisation in children with cystic fibrosis following a hospital outbreak. Thorax, 50, 1194-8. 
WHITNALL, M., HOWARD, J., PONKA, P. & RICHARDSON, D. R. 2006. A class of iron chelators 
with a wide spectrum of potent antitumor activity that overcomes resistance to 
chemotherapeutics. Proc Natl Acad Sci U S A, 103, 14901-6. 
Bibliography 
142 | P a g e  
 
WILLIAMS, K., MINKOWSKI, A., AMOABENG, O., PELOQUIN, C. A., TAYLOR, D., ANDRIES, 
K., WALLIS, R. S., MDLULI, K. E. & NUERMBERGER, E. L. 2012. Sterilizing activities of 
novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. 
Antimicrob Agents Chemother, 56, 3114-20. 
WILSCHANSKI, M., MILLER, L. L., SHOSEYOV, D., BLAU, H., RIVLIN, J., AVIRAM, M., 
COHEN, M., ARMONI, S., YAAKOV, Y., PUGATSCH, T., COHEN-CYMBERKNOH, M., 
MILLER, N. L., REHA, A., NORTHCUTT, V. J., HIRAWAT, S., DONNELLY, K., 
ELFRING, G. L., AJAYI, T. & KEREM, E. 2011. Chronic ataluren (PTC124) treatment of 
nonsense mutation cystic fibrosis. Eur Respir J, 38, 59-69. 
WINKELMANN, G. 2002. Microbial siderophore-mediated transport. Biochem Soc Trans, 30, 691-6. 
WU, W. H., LEI, P., LIU, Q., HU, J., GUNN, A. P., CHEN, M. S., RUI, Y. F., SU, X. Y., XIE, Z. P., 
ZHAO, Y. F., BUSH, A. I. & LI, Y. M. 2008. Sequestration of copper from beta-amyloid 
promotes selective lysis by cyclen-hybrid cleavage agents. J Biol Chem, 283, 31657-64. 
XU, J., DUAN, X., WU, H. & ZHOU, Q. 2013. Surveillance and Correlation of Antimicrobial Usage 
and Resistance of Pseudomonas aeruginosa: A Hospital Population-Based Study. PLoS One, 8, 
e78604. 
YAMAZAKI, Y., DANELISHVILI, L., WU, M., MACNAB, M. & BERMUDEZ, L. E. 2006. 
Mycobacterium avium genes associated with the ability to form a biofilm. Appl Environ 
Microbiol, 72, 819-25. 
YELLABOINA, S., RANJAN, S., VINDAL, V. & RANJAN, A. 2006. Comparative analysis of iron 
regulated genes in mycobacteria. FEBS Lett, 580, 2567-76. 
YESUDIAN, H. M. & RAVIGLIONE, M. C. 2009. World Tuberculosis Day 2009: Partnership for TB 
care. The Indian Journal of Medical Research, 129, 215-8. 
YMELE-LEKI, P., CAO, S., SHARP, J., LAMBERT, K. G., MCADAM, A. J., HUSSON, R. N., 
TAMAYO, G., CLARDY, J. & WATNICK, P. I. 2012. A high-throughput screen identifies a 
new natural product with broad-spectrum antibacterial activity. PLoS One, 7, e31307. 
YU, M., LIM, N. H., ELLIS, S., NAGASE, H., TRICCAS, J. A., RUTLEDGE, P. J. & TODD, M. H. 
2013a. Incorporation of Bulky and Cationic Cyclam-Triazole Moieties into Marimastat Can 
Generate Potent MMP Inhibitory Activity without Inducing Cytotoxicity. ChemistryOpen, 2, 
99-105. 
YU, M., PRICE, J. R., JENSEN, P., LOVITT, C. J., SHELPER, T., DUFFY, S., WINDUS, L. C., 
AVERY, V. M., RUTLEDGE, P. J. & TODD, M. H. 2011. Copper, nickel, and zinc cyclam-
amino acid and cyclam-peptide complexes may be synthesized with "click" chemistry and are 
noncytotoxic. Inorg Chem, 50, 12823-35. 
YU, M., YU, Q., RUTLEDGE, P. J. & TODD, M. H. 2013b. A fluorescent "allosteric scorpionand" 
complex visualizes a biological recognition event. Chembiochem, 14, 224-9. 
YU, Y., KALINOWSKI, D. S., KOVACEVIC, Z., SIAFAKAS, A. R., JANSSON, P. J., STEFANI, C., 
LOVEJOY, D. B., SHARPE, P. C., BERNHARDT, P. V. & RICHARDSON, D. R. 2009. 
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide 
reductase inhibitors. J Med Chem, 52, 5271-94. 
Bibliography 
143 | P a g e  
 
YU, Y., WONG, J., LOVEJOY, D. B., KALINOWSKI, D. S. & RICHARDSON, D. R. 2006. 
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res, 12, 
6876-83. 
ZAGER, E. M. & MCNERNEY, R. 2008. Multidrug-resistant tuberculosis. BMC Infect Dis, 8, 10. 
ZHANG, J. H., CHUNG, T. D. & OLDENBURG, K. R. 1999. A Simple Statistical Parameter for Use 
in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen, 4, 67-73. 
ZUMLA, A., NAHID, P. & COLE, S. T. 2013a. Advances in the development of new tuberculosis 
drugs and treatment regimens. Nat Rev Drug Discov, 12, 388-404. 
ZUMLA, A., RAVIGLIONE, M., HAFNER, R. & VON REYN, C. F. 2013b. Tuberculosis. N Engl J 
Med, 368, 745-55. 
 
 
